0001104659-19-054220.txt : 20191015 0001104659-19-054220.hdr.sgml : 20191015 20191015172938 ACCESSION NUMBER: 0001104659-19-054220 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20190831 FILED AS OF DATE: 20191015 DATE AS OF CHANGE: 20191015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Q BioMed Inc. CENTRAL INDEX KEY: 0001596062 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464013793 STATE OF INCORPORATION: NV FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55535 FILM NUMBER: 191151662 BUSINESS ADDRESS: STREET 1: 366 MADISON AVE. STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-588-0022 MAIL ADDRESS: STREET 1: 366 MADISON AVE. STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: ISMO Tech Solutions, Inc. DATE OF NAME CHANGE: 20140107 10-Q 1 tv531008_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: August 31, 2019

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to _____________

Commission File Number: 000-55535

Q BIOMED INC.

(Exact name of registrant as specified in its charter)

Nevada	46-4013793
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

c/o Ortoli Rosenstadt LLP

366 Madison Avenue, 3rd Floor

New York, NY 10017

(Address of principal executive offices)

(212) 588-0022

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Symbol	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Common Stock, $0.001 par value	16,720,871 shares
(Class)	(Outstanding as at October 14, 2019)

Q BIOMED INC.

Table of Contents

	Page
PART I - FINANCIAL INFORMATION		2
Item 1. Condensed Consolidated Financial Statements (Unaudited)		2
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
Item 3. Quantitative and Qualitative Disclosure About Market Risk		22
Item 4. Controls and Procedures		22
PART II - OTHER INFORMATION		22
Item 1. Legal Proceedings		22
Item 1A. Risk Factors		23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		23
Item 3. Defaults Upon Senior Securities		24
Item 4. Mine Safety Disclosures		24
Item 5. Other Information		24
Item 6. Exhibits		24
SIGNATURES		25

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Q BIOMED INC.
Condensed Consolidated Balance Sheets
(Unaudited)

	August 31, 2019			November 30, 2018
ASSETS
Current assets:
Cash	$	301,673		$	2,684,413
Prepaid expenses		28,546			12,500
Total current assets		330,219			2,696,913
Intangible assets, net		462,500			500,000
Total Assets	$	792,719		$	3,196,913

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	751,402		$	172,628
Accrued expenses		1,302,527			219,602
Accrued expenses - related party		25,000			7,500
Accrued interest payable		101,626			29,639
Investor advances		193,250			-
Convertible note payable, net		485,000			-
Total current liabilities		2,858,805			429,369

Long-term liabilities:
Convertible notes payable, net		3,976,709			2,873,272
Total long term liabilities		3,976,709			2,873,272
Total Liabilities		6,835,514			3,302,641

Commitments and Contingencies (Note 6)

Stockholders' Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2019 and November 30, 2018		-			-
Common stock, $0.001 par value; 250,000,000 shares authorized; 15,182,227 and 14,290,236 shares issued and outstanding as of August 31, 2019 and November 30, 2018, respectively		15,182			14,290
Additional paid-in capital		33,866,087			31,994,129
Accumulated deficit		(39,924,064	)		(32,114,147	)
Total Stockholders' Deficit		(6,042,795	)		(105,728	)
Total Liabilities and Stockholders' Deficit	$	792,719		$	3,196,913

The accompanying notes are an integral part of these condensed consolidated financial statements

Q BioMed Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	For the three months ended August 31,						For the nine months ended August 31,
	2019			2018			2019			2018
Operating expenses:
General and administrative expenses	$	968,383		$	1,996,391		$	3,406,853		$	4,547,761
Research and development expenses		786,600			989,140			2,672,715			2,624,753
Total operating expenses		1,754,983			2,985,531			6,079,568			7,172,514

Other expenses:
Interest expense		476,627			-			1,137,271			-
Change in fair value of embedded derivatives		118,000			-			396,000			-
Loss on induced conversion of debt		197,078			-			197,078			-
Total other expenses		791,705			-			1,730,349			-

Net loss	$	(2,546,688	)	$	(2,985,531	)	$	(7,809,917	)	$	(7,172,514	)

Net loss per share - basic and diluted	$	(0.17	)	$	(0.21	)	$	(0.54	)	$	(0.53	)

Weighted average shares outstanding, basic and diluted		14,756,302			14,019,683			14,580,630			13,579,917

The accompanying notes are an integral part of these condensed consolidated financial statements

Q BIOMED INC.

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit)

(Unaudited)

	For the Three months Ended August 31, 2019
	Common Stock				Additional Paid in		Accumulated			Total Stockholders'
	Shares		Amount		Capital		Deficit				Deficit
Balance as of May 31, 2019		14,677,136	$	14,676	$	33,002,224	$	(37,377,376	)	$	(4,360,476	)
Share based compensation for services		139,641		141		340,986		-			341,127
Issuance of common stock to partially convert notes payable		146,863		147		293,579		-			293,726
Issuance of common stock as inducement to partially convert notes payable		187,693		188		196,890		-			197,078
Issuance of common stock to defer monthly contingent payment of convertible note		30,894		30		32,408		-			32,438
Net loss		-		-		-		(2,546,688	)		(2,546,688	)
Balance as of August 31, 2019		15,182,227	$	15,182	$	33,866,087	$	(39,924,064	)	$	(6,042,795	)

	For the Three Months Ended August 31, 2018
	Common Stock				Additional Paid in		Accumulated			Total Stockholders'
	Shares		Amount		Capital			Deficit			Equity
Balance as of May 31, 2018		13,987,130	$	13,987	$	28,902,745	$	(27,030,353	)	$	1,886,379
Share based compensation for services		90,182		90		1,181,361		-			1,181,450
Net loss		-		-		-		(2,985,531	)		(2,985,531	)
Balance as of August 31, 2018		14,077,312	$	14,077	$	30,084,105	$	(30,015,884	)	$	82,298

	For the Nine Months Ended August 31, 2019
	Common Stock				Additional Paid in		Accumulated			Total Stockholders'
	Shares		Amount			Capital		Deficit			Deficit
Balance as of November 30, 2018		14,290,236	$	14,290	$	31,994,129	$	(32,114,147	)	$	(105,728	)
Share based compensation for services		526,541		527		1,349,081		-			1,349,608
Issuance of common stock to partially convert notes payable		146,863		147		293,579		-			293,726
Issuance of common stock as inducement to partially convert notes payable		187,693		188		196,890		-			197,078
Issuance of common stock to defer monthly contingent payment of convertible note		30,894		30		32,408		-			32,438
Net loss		-		-		-		(7,809,917	)		(7,809,917	)
Balance as of August 31, 2019		15,182,227	$	15,182	$	33,866,087	$	(39,924,064	)	$	(6,042,795	)

	For the Nine Months Ended August 31, 2018
	Common Stock				Additional Paid in		Accumulated			Total Stockholders'
	Shares		Amount			Capital		Deficit			Equity
Balance as of November 30, 2017		12,206,409	$	12,206	$	23,187,408	$	(22,843,370	)	$	356,244
Share based compensation for services		159,028		159		1,953,158		-			1,953,317
Issuance of common stock and warrants for cash, net of offering costs		1,711,875		1,712		4,943,539		-			4,945,251
Net loss		-		-		-		(7,172,514	)		(7,172,514	)
Balance as of August 31, 2018		14,077,312	$	14,077	$	30,084,105	$	(30,015,884	)	$	82,298

The accompanying notes are an integral part of these condensed consolidated financial statements

Q BIOMED INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	For the nine months ended August 31,
	2019			2018
Cash flows from operating activities:
Net loss	$	(7,809,917	)	$	(7,172,514	)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services		1,349,608			1,953,317
Change in fair value of embedded conversion option		396,000			-
Accretion of debt discount		907,437			-
Amortization expense		37,500			-
Loss on induced conversion of debt		197,078			-
Non-cash interest expense		32,438			-
Changes in operating assets and liabilities:
Prepaid expenses		(16,046	)		-
Accounts payable and accrued expenses		1,646,699			236,015
Accrued expenses - related party		17,500			-
Accrued interest payable		165,713			-
Net cash used in operating activities		(3,075,990	)		(4,983,182	)

Cash flows from financing activities:
Proceeds from investor advances		193,250			-
Proceeds received from issuance of short-term convertible note, net of original issuance discount and lender's fees		500,000			-
Proceeds received for issuance of common stock and warrants, net of offering costs		-			4,945,251
Net cash provided by financing activities		693,250			4,945,251

Net decrease in cash		(2,382,740	)		(37,931	)

Cash at beginning of period		2,684,413			824,783
Cash at end of period	$	301,673		$	786,852

Supplemental disclosures:
Cash paid for interest	$	31,524		$	-
Cash paid for income taxes	$	-		$	-

Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to partially convert notes payable	$	293,726		$	-
Accrued debt issuance costs	$	15,000		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 1 - Organization of the Company and Description of the Business

Q BioMed Inc. (“Q BioMed” or “the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies.

On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”). The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentation

The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year.

The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business.

Going Concern

The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern.

The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations.

Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Note 3 - Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2018 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Recent accounting pronouncements

On February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017-11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

Recent adopted pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 4 - Loss per share

Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.

	August 31,
Potentially dilutive securities	2019		2018
Warrants		4,984,000		4,955,058
Convertible Notes		2,171,000		-
Stock Options		1,200,000		900,000

Note 5 - Convertible Notes

	August 31, 2019			November 30, 2018
Convertible Notes Payable, current:
Principal value of 2019 Debenture	$	550,000		$	-
Debt discount		(65,000	)		-
Carrying value of 2019 Debenture		485,000			-
Total carrying value of convertible notes payable, current	$	485,000		$	-
Convertible Notes Payable, long-term:
Principal value of 2018 Debenture	$	3,800,000		$	4,000,000.00
Fair value of bifurcated contingent put option		658,000			262,000
Debt discount		(481,291	)		(1,388,728	)
Carrying value of 2018 Debenture		3,976,709			2,873,272
Total carrying value of convertible notes, long-term	$	3,976,709		$	2,873,272

2019 Debenture

On August 28, 2019, the Company entered into a securities purchase agreement with an accredited investor pursuant to which the Company sold a convertible debenture (the “2019 Debenture”) with a maturity date of twelve months after the issuance thereof for $500,000. The 2019 Debenture is in the aggregate principal amount of $550,000, which amount includes an original issue discount of $40,000 and payment of the lender’s legal fees of $10,000. The 2019 Debenture carries an interest rate of 10% per annum. Upon an event of default, as defined, the outstanding balance of the 2019 Debenture bears interest at a rate of 18% per annum. The Company may prepay the 2019 Debenture at 110% of the outstanding aggregate principal amount within the first six months of issuance and at 125% of the outstanding aggregate principal amount thereafter.

In certain circumstances, a premium is due upon the outstanding balance upon written notice from the lender. A premium of fifteen percent is due for each occurrence of any major default, a premium of ten percent is due for each occurrence of an unapproved variable security issuance default, and a premium of five percent is due for each occurrence of any minor default.

The lender has the right to convert the outstanding aggregate principal amount at any time at the conversion price of $2.50 per share. At any time that is six months after the issuance, the lender may redeem a portion of the 2019 Debenture, not to exceed $150,000 in any month. The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture’s outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

2018 Debentures

The monthly payment provision within the 2018 Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs:

	August 31, 2019	November 30, 2018
Stock price	$0.91	$1.95 - $2.97
Terms (years)	0.50 – 0.66	1.2 - 1.4
Volatility	79.78%	72.1% - 76.5%
Risk-free rate	1.89% - 2.10%	2.4% - 2.5%
Dividend yield	0.00%	0.00%
Discount rate	35.17%	35.17%

In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and accrued interest under the previously existing conversion terms, the holders would have received 146,863 shares of the Company’s common stock. The additional 187,693 shares received upon conversion, with an aggregate fair value of $197,078, is recognized in the accompanying Condensed Consolidated Statements of Operations as a loss on induced conversion of debt.

Interest expense

Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Interest expense based on the coupon interest rate of the outstanding debt	$	55,000	$	-	$	166,000	$	-
Accretion of debt discount	$	389,000	$	-	$	907,000	$	-
Costs incurred to defer monthly contingent payments of convertible notes	$	32,000	$	-	$	64,000	$	-

Note 6 - Commitments and Contingencies

Legal

Periodically, the Company reviews the status of significant matters, if any exist, and assesses our potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

BNI matter

On December 28, 2018, the Company commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County (removed to federal court in February 2019). The litigation stems from a license agreement that the Company entered into with BNI in 2016 and amended from time to time. Under the agreement with BNI, the Company were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy.

The Company believes that it has fulfilled the obligations under the agreement to exercise an option to acquire the BNI IP and has notified BNI of such exercise, but BNI has not transferred the BNI IP to the Company. As a result, the Company has commenced litigation to, among other actions, obtain all of the BNI IP. The Company also seeks judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. See Note 10 – Subsequent Events, below.

Advisory Agreements

The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received.

Lease Agreement

In December 2016, the Subsidiary entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years.

Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Rent expense	$	7,500	$	7,500	$	22,500	$	23,000

License Agreement

Mannin

On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License.

On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.

During the nine months ended August 31, 2019 and 2018, the Company incurred approximately $1.9 million and $1.7 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Washington University

On March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones:

The first commercial sale of a companion diagnostic product;

Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent;

PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and

The first commercial sale of a diagnostic product.

In additional to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required.

Note 7 - Related Party Transactions

The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Consulting and legal expenses	$	78,000	$	60,000	$	270,000	$	180,000

Note 8 - Stockholders’ Equity Deficit

As of August 31, 2019 and November 30, 2018, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock.

Issuance of shares for services

During the nine months ended August 31, 2019, the Company issued an aggregate of 526,541 shares of the Company common stock to various vendors for advisory services, valued at approximately $886,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

Issuance of shares to partially convert notes payable

In August 2019, the Company issued an aggregate of 334,556 shares of the Company’s common stock to convert $293,726 of principal and accrued interest outstanding under the 2018 Debentures. Of the 334,556 shares, 146,863 shares were recognized as a conversion of debt at a conversion price of $2.00, while 187,693 shares were recognized as loss on induced conversion of convertible debt in the accompanying Condensed Consolidated Statements of Operations. See Note 5, above, for further discussion.

Issuance of shares to defer monthly contingent payment of convertible note

In August 2019, the Company issued an aggregate of 30,894 shares of the Company’s common stock, valued at approximately $31,000, to holders of the 2018 Debentures to defer a monthly contingent payment that became due. The estimated fair market value of the shares issued was recognized within interest expense in the accompanying Condensed Consolidated Statements of Operations.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Note 9 - Warrants and Options

Summary of warrants

The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at August 31, 2019 and the changes during the period then ended:

	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Intrinsic Value
Outstanding at November 30, 2018		4,984,058	$	3.48		3.51	$	250,000
Issued		-	$	-		-	$	-
Expired		-	$	-		-	$	-
Outstanding at August 31, 2019		4,984,058	$	3.48		2.76	$	-
Exercisable at August 31, 2019		4,921,558	$	3.49		2.75	$	-

Fair value of all outstanding warrants issued to non-employees for services was calculated with the following key inputs:

		For the nine months ended August 31,
		2018
Stock price		$2.14 - $3.61
Term (years)		3.0 – 5.0
Volatility		123.00% - 128.49%
Risk-free rate		2.47% - 2.78%
Dividend yield		0.00%

There were no warrants issued for the nine months ended August 31, 2019.

Options issued for services

The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2019 and the changes during the period then ended:

	Options		Weighted Average Exercise Price		Weightd Average Remaining Contractual Life (years)		Intrinsic Value
Outstanding at November 30, 2018		900,000	$	3.68		3.99	$	-
Issued		300,000	$	1.53		4.75	$	-
Outstanding at August 31, 2019		1,200,000	$	3.15		3.62	$	-
Exercisable at August 31, 2019		1,050,000	$	3.38		3.46	$	-

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Fair value of options issued in the nine-month period ended August 31, 2018 was calculated with the following key inputs. No options were granted in the nine-month period ended August 31, 2019.

	For the nine months ended August 31,
	2019			2018
Exercise price	$	1.53			$3.00 - $3.61
Expected term (years)		5.0			5.0
Volatility		98.75	%		128.00% - 130.00%
Risk-free rate		2.03	%		2.52% - 2.71%
Dividend yield		0.00	%		0.00%

Stock-based Compensation

Stock-based compensation expense is classified within general and administrative expenses as a result of the shares, outstanding warrants and options issued to consultants and employees and included in the accompanying Condensed Consolidated Statements of Operations as follows:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Stock-based compensation expense		183,000		946,000		463,000		1,500,000

As of August 31, 2019, the estimated unrecognized stock-based compensation associate with these agreements is approximately $136,000 and will be fully recognized over the next five months.

Note 10 – Subsequent events

Research Collaboration

On September 5, 2019, the Company entered into a research collaboration and master services agreement (the “Agreement”) with Chemveda Life Sciences India Private Limited (“Chemveda”), a contract research and manufacturing services company. The Company and Chemveda have been engaged in a collaborative joint research program since February 2017. Under the Agreement, the Company will continue the collaborative joint research program with Chemveda regarding the synthesis of Uttroside B, isolated from the leaves of Solanum nigrum, and any of its analogues for use in the clinical trials and treatment of Hepatocellular Carcinomas and any other targets and therapeutic areas (the “Program”). The term of the Agreement is for up to two years from execution.

Under the Agreement and depending upon reaching certain milestones, the Company have agreed to pay Chemveda total compensation of up to $660,000, $360,000 of which will be payable in cash and $300,000 of which will be payable in stock. To date, the Company have paid Chemveda $210,000 in cash compensation under the Agreement and have made no compensation payments in stock. The Company have also agreed to pay royalties (capped at a total amount) to Chemveda based on net sales of any and all drug product(s) resulting from the collaboration, being developed by us.

Subject to the terms of the Agreement, Chemveda shall have the first right of refusal and, if exercised, the exclusive right to manufacture any products developed as a result of the Program for precommercial and commercial production.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Securities Purchase Agreements

In September 2019, the Company executed securities purchase agreements with various investors to purchase units, each unit consisting of (i) one share of common stock and (ii) one and one half (1.5) warrants to purchase a share of common stock, at $0.86, which is 110% of the closing price of the Company’s common stock as listed on OTCQB on September 18, 2019, raising approximately $208,000 in cash.

In October 2019, the Company issued 148,261 units (with each unit consisting of one share of common stock and 1.5 warrants to purchase a share of common stock) to the Company’s legal counsel in exchange for $91,922 of services provided. The Company’s Chief Legal Officer and a Director is the Managing Partner at the law firm where these services were provided.

Amendment to 2018 Debentures

On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020.

On September 23 and October 7, 2019, holders of the 2018 Debentures converted an aggregate of $531,992 of principal and accrued interest outstanding under the revised conversion terms and received an aggregate of 1,163,204 shares of the Company’s common stock. Had the holders converted $531,992 of principal and accrued interest under the previously existing conversion terms, the holders would have received 265,996 shares of the Company’s common stock. The additional 897,208 shares received upon conversion had an aggregate fair value of $589,223.

Settlement Agreement

As described in Note 6, above, the Company commenced litigation against BNI and parties related to BNI in the Supreme Court of New York, New York County o December 28, 2018. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. Pursuant to the terms of the settlement agreement, the Company settled its dispute with BNI and all parties to the litigation dismissed their claims in exchange for entering into a Second Amendment to the License Agreement (entered into on September 23, 2019) pursuant to which:

BNI agreed to immediately transfer and/or assign to the Company all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89;

The Company agreed to issue BNI 50,000 shares of its common stock upon the entry into the settlement agreement and 100,000 shares of its common stock upon the approval of the U.S. Food and Drug Administration (“FDA”) approval of BNI’s Prior Approval Supplements filing

The Company agreed to make a cash payment to BNI of $25,000

The Company agreed to an on-going royalty payment of 3% on all gross profits derived by the Company from the sale of Strontium-Chloride 89 and MetastronTM; and

The Company agreed to assume fees and expenses related to (i) all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), (ii) all outstanding fees owed by BNI to the FDA relating to Strontium-Chloride 89 (approximately $208,000) and (iii) related fees for the development and approval of Strontium-Chloride 89 following the date of the settlement agreement.

The agreement to (i) make a cash payment of $25,000 to BNI, (ii) pay all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), and (iii) issue to BNI 50,000 shares of the Company’s common stock are recognizable subsequent events with an aggregate fair value of approximately $125,000. All other portions of the settlement agreement are not recognizable subsequent events. As of August 31, 2019, the Company had recognized $125,000 in accrued expenses related to this matter. The agreement to assume fees owed by BNI to the FDA relating to Strontium-Chloride 89 is not a recognizable subsequent event as of August 31, 2019, as the fee is contingent as of the settlement agreement date and payment of the fee by the Company is not probable as of the settlement agreement date.

Q BIOMED INC.

Notes to Condensed Consolidated Financial Statements

Repricing of Existing Warrants

On September 24, 2019, the Company reduced the exercise price of 950,000 options and warrants previously issued to Denis Corin for services as a director and for services as an officer to $1.25 per share and reduced the exercise price of 1,250,000 options and warrants previously issued to William Rosenstadt for services as a director and for services as an offer to $1.25 per share. On September 24, 2019, the Company reduced the exercise price of 360,000 options and warrants previously issued to Ari Jatwes for services as a consultant to $1.25 per share and reduced the exercise price of 50,000 warrants previously issued to Rick Panicucci for services as a director to $1.25 per share.

Distribution Agreement

On October 3, 2019, the Company entered into an exclusive distribution agreement for Strontium-89/Metastron™ with Jubilant Radiopharma for the U.S. market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.

Issuance of Debentures

On October 11, 2019, the Company entered into a securities purchase agreement with an accredited investor to place convertible debentures with a maturity date of eighteen months after the issuance thereof in the aggregate principal amount of up to $750,000 (the “Transaction”), provided that in case of an event of default, the debentures may become at the holder’s election immediately due and payable. The initial closing of the Transaction occurred on October 11, 2019 when the Company issued a debenture for $500,000. The second closing is scheduled for within thirty days of October 11, 2109 provided that the holder has converted a minimum of $250,000 of a different convertible debenture previously issued to the holder. The debentures bear interest at the rate of 5.5% per annum. In addition, the Company must pay to the holder a fee equal to 2.5% of the amount of the debentures.

The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days’ notice.

Any time after the six-month anniversary of the issuance of a debenture that the daily VWAP is less than $0.50 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date as that term is defined in the Transaction documents, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

Forward-Looking Statements

This Quarterly Report contains forward-looking statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based on information currently available. The expectations indicated by such forward-looking statements might not be realized. If any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations should materialize, our actual results may differ materially from those indicated by the forward-looking statements.

The key factors that are not within our control and that may have a direct bearing on operating results include, but are not limited to, acceptance of our services, our ability to create and expand our customer base, managements’ ability to raise capital in the future, the retention of key employees and changes in the regulation of our industry.

There may be other risks and circumstances that management may be unable to predict. When used in this Quarterly Report, words such as, “believes,” “expects,” “intends,” “plans,” “anticipates,” “estimates” and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.

Overview

Q BioMed Inc. (or “the Company”) was incorporated in the State of Nevada on November 22, 2013 and is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. We intend to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. We intend to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spin out.

Recent Developments

Metastron™ and Strontium-89 Chloride USP Injection

We have been working hard to commercialize both our Strontium-89 products. We have settled our litigation with BioNucleonics Inc. and now have outright ownership of the generic Strontium-89 Chloride drug, which is FDA approved. We also own Metastron™, the branded drug, purchased from GE Healthcare in November of 2018. As a result, we now control significant market share for this injectable non-opioid metastatic cancer palliation drug in North America and much of the world.

The FDA approval of our contract manufacturer IsoTherapeutics to produce a commercial drug product is one of several milestone catalysts we expect to positively impact our business over the next few months. As we have reported, we believe that we are in the final stage of the approval process, having completed a prior approval inspection and having made and submitted all the required changes to the regulator. Our Strontium-89 products are our lead revenue opportunities and an important step for both Q BioMed and the many patients that will benefit from finally having access to the non-opioid palliation treatments. Once the FDA approves IsoTherapeutics Group to manufacture product, this radiopharmaceutical is well positioned to generate revenues almost immediately.

Although the commercial manufacturing approval process has taken longer than anticipated, we are now confident in the timing around the commercial launch.

In anticipation of the approval, we have proactively on-boarded our commercial team tasked with infrastructure set-up, including: medical information and pharmacovigilance, government contracting, marketing, contract sales and telesales. We have announced a distribution partnership with Julibilant Radiopharma who have all the capabilities we require to access the US market, including warehousing/inventory management, invoicing and customer service/ordering. It also has a sales team that calls on major providers, a national network of nuclear pharmacies in the U.S. and distribution and coverage throughout the U.S. We have completed a reimbursement landscape and set our pricing strategy. Our scientific platform is complete which is informing a creative advertising campaign to coincide with the commercial launch of our product. We are assembling a world class scientific advisory board specific to this product to assist in market access and phase 4 clinical trial planning.

Our Strontium-89 radiopharmaceutical drug addresses an underserved patient group in the cancer pain palliation market, but also has a significant opportunity to expand into a much larger market through our planned phase IV clinical trial designed to expand the label from a pain palliation to a cancer therapeutic. A similar radiopharmaceutical with a much narrower indication in metastatic disease, but with survival benefits (two months), was acquired by Bayer for $2.9 billion in 2013 and is expected to have sales exceeding $700 million this year.

The acquisition of Metastron has given Q BioMed access to a global market much sooner than expected and we continue to be extremely excited about its prospects to re-establish a deserved niche in the late stage cancer treatment landscape.

QBM001

There is currently no treatment for this 20,000 US and 250,000 worldwide subgroup of autistic children that are minimally verbal or non-verbal. We recently filed for Orphan Drug Designation with the FDA and look forward to working with the regulators on this application. We worked with 7 centers of excellence for autism to define a differential diagnosis for our targeted subgroup, and all are on board. We completed a biomarker study that allows us to better define which children should be included in our planned trial. The biomarker also provided insight into how to improve the dosing. We believe that a very targeted population with an improved, targeted dose, will allow our planned trials to be smaller and increases the likelihood of being successful. We have completed formulation of a slow release version of a drug candidate that is required for this clinical application. We believe that our target dose is effective and is safer than a non-formulated drug. We recently filed an orphan drug application and plan on filing an IND and believe the green light will allow us to commence a relatively short pivotal clinical trial of QBM-001 in 2020. We expect to see interim data within 6 months of the start of the trial. This would represent a significant catalyst in 2020 given the acute need for a therapy in this neglected pediatric patient population.

Uttroside-B

Over 40,000 liver cancer patients in the US are diagnosed every year, and the total diagnoses per year has increased by 3% each year over the last 15 years. Each patient has a life expectancy of less than four months. Our initial data from both animals and cell lines suggests that our developing molecule could be very effective - as much as 10 times more effective than current treatments. As a result, we intend to bring this product to a proof of concept trial. If demonstrated, we will actively seek partnerships in order to realize a return on our investment. We believe that we are the only entity to have successfully synthesized Uttroside B and have filed a patent for the synthesis. The synthesized product is now being tested for pre-clinical efficacy in comparison to the natural product.

MAN-01 and GDF15

There are over 60 million patients worldwide with Primary Open-Angle Glaucoma. MAN-01 aims to reduce the pressure build-up in the eye by assisting with, and correcting, drainage problems in tiny vessels in the eye called the Schlemm’s Canal. MAN-01 is being designed to target these unique and extremely important vessels, as over 70% of all fluid in the eye flows through the Schlemm’s Canal. Currently, the MAN-01 program is finalizing its preclinical lead candidate optimization by completing a series of ophthalmic in vivo studies to demonstrate efficacy. After successful completion of the in vivo studies, Mannin Research will begin preparing for preclinical toxicology and filing of its IND. Our research shows that the drug’s mechanism of action may ameliorate vessel damage in several other diseases such as: kidney disease, cardiovascular disease, and against infectious diseases. We believe these programs comprise a multi-disease platform technology that has several valuable applications. Adding the GDF15 biomarker to our portfolio is a significant step to securing a unique product offering that put precision medicine and patient specific treatment in the hands of clinicians. GDF15 is a companion diagnostic marker to the MAN-01 drug for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15). Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Recent buyouts in the Biotechnology space has us believing that large pharma companies could be looking for valuable assets like this with multiple downlines because of expiring patient protection on current drugs. Our collaborators at the Washington University in St. Louis are currently examining the effectiveness of GDF15 as a clinical biomarker in a clinical trial. In parallel, Q BioMed and Mannin Research are working with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression. The aim is to develop a simple integrated diagnostic test that can be performed at a physician’s office with no external, expensive equipment.

While we continue advance all our assets, our key focus for both capital expense and time is on the commercialization of Strontium 89 Chloride USP Injection. This is a near-term revenue generator and we believe a significant catalyst and long-term value driver for us.

Financial Overview

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments, research and development costs, accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Other than as set out in Note 3 to our accompanying unaudited condensed consolidated financial statements we believe there have been no significant changes in our critical accounting policies as described in the Form 10-K.

Unaudited Results of Operations for the three months ended August 31, 2019 and 2018:

	For the three months ended August 31,
	2019			2018
Operating expenses:
General and administrative expenses	$	968,383		$	1,996,391
Research and development expenses		786,600			989,140
Total operating expenses		1,754,983			2,985,531

Other expenses:
Interest expense		476,627			-
Change in fair value of embedded derivatives		118,000			-
Loss on induced conversion of debt		197,078			-
Total other expenses		791,705			-

Net loss	$	(2,546,688	)	$	(2,985,531	)

Operating expenses

We incur various costs and expenses in the execution of our business. The decrease in operating expenses was mainly due to less professional and research & development fees incurred in connection with the license agreements with Mannin and Washington University.

Other expenses

During the three months ended August 31, 2019, interest expense increased to $477,000 from $0 in the prior year. Interest expense in the three months ended August 31, 2019 is comprised of approximately $389,000 accretion of debt discount, approximately $55,000 of accrued interest expense based on the coupon interest rate of the outstanding debt and approximately $32,000 of costs incurred to defer monthly payments of convertible notes. During the three months ended August 31, 2019, we recognized a loss of $118,000 resulting from the change in fair value of embedded contingent put options in convertible notes with a principal balance of $4 million. During the three months ended August 31, 2019, we recognized a loss of $197,000 resulting from the share settlement of deferral fee and additional shares issued beyond conversion terms for conversion of $200,000 principal and accrued interest of $93,726 on 2018 Debentures.

Net loss

In the three months ended August 31, 2019 and 2018, we incurred net losses of approximately $2.5 million and $3.0 million, respectively. Our management expects to continue to incur net losses for the foreseeable future, due to our need to continue to establish a broader pipeline of assets, expenditure on R&D and implement other aspects of our business plan.

Unaudited Results of Operations for the nine months ended August 31, 2019 and 2018:

	For the nine months ended August 31,
	2019			2018
Operating expenses:
General and administrative expenses	$	3,406,853		$	4,547,761
Research and development expenses		2,672,715			2,624,753
Total operating expenses		6,079,568			7,172,514

Other expenses:
Interest expense		1,137,271			-
Change in fair value of embedded derivatives		396,000			-
Loss on induced conversion of debt		197,078			-
Total other expenses		1,730,349			-

Net loss	$	(7,809,917	)	$	(7,172,514	)

Operating expenses

Other expenses

During the nine months ended August 31, 2019, interest expense increased to $1.1 million from $0 in the prior year. Interest expense in the nine months ended August 31, 2019 is comprised of approximately $907,000 accretion of debt discount, approximately $166,000 of accrued interest expense based on the coupon interest rate of the outstanding debt and approximately $64,000 of costs incurred to defer monthly payments of convertible notes. During the nine months ended August 31, 2019, we recognized a loss of $396,000 resulting from the change in fair value of embedded contingent put options in convertible notes with a principal balance of $4 million. During the nine months ended August 31, 2019, we recognized a loss of $197,000 resulting from the share settlement of deferral fee and additional shares issued beyond conversion terms for conversion of $200,000 principal and accrued interest of $93,726 on 2018 Debentures.

Net loss

In the nine months ended August 31, 2019 and 2018, we incurred net losses of approximately $7.8 million and $7.2 million, respectively. Our management expects to continue to incur net losses for the foreseeable future, due to our need to continue to establish a broader pipeline of assets, expenditure on R&D and implement other aspects of our business plan.

Liquidity and Capital Resources

We prepared the accompanying condensed consolidated financial statements assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

We have not yet established an ongoing source of revenues and must cover our operating through debt and equity financings to allow us to continue as a going concern. We had approximately $302,000 in cash as of August 31, 2019. Our ability to continue as a going concern depends on the ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.

We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern within one year after the condensed consolidated financial statements were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.

The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods addressed in this report:

	For the Nine Months Ended August 31,
	2019			2018
Net cash (used in) provided by:
Operating activities	$	(3,075,990	)	$	(4,983,182	)
Financing activities		693,250			4,945,251
Net decrease in cash	$	(2,382,740	)	$	(37,931	)

Net cash used in operating activities was approximately $3.1 million for the nine months ended August 31, 2019 as compared to approximately $5.0 million for the nine months ended August 31, 2018. The decrease in net cash used in operating activities relates to the net loss of approximately $7.8 million for the nine months ended August 31, 2019, partially offset by aggregate non-cash expenses of approximately $2.9 million and changes in operating assets and liabilities of approximately $1.8 million. The net cash used in operating activities of approximately $5.0 million for the nine months ended August 31, 2018 results from the net loss of approximately $7.2 million, partially offset by aggregate non-cash expenses of approximately $2.0 million.

Net cash provided by financing activities was approximately $693,000 for the nine months ended August 31, 2019, resulting from proceeds from investor advances of $193,000 and proceeds received from issuance of 2019 Debenture of $500,000. Net cash provided by financing activities was approximately $4.9 million for the nine months ended August 31, 2018, resulting from proceeds received from the issuance of common stock and warrants of approximately $5.4 million, offset by offering costs of approximately $0.5 million.

Commitments and Contingencies

Legal

On December 28, 2018, we commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County. The litigation stems from a license agreement that we entered into with BNI in 2016 and amended from time to time. Under the agreement with BNI, we were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy.

We believe that we fulfilled the obligations under the agreement to exercise an option to acquire the BNI IP and notified BNI of such exercise, but BNI did not transfer the BNI IP to us. As a result, we commenced litigation to, among other actions, obtain all of the BNI IP. We also sought judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York.

On September 23, 2019, we entered into a settlement agreement with BNI and parties related to BNI. Pursuant to the terms of the settlement agreement, we settled our dispute with BNI and all parties to the litigation dismissed their claims in exchange for entering into a Second Amendment to the License Agreement (entered into on September 23, 2019) pursuant to which:

BNI agreed to immediately transfer and/or assign to us all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89;

We agreed to issue BNI 50,000 shares of our common stock upon the entry into the settlement agreement and 100,000 shares of our common stock upon the approval of the U.S. Food and Drug Administration (“FDA”) approval of BNI’s Prior Approval Supplements filing

We agreed to make a cash payment to BNI of $25,000

We agreed to an on-going royalty payment of 3% on all gross profits derived by us from the sale of Strontium-Chloride 89 and MetastronTM; and

We agreed to assume fees and expenses related to (i) all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), (ii) all outstanding fees owed by BNI to the FDA relating to Strontium-Chloride 89 (approximately $208,000) and (iii) related fees for the development and approval of Strontium-Chloride 89 following the date of the settlement agreement.

Advisory Agreements

We entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which we agreed to issue shares of common stock as services are received.

Lease Agreement

In December 2016, we entered into a lease agreement for office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years.

Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Rent expense	$	7,500	$	7,500	$	22,500	$	23,000

License Agreement

Mannin

On October 29, 2015, we entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby we were granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License.

On March 26, 2019, we entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for our issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.

During the nine months ended August 31, 2019 and 2018, we incurred approximately $1.9 million and $1.7 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License.

Washington University

On March 9, 2019, we entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for us to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones:

The first commercial sale of a companion diagnostic product;

Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent;

PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and

The first commercial sale of a diagnostic product.

In additional to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required.

Related Party Transactions

We entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	For the three months ended August 31,				For the nine months ended August 31,
	2019		2018		2019		2018
Consulting and legal expenses	$	78,000	$	60,000	$	270,000	$	180,000

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not applicable as we are currently considered a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Principal Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the period covered by this Report. Based on that evaluation, it was concluded that our disclosure controls and procedures are not effective to reasonably assure that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We do not have an Audit Committee; our board of directors currently acts as our Audit Committee. Only one of our three directors is an independent director, and none of our directors is considered a “Financial Expert,” within the meaning of Section 407 of the Sarbanes-Oxley Act. We have interviewed additional potential independent directors, but have not engaged any.

Changes in internal controls over financial reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. We have engaged accounting and compliance consultants to review our internal controls over financial reporting and other compliance requirements.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On December 28, 2018, we commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI. The litigation stems from a license agreement that we entered into with BNI in 2016, as amended. Under the agreement with BNI, we were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy.

Under the agreement, once we funded up to $850,000 in cash, we could exercise the option to acquire the BNI IP at no additional charge. By our accounts, we provided BNI with over $950,000 in cash. We exercised our option to acquire the BNI IP, but BNI did not transfer the BNI IP to us. As a result, we commenced litigation to, among other actions, obtain all of the BNI IP. We also sought judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York.

BNI agreed to immediately transfer and/or assign to us all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89;

We agreed to make a cash payment to BNI of $25,000

We agreed to an on-going royalty payment of 3% on all gross profits derived by us from the sale of Strontium-Chloride 89 and MetastronTM; and

Item 1A. Risk Factors

As a Smaller Reporting Company, we are not required to provide this information.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 24, 2019, we issued our director Rick Panicucci 50,000 warrants exercisable for five years at an exercise price of $1.25 per warrant.

On September 24, 2019, we issued a consultant in exchange for services rendered 50,000 warrants exercisable for five years at an exercise price of $1.25 per warrant.

On September 24, 2019, we issued a consultant in exchange for services rendered 84,000 warrants exercisable for three years at an exercise price of $1.25 per warrant.

On September 24, 2019, we issued a consultant in exchange for services rendered and to be rendered 100,000 warrants exercisable for five years to a consult at an exercise price of $1.25 per warrant. Such warrants vest in equal portions each quarter.

In September 2019, we entered into a series of related Securities Purchase Agreements with seven investors for a total of $208,250. Pursuant to the terms of the investment, such investors received 335,887 shares of our common stock and 503,831 warrants to purchase shares of our common stock at an exercise price of $0.86.

On October 7, we issued 496,109 shares of common stock upon the conversion of $198,443.84 of principal and interest of a convertible note issued by us in September 2018.

In October 2019, we issued 148,261 units (with each unit consisting of one share of common stock and 1.5 warrants to purchase a share of common stock) to our legal counsel in exchange for $91,922 of services provided. Our Chief Legal Officer and a Director is the Managing Partner at the law firm where these services were provided.

The issuance of the Securities mentioned above qualified for the exemption from registration continued in section 4(a) of the securities act of 1933.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number		Name and/or Identification of Exhibit

31.1		Rule 13a-14(a)/15d-14(a) Certifications

32.1		Certification under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)

101		Interactive Data File

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Q BIOMED INC.

Dated: October 15, 2019	By:	/s/ Denis Corin
		Denis Corin
		President, Chief Executive Officer, Acting Principal Accounting Officer, Principal Financial Officer

EX-31.1 2 tv531008_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Denis Corin, certify that:

(1)

I have reviewed the quarterly report on Form 10-Q for the quarterly period ended August 31, 2019 of Q BioMed Inc.;

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Dated: October 15, 2019
	/s/ Denis Corin
	Denis Corin
	Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer)

EX-32.1 3 tv531008_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Q BioMed Inc. (the “Company”) for the quarterly period ended August 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Denis Corin, Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Dated: October 15, 2019
	/s/ Denis Corin
	Denis Corin
	Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer)

EX-101.INS 4 qbio-20190831.xml XBRL INSTANCE DOCUMENT 0001596062 qbio:ManninAgreementMember 2019-04-01 2019-04-09 0001596062 us-gaap:GeneralAndAdministrativeExpenseMember 2018-12-01 2019-08-31 0001596062 us-gaap:RetainedEarningsMember 2019-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2019-08-31 0001596062 us-gaap:RetainedEarningsMember 2019-05-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0001596062 2019-05-31 0001596062 us-gaap:RetainedEarningsMember 2018-11-30 0001596062 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0001596062 us-gaap:RetainedEarningsMember 2018-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2018-08-31 0001596062 us-gaap:RetainedEarningsMember 2018-05-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001596062 2018-05-31 0001596062 us-gaap:RetainedEarningsMember 2017-11-30 0001596062 us-gaap:AdditionalPaidInCapitalMember 2017-11-30 0001596062 us-gaap:CommonStockMember 2019-08-31 0001596062 us-gaap:CommonStockMember 2019-05-31 0001596062 us-gaap:CommonStockMember 2018-11-30 0001596062 us-gaap:CommonStockMember 2018-08-31 0001596062 us-gaap:CommonStockMember 2018-05-31 0001596062 us-gaap:CommonStockMember 2017-11-30 0001596062 qbio:RickPanicucciMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-24 0001596062 qbio:AriJatwesMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-24 0001596062 qbio:DirectorWilliamRosenstadtMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-23 0001596062 qbio:DirectorDenisCorinMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:SubsequentEventMember 2019-09-23 0001596062 srt:MinimumMember us-gaap:WarrantMember 2018-08-31 0001596062 srt:MaximumMember us-gaap:WarrantMember 2018-08-31 0001596062 us-gaap:WarrantMember 2019-08-31 0001596062 us-gaap:WarrantMember 2018-11-30 0001596062 us-gaap:EmployeeStockOptionMember 2018-11-30 0001596062 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2017-12-01 2018-08-31 0001596062 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2017-12-01 2018-08-31 0001596062 srt:MinimumMember us-gaap:WarrantMember 2018-06-01 2018-08-31 0001596062 srt:MaximumMember us-gaap:WarrantMember 2018-06-01 2018-08-31 0001596062 us-gaap:WarrantMember 2018-06-01 2018-08-31 0001596062 us-gaap:EmployeeStockOptionMember 2017-12-01 2018-08-31 0001596062 us-gaap:EmployeeStockOptionMember 2019-08-31 0001596062 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-08-31 0001596062 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-08-31 0001596062 qbio:ConsultantsAndEmployeesMember qbio:WarrantsAndOptionsMember 2019-06-01 2019-08-31 0001596062 qbio:ConsultantsAndEmployeesMember qbio:WarrantsAndOptionsMember 2018-12-01 2019-08-31 0001596062 qbio:ConsultantsAndEmployeesMember qbio:WarrantsAndOptionsMember 2018-06-01 2018-08-31 0001596062 qbio:ConsultantsAndEmployeesMember qbio:WarrantsAndOptionsMember 2017-12-01 2018-08-31 0001596062 qbio:ManninAgreementMember 2018-12-01 2019-08-31 0001596062 qbio:ManninAgreementMember 2017-12-01 2018-11-30 0001596062 us-gaap:RetainedEarningsMember 2018-06-01 2018-08-31 0001596062 us-gaap:CommonStockMember 2018-06-01 2018-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2018-06-01 2018-08-31 0001596062 2018-03-01 2018-11-30 0001596062 qbio:LeaseAgreementMember 2016-12-31 0001596062 qbio:LeaseAgreementMember 2016-12-01 2016-12-31 0001596062 qbio:RickPanicucciMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-24 2019-09-24 0001596062 qbio:AriJatwesMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-24 2019-09-24 0001596062 qbio:DirectorWilliamRosenstadtMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-23 2019-09-23 0001596062 qbio:DirectorDenisCorinMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember qbio:OptionsAndWarrantsMember us-gaap:SubsequentEventMember 2019-09-23 2019-09-23 0001596062 us-gaap:WarrantMember 2017-12-01 2018-11-30 0001596062 us-gaap:EmployeeStockOptionMember 2017-12-01 2018-11-30 0001596062 us-gaap:WarrantMember 2018-12-01 2019-08-31 0001596062 us-gaap:EmployeeStockOptionMember 2018-12-01 2019-08-31 0001596062 qbio:Debenture2019Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-08-28 2019-08-28 0001596062 qbio:Debenture2019Member us-gaap:DebtInstrumentRedemptionPeriodOneMember 2019-08-28 2019-08-28 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-08-31 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputExpectedTermMember 2019-08-31 0001596062 srt:MaximumMember qbio:Debenture2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-08-31 0001596062 srt:MaximumMember qbio:Debenture2018Member us-gaap:MeasurementInputExpectedTermMember 2019-08-31 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputPriceVolatilityMember 2019-08-31 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputExpectedDividendRateMember 2019-08-31 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputExercisePriceMember 2019-08-31 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-11-30 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputPriceVolatilityMember 2018-11-30 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputExpectedTermMember 2018-11-30 0001596062 srt:MinimumMember qbio:Debenture2018Member us-gaap:MeasurementInputExercisePriceMember 2018-11-30 0001596062 srt:MaximumMember qbio:Debenture2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-11-30 0001596062 srt:MaximumMember qbio:Debenture2018Member us-gaap:MeasurementInputExpectedTermMember 2018-11-30 0001596062 srt:MaximumMember qbio:Debenture2018Member us-gaap:MeasurementInputExercisePriceMember 2018-11-30 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputPriceVolatilityMember 2018-11-30 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputExpectedDividendRateMember 2018-11-30 0001596062 qbio:Debenture2018Member us-gaap:MeasurementInputDiscountRateMember 2018-11-30 0001596062 srt:MaximumMember us-gaap:SubsequentEventMember qbio:IssuanceOfDebenturesMember 2019-10-11 0001596062 srt:MaximumMember qbio:Debenture2019Member 2019-08-28 0001596062 qbio:Debenture2019Member 2019-08-28 0001596062 us-gaap:SubsequentEventMember qbio:IssuanceOfDebenturesMember 2019-09-23 2019-09-23 0001596062 2019-08-28 2019-08-28 0001596062 qbio:Debenture2019Member 2019-08-31 0001596062 qbio:Debenture2018Member 2019-08-31 0001596062 qbio:Debenture2018Member 2018-11-30 0001596062 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-11-30 0001596062 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2019-10-31 0001596062 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-10-31 0001596062 us-gaap:SubsequentEventMember 2019-10-31 0001596062 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2019-09-30 0001596062 2018-08-31 0001596062 2017-11-30 0001596062 2018-06-01 2018-08-31 0001596062 qbio:BniAndPartiesRelatedToBniMember 2019-08-31 0001596062 us-gaap:SubsequentEventMember qbio:IssuanceOfDebenturesMember 2019-10-11 0001596062 us-gaap:RetainedEarningsMember 2019-06-01 2019-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0001596062 2019-06-01 2019-08-31 0001596062 us-gaap:RetainedEarningsMember 2018-12-01 2019-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2018-12-01 2019-08-31 0001596062 qbio:Debenture2018Member us-gaap:SubsequentEventMember 2019-10-07 2019-10-07 0001596062 qbio:Debenture2018Member us-gaap:SubsequentEventMember 2019-09-23 2019-09-23 0001596062 qbio:Debenture2018Member 2019-08-01 2019-08-31 0001596062 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001596062 us-gaap:CommonStockMember 2018-12-01 2019-08-31 0001596062 2019-08-01 2019-08-31 0001596062 qbio:ChemvedaLifeSciencesIndiaPrivateLimitedMember qbio:ResearchCollaborationAndMasterServicesAgreementMember us-gaap:SubsequentEventMember 2019-09-05 2019-09-05 0001596062 qbio:ChemvedaLifeSciencesIndiaPrivateLimitedMember srt:MaximumMember qbio:ResearchCollaborationAndMasterServicesAgreementMember us-gaap:SubsequentEventMember 2019-09-05 0001596062 qbio:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-09-01 2019-09-30 0001596062 qbio:LegalAgreementMember 2018-12-01 2019-08-31 0001596062 qbio:BniAndPartiesRelatedToBniMember us-gaap:PositiveOutcomeOfLitigationMember us-gaap:SubsequentEventMember 2019-09-23 2019-09-23 0001596062 qbio:BniAndPartiesRelatedToBniMember qbio:StrontiumChloride89Member us-gaap:PositiveOutcomeOfLitigationMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2019-09-23 0001596062 qbio:BniAndPartiesRelatedToBniMember us-gaap:PositiveOutcomeOfLitigationMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2019-09-23 2019-09-23 0001596062 qbio:ManninAgreementMember 2015-10-01 2015-10-29 0001596062 us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0001596062 us-gaap:RetainedEarningsMember 2017-12-01 2018-08-31 0001596062 us-gaap:CommonStockMember 2017-12-01 2018-08-31 0001596062 us-gaap:AdditionalPaidInCapitalMember 2017-12-01 2018-08-31 0001596062 2019-08-31 0001596062 2018-11-30 0001596062 qbio:WashingtonUniversityMember 2019-03-01 2019-03-09 0001596062 srt:MinimumMember qbio:WashingtonUniversityMember 2019-03-01 2019-03-09 0001596062 srt:MaximumMember qbio:WashingtonUniversityMember 2019-03-01 2019-03-09 0001596062 srt:MaximumMember qbio:Debenture2019Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-08-28 0001596062 qbio:Debenture2019Member 2019-08-28 2019-08-28 0001596062 us-gaap:SubsequentEventMember qbio:IssuanceOfDebenturesMember 2019-10-11 2019-10-11 0001596062 2017-12-01 2018-08-31 0001596062 2019-10-14 0001596062 2018-12-01 2019-08-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --11-30 Q3 2019 2019-08-31 10-Q 0001596062 16720871 Yes false Non-accelerated Filer Q BIOMED INC. false true 907437 0.025 <div> <div> Note 2 - Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. <div /></div> </div> -396000 0.18 0.055 150000 75000 15000 88000 262000 658000 4945251 4943539 1712 1711875 91922 P4Y 25000 67000 208000 0.03 100000 50000 -165713 197078 0.10 32438 P3Y 0.93 -193250 1.10 660000 210000 360000 300000 <div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Interest expense based on the coupon interest rate of the outstanding debt </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 55,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accretion of debt discount </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 389,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 907,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Costs incurred to defer monthly contingent payments of convertible notes </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 64,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div> 187693 30894 30894 30894 187693 187693 187693 897208 897208 31000 32438 32408 30 32438 32408 30 197078 196890 188 197078 196890 188 P5M 500000 <div> <div> Note 9 - Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at August 31, 2019 and the changes during the period then ended: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (years) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at November 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,984,058 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.48 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.51 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,000 </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Issued </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,984,058 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.48 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.76 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,921,558 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.49 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.75 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   Fair value of all outstanding warrants issued to non-employees for services was calculated with the following key inputs: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock price </td> <td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $2.14 - $3.61 </td> </tr> <tr> <td valign="top" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Term (years) </td> <td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.0 – 5.0 </td> </tr> <tr> <td valign="top" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Volatility </td> <td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 123.00% - 128.49% </td> </tr> <tr> <td valign="top" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free rate </td> <td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.47% - 2.78% </td> </tr> <tr> <td valign="top" style="width:63.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:34.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> </tr> </table></div>   There were no warrants issued for the nine months ended August 31, 2019.   Options issued for services The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2019 and the changes during the period then ended: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (years) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at November 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 900,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.68 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.99 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Issued </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.53 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4.75 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,200,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.15 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.62 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,050,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.38 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.46 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   Fair value of options issued in the nine-month period ended August 31, 2018 was calculated with the following key inputs. No options were granted in the nine-month period ended August 31, 2019. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:38.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $1.53 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $3.00 - $3.61 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.0 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.0 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98.75% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 128.00% - 130.00% </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.03% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.52% - 2.71%  </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> </tr> </table></div>   Stock-based Compensation Stock-based compensation expense is classified within general and administrative expenses as a result of the shares, outstanding warrants and options issued to consultants and employees and included in the accompanying Condensed Consolidated Statements of Operations as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation expense </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 183,000 </td> <td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 946,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 463,000 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,500,000 </td> </tr> </table></div>   As of August 31, 2019, the estimated unrecognized stock-based compensation associate with these agreements is approximately $136,000 and will be fully recognized over the next five months. <div /></div> </div>

172628

751402

7500

25000

219602

1302527

125000

31994129

33866087

37500

23000

7500

22500

7500

907000

389000

3196913

792719

2696913

330219

<div> <div> Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed” or “the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies. On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”). The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. <div /></div> </div>

2684413

301673

824783

786852

2684413

301673

-37931

-2382740

<div> <div> Note 6 - Commitments and Contingencies Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses our potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss.  Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict.  Because of such uncertainties, accruals are based on the best information available at the time.  As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. BNI matter On December 28, 2018, the Company commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County (removed to federal court in February 2019). The litigation stems from a license agreement that the Company entered into with BNI in 2016 and amended from time to time. Under the agreement with BNI, the Company were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy. The Company believes that it has fulfilled the obligations under the agreement to exercise an option to acquire the BNI IP and has notified BNI of such exercise, but BNI has not transferred the BNI IP to the Company. As a result, the Company has commenced litigation to, among other actions, obtain all of the BNI IP. The Company also seeks judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. See Note 10 - Subsequent Events, below. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. Lease Agreement In December 2016, the Subsidiary entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years. Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Rent expense </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,500 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 23,000 </td> </tr> </table></div>   License Agreement Mannin On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License. On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019. During the nine months ended August 31, 2019 and 2018, the Company incurred approximately $1.9 million and $1.7 million,  respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License. Washington University On March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15.  The agreement calls for the Company to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The first commercial sale of a companion diagnostic product;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The first commercial sale of a diagnostic product.</td></tr></table></div> In additional to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required. <div /></div> </div>

0.86

0.001

250000000

14290236

15182227

14290236

15182227

14290

15182

1.5

148261

1.5

193250

<div> <div> Note 5 - Convertible Notes <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31, 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> November 30, 2018 </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Convertible Notes Payable, current: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Principal value of 2019 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 550,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (65,000) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying value of 2019 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 485,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total carrying value of convertible notes payable, current </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible Notes Payable, long-term: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Principal value of 2018 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,800,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,000,000.00 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of bifurcated contingent put option </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 658,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 262,000 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (481,291) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,388,728) </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying value of 2018 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,976,709 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,873,272 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total carrying value of convertible notes, long-term </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,976,709 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,873,272 </td> </tr> </table></div>   2019 Debenture On August 28, 2019, the Company entered into a securities purchase agreement with an accredited investor pursuant to which the Company sold a convertible debenture (the “2019 Debenture”) with a maturity date of twelve months after the issuance thereof for $500,000. The 2019 Debenture is in the aggregate principal amount of $550,000, which amount includes an original issue discount of $40,000 and payment of the lender’s legal fees of $10,000.  The 2019 Debenture carries an interest rate of 10% per annum. Upon an event of default, as defined, the outstanding balance of the 2019 Debenture bears interest at a rate of 18% per annum. The Company may prepay the 2019 Debenture at 110% of the outstanding aggregate principal amount within the first six months of issuance and at 125% of the outstanding aggregate principal amount thereafter. In certain circumstances, a premium is due upon the outstanding balance upon written notice from the lender. A premium of fifteen percent is due for each occurrence of any major default, a premium of ten percent is due for each occurrence of an unapproved variable security issuance default, and a premium of five percent is due for each occurrence of any minor default. The lender has the right to convert the outstanding aggregate principal amount at any time at the conversion price of $2.50 per share. At any time that is six months after the issuance, the lender may redeem a portion of the 2019 Debenture, not to exceed $150,000 in any month. The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture’s outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates. 2018 Debentures The monthly payment provision within the 2018 Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 104.94%;"> <tr> <td valign="bottom" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31, 2019 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> November 30, 2018 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock price </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $0.91 </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $1.95 - $2.97 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Terms (years) </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.50-0.66 </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.2 - 1.4 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Volatility </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 79.78% </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 72.1% - 76.5% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free rate </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1.89% - 2.10%   </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2.4% - 2.5% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Discount rate </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 35.17% </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 35.17% </td> </tr> </table></div>   In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock.  Had the holders converted $293,726 of principal and accrued interest under the previously existing conversion terms, the holders would have received 146,863 shares of the Company's common stock. The additional 187,693 shares received upon conversion, with an aggregate fair value of $197,078, is recognized in the accompanying Condensed Consolidated Statements of Operations as a loss on induced conversion of debt.   Interest expense Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Interest expense based on the coupon interest rate of the outstanding debt </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 55,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accretion of debt discount </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 389,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 907,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Costs incurred to defer monthly contingent payments of convertible notes </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,000 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 64,000 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

2873272

3976709

2873272

3976709

485000

293726

531992

250000

334556

1163204

The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

4000000.00

3800000

2.50

2.00

0.50

500000

0.10

35.17

0.00

76.5

2.97

1.4

2.5

1.95

1.2

72.1

2.4

0.91

0.0

79.78

0.66

2.1

0.50

1.89

1.10

1.25

0.20

65000

1388728

481291

15000

40000

208000

-0.53

-0.21

-0.54

-0.17

<div> <div> Note 4 - Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Potentially dilutive securities </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,984,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,955,058 </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible Notes </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,171,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,200,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 900,000 </td> </tr> </table></div>   <div /></div> </div>

-396000

-118000

136000

<div> <div> The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 104.94%;"> <tr> <td valign="bottom" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31, 2019 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> November 30, 2018 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock price </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $0.91 </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $1.95 - $2.97 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Terms (years) </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.50-0.66 </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.2 - 1.4 </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Volatility </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 79.78% </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 72.1% - 76.5% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free rate </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1.89% - 2.10%   </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2.4% - 2.5% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> <td valign="top" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> </tr> <tr> <td valign="top" style="width:62.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Discount rate </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 35.17% </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 35.17% </td> </tr> </table></div>   In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock.  Had the holders converted $293,726 of principal and <div /></div> </div>

P3Y5M16D

P2Y9M

P3Y11M27D

P3Y6M4D

P4Y9M

P0Y

P3Y7M13D

P2Y9M4D

500000

462500

4547761

1996391

3406853

968383

236015

1646699

17500

16046

4955058

4984000

2171000

900000

1200000

197078

589223

1137271

476627

166000

55000

31524

29639

101626

<div> <div> Recent adopted pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08,  Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),  ASU 2016‑10,  Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12,  Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. <div /></div> </div>

950000

1250000

360000

50000

30000

10000

P3Y

3302641

6835514

3196913

792719

429369

2858805

125000

2873272

3976709

$64,000

$32,000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31, 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> November 30, 2018 </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Convertible Notes Payable, current: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Principal value of 2019 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 550,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (65,000) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying value of 2019 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 485,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total carrying value of convertible notes payable, current </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 485,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible Notes Payable, long-term: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Principal value of 2018 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,800,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,000,000.00 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of bifurcated contingent put option </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 658,000 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 262,000 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (481,291) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,388,728) </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying value of 2018 Debenture </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,976,709 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,873,272 </td> </tr> <tr> <td valign="bottom" style="width:71.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total carrying value of convertible notes, long-term </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,976,709 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,873,272 </td> </tr> </table></div>   <div /></div> </div>

4945251

693250

-4983182

-3075990

-7172514

-2985531

-7809917

-2546688

<div> <div> Recent accounting pronouncements On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. <div /></div> </div>

485000

7172514

2985531

6079568

1754983

1730349

791705

0.001

100000000

12500

28546

4945251

500000

-7172514

-2985531

-7809917

-2546688

180000

60000

270000

78000

<div> <div> Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Consulting and legal expenses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78,000 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 60,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 270,000 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 180,000 </td> </tr> </table></div>   <div /></div> </div>

2624753

1700000

989140

2672715

1900000

786600

-32114147

-39924064

<div> <div> The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:24.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> August 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Potentially dilutive securities </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,984,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,955,058 </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible Notes </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,171,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,200,000 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 900,000 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the three months ended August 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:41.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Rent expense </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,500 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 23,000 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (years) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at November 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 900,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.68 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.99 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Issued </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.53 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4.75 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,200,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.15 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.62 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,050,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.38 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.46 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (years) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at November 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,984,058 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.48 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.51 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,000 </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Issued </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,984,058 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.48 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.76 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:53.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable at August 31, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,921,558 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.49 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.75 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:38.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the nine months ended August 31,  </td> </tr> <tr> <td valign="bottom" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $1.53 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $3.00 - $3.61 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.0 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.0 </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98.75% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 128.00% - 130.00% </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.03% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.52% - 2.71%  </td> </tr> <tr> <td valign="top" style="width:58.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.00% </td> </tr> </table></div>   <div /></div> </div>

1953317

1500000

946000

1349608

463000

183000

3.61

3.00

1.53

P5Y

P3Y

P5Y

1.3

1.28

1.2849

1.23

0.9875

0.0271

0.0252

0.0278

0.0247

0.0203

300000

250000

900000

4984058

1200000

4984058

3.68

3.48

3.15

3.48

3.38

3.49

1.53

3.61

2.14

1.25

12206409

13987130

14077312

14290236

14677136

15182227

550000

750000

<div> <div> Note 3 - Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2018 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. Recent accounting pronouncements On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. Recent adopted pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08,  Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),  ASU 2016‑10,  Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12,  Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. <div /></div> </div>

356244

23187408

12206

-22843370

1886379

28902745

13987

-27030353

82298

30084105

14077

-30015884

-105728

31994129

14290

-32114147

-4360476

33002224

14676

-37377376

-6042795

33866087

15182

-39924064

<div> <div> Note 8 - Stockholders’ Equity Deficit As of August 31, 2019 and November 30, 2018, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Issuance of shares for services During the nine months ended August 31, 2019, the Company issued an aggregate of 526,541 shares of the Company common stock to various vendors for advisory services, valued at approximately $886,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. Issuance of shares to partially convert notes payable In August 2019, the Company issued an aggregate of 334,556 shares of the Company’s common stock to convert $293,726 of principal and accrued interest outstanding under the 2018 Debentures.  Of the 334,556 shares, 146,863 shares were recognized as a conversion of debt at a conversion price of $2.00, while 187,693 shares were recognized as loss on induced conversion of convertible debt in the accompanying Condensed Consolidated Statements of Operations.  See Note 5, above, for further discussion. Issuance of shares to defer monthly contingent payment of convertible note In August 2019, the Company issued an aggregate of 30,894 shares of the Company’s common stock, valued at approximately $31,000, to holders of the 2018 Debentures to defer a monthly contingent payment that became due. The estimated fair market value of the shares issued was recognized within interest expense in the accompanying Condensed Consolidated Statements of Operations. <div /></div> </div>

146863

265996

159028

90182

526541

139641

100000

1050000

4921558

293726

293579

147

293726

293579

147

1953317

1953158

159

1181450

1181361

1349608

1349081

527

886000

341127

340986

141

<div> <div> Note 10 – Subsequent events Research Collaboration On September 5, 2019, the Company entered into a research collaboration and master services agreement (the “Agreement”) with Chemveda Life Sciences India Private Limited (“Chemveda”), a contract research and manufacturing services company. The Company and Chemveda have been engaged in a collaborative joint research program since February 2017. Under the Agreement, the Company will continue the collaborative joint research program with Chemveda regarding the synthesis of Uttroside B, isolated from the leaves of Solanum nigrum, and any of its analogues for use in the clinical trials and treatment of Hepatocellular Carcinomas and any other targets and therapeutic areas (the “Program”). The term of the Agreement is for up to two years from execution. Under the Agreement and depending upon reaching certain milestones, the Company have agreed to pay Chemveda total compensation of up to $660,000,  $360,000 of which will be payable in cash and $300,000 of which will be payable in stock. To date, the Company have paid Chemveda $210,000 in cash compensation under the Agreement and have made no compensation payments in stock. The Company have also agreed to pay royalties (capped at a total amount) to Chemveda based on net sales of any and all drug product(s) resulting from the collaboration, being developed by us. Subject to the terms of the Agreement, Chemveda shall have the first right of refusal and, if exercised, the exclusive right to manufacture any products developed as a result of the Program for precommercial and commercial production. Securities Purchase Agreements In September 2019, the Company executed securities purchase agreements with various investors to purchase units, each unit consisting of (i) one share of common stock and (ii) one and one half (1.5)  warrants to purchase a share of common stock, at $0.86, which is 110% of the closing price of the Company’s common stock as listed on OTCQB on September 18, 2019, raising approximately $208,000 in cash. In October 2019, the Company issued 148,261 units (with each unit consisting of one share of common stock and 1.5 warrants to purchase a share of common stock) to the Company’s legal counsel in exchange for $91,922 of services provided. The Company’s Chief Legal Officer and a Director is the Managing Partner at the law firm where these services were provided. Amendment to 2018 Debentures On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020. On September 23 and October 7, 2019, holders of the 2018 Debentures converted an aggregate of $531,992 of principal and accrued interest outstanding under the revised conversion terms and received an aggregate of 1,163,204 shares of the Company’s common stock.  Had the holders converted $531,992 of principal and accrued interest under the previously existing conversion terms, the holders would have received 265,996 shares of the Company’s common stock.  The additional 897,208 shares received upon conversion had an aggregate fair value of $589,223. Settlement Agreement As described in Note 6, above, the Company commenced litigation against BNI and parties related to BNI in the Supreme Court of New York, New York County o December 28, 2018. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. Pursuant to the terms of the settlement agreement, the Company settled its dispute with BNI and all parties to the litigation dismissed their claims in exchange for entering into a Second Amendment to the License Agreement (entered into on September 23, 2019) pursuant to which: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> BNI agreed to immediately transfer and/or assign to the Company all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The Company agreed to issue BNI 50,000 shares of its common stock upon the entry into the settlement agreement and 100,000 shares of its common stock upon the approval of the U.S. Food and Drug Administration (“FDA”) approval of BNI’s Prior Approval Supplements filing</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The Company agreed to make a cash payment to BNI of $25,000</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The Company agreed to an on-going royalty payment of 3% on all gross profits derived by the Company from the sale of Strontium-Chloride 89 and MetastronTM; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> The Company agreed to assume fees and expenses related to (i) all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), (ii) all outstanding fees owed by BNI to the FDA relating to Strontium-Chloride 89 (approximately $208,000) and (iii) related fees for the development and approval of Strontium-Chloride 89 following the date of the settlement agreement.</td></tr></table></div> The agreement to (i) make a cash payment of $25,000 to BNI, (ii) pay all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), and (iii) issue to BNI 50,000 shares of the Company’s common stock are recognizable subsequent events with an aggregate fair value of approximately $125,000.  All other portions of the settlement agreement are not recognizable subsequent events.  As of August 31, 2019, the Company had recognized $125,000 in accrued expenses related to this matter.  The agreement to assume fees owed by BNI to the FDA relating to Strontium-Chloride 89 is not a recognizable subsequent event as of August 31, 2019, as the fee is contingent as of the settlement agreement date and payment of the fee by the Company is not probable  as of the settlement agreement date. Repricing of Existing Warrants On September 24, 2019, the Company reduced the exercise price of 950,000 options and warrants previously issued to Denis Corin for services as a director and for services as an officer to $1.25 per share and reduced the exercise price of 1,250,000 options and warrants previously issued to William Rosenstadt for services as a director and for services as an offer to $1.25 per share. On September 24, 2019, the Company reduced the exercise price of 360,000 options and warrants previously issued to Ari Jatwes for services as a consultant to $1.25 per share and reduced the exercise price of 50,000 warrants previously issued to Rick Panicucci for services as a director to $1.25 per share. Distribution Agreement On October 3, 2019, the Company entered into an exclusive distribution agreement for Strontium-89/Metastron™ with Jubilant Radiopharma for the U.S. market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.    Issuance of Debentures On October 11, 2019, the Company entered into a securities purchase agreement with an accredited investor to place convertible debentures with a maturity date of eighteen months after the issuance thereof in the aggregate principal amount of up to $750,000 (the “Transaction”), provided that in case of an event of default, the debentures may become at the holder’s election immediately due and payable. The initial closing of the Transaction occurred on October 11, 2019 when the Company <a name="_Hlk22081637"></a>issued a debenture for $500,000. The second closing is scheduled for within thirty days of October 11, 2109 provided that the holder has converted a minimum of $250,000 of a different convertible debenture previously issued to the holder. The debentures bear interest at the rate of 5.5% per annum.  In addition, the Company must pay to the holder a fee equal to 2.5% of the amount of the debentures. The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days’ notice. Any time after the six-month anniversary of the issuance of a debenture that the daily VWAP is less than $0.50 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date as that term is defined in the Transaction documents, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.   <div /></div> </div>

13579917

14019683

14580630

14756302

EX-101.SCH 5 qbio-20190831.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Convertible Notes - Fair Value Measurement Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Convertible Notes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Convertible Notes (Details) - old link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stockholders' Equity Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Warrants and Options - Summary of warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Warrants and Options - Fair value of outstanding warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Warrants and Options - Options issued for services (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Warrants and Options - Fair value of options (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - Warrants and Options - Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Subsequent events - Repricing of Existing Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Subsequent events - Issuance of Debentures (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization of the Company and Description of the Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Loss per share link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stockholders' Equity Deficit link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Warrants and Options link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Convertible Notes - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 qbio-20190831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 qbio-20190831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 qbio-20190831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Entity Registrant Name Document Type Document Period End Date Entity Current Reporting Status Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Filer Category Document Fiscal Year Focus Document Fiscal Period Focus Entity Emerging Growth Company Entity Small Business Entity Shell Company Condensed Consolidated Balance Sheets Assets Current assets: Cash Prepaid expenses Assets, Current Total current assets Intangible assets, net Assets [Default Label] Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses - related party Accrued expenses - related party Accrued interest payable Contract with Customer, Liability, Current Investor advances Convertible Notes Payable, Current Convertible note payable, net Carrying value Liabilities, Current Total current liabilities Long-term liabilities: Long-term Liabilities: Convertible notes payable, net Total long-term carrying value of convertible notes Carrying value of convertible notes Total long term liabilities Liabilities Total Liabilities Commitments and Contingencies (Note 7) Commitments and Contingencies (Note 6) Stockholders' Equity: Stockholders' Deficit: Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2019 and November 30, 2018 Common stock, $0.001 par value; 250,000,000 shares authorized; 15,182,227 and 14,290,236 shares issued and outstanding as of August 31, 2019 and November 30, 2018, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance, Amount Beginning balance, Amount Total Stockholders' Deficit Liabilities and Equity Total Liabilities and Stockholders' Deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Condensed Consolidated Statements of Operations Operating expenses: General and administrative expenses Research and development expenses Research and development expenses Operating Expenses Total operating expenses Other expenses: Interest expense Change in fair value of embedded derivatives Change in fair value of embedded derivatives Induced Conversion of Convertible Debt Expense Loss on induced conversion of debt Other Expenses Other Expenses, Total Other Nonoperating Expense Total other expenses Net loss Net loss Net loss per share - basic and diluted Weighted average shares outstanding, basic and diluted Condensed Consolidated Statements of Changes in Shareholders? Equity (Deficit) Statement [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid in Capital Retained Earnings [Member] Accumulated Deficit Statement [Line Items] Warrants and Options Stockholders? Equity Deficit Shares, Outstanding Ending balance, Shares Beginning balance, Shares Share based compensation for services, Amount Stock issued for services Share based compensation for services, Shares Stock issued for services (in shares) Issuance of common stock upon conversion of convertible notes payable Issuance of common stock to partially convert notes payable Issuance of common stock upon conversion of convertible notes , Shares Issuance of common stock to partially convert notes payable (in shares) The gross value of stock issued during the period upon the conversion of convertible securities. Stock Issued During Period, Value, Inducement To Convertible Securities Issuance of common stock as inducement to partially convert notes payable Number of shares issued during the period as a result of the conversion of convertible securities. Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities Issuance of common stock as inducement to partially convert notes payable The gross value of stock issued during the period upon the conversion of convertible securities. Stock Issued During Period, Value, Deferred Payment, Conversion of Convertible Securities Issuance of common stock to defer monthly contingent payment of convertible note Number of shares issued during the period as a result of the conversion of convertible securities. Stock Issued During Period, Shares, Deferred Payment, Conversion of Convertible Securities Issuance of common stock to defer monthly contingent payment of convertible note Issuance of common stock and warrants for cash, net of offering costs, Amount Issuance of common stock and warrants for cash, net of offering costs, Shares Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Condensed Consolidated Statements of Cash Flows Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities Share-based Compensation Share based compensation for services Change in fair value of embedded conversion option Change in fair value of embedded conversion option Amount of noncash expense included in interest expense to accretion of debt discount. Accretion Of Debt Discount. Accretion of debt discount Amortization expense Represents the information pertaining to the Loss on induced conversion of debt Loss On Induced Conversion Of Debt Loss on induced conversion of debt Represents the information pertaining to the Non-cash interest expense. Non Cash Interest Expense Non-cash interest expense Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Accounts Payable Accounts payable and accrued expenses Increase (Decrease) in Accrued Liabilities Accrued expenses - related party Accrued interest payable [Default Label] Accrued interest payable Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from financing activities: Represents the information pertaining to the Proceeds From Investor Advances. Proceeds From Investor Advances Proceeds from investor advances Proceeds from (Repayments of) Short-term Debt Proceeds received from issuance of short-term convertible note, net of original issuance discount and lender's fees Proceeds received for issuance of common stock and warrants, net of offering costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in cash Cash and Cash Equivalents, at Carrying Value Cash at end of period Cash at beginning of period Supplemental disclosures: Cash paid for interest Cash paid for income taxes Non-cash financing activities: Conversion of note Convertible notes value Issuance of common stock to partially convert notes payable Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Accrued debt issuance costs Organization of the Company and Description of the Business Business Description and Basis of Presentation [Text Block] Organization of the Company and Description of the Business n/a Basis of Presentation The entire disclosure of basis of presentation. Basis of Presentation [Text Block] Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Loss per share Earnings Per Share [Text Block] Loss per share Convertible Notes. Convertible Debt [Table Text Block] Convertible Notes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Stockholders' Equity Deficit Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity (Deficit) Warrants and Options The entire disclosure for Warrants and options. Warrants and Options. Warrants and Options Subsequent events Subsequent Events [Text Block] Subsequent events Recent accounting pronouncements Recent adopted pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Loss per share Long-term carrying value of convertible notes Fair Value Measurement Inputs and Valuation Techniques Fair value measurement inputs and valuation techniques Tabular disclosure of interest expense. Schedule Of Interest Expense, Debt [Table Text Block] Schedule of interest expense Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Commitments and contingencies Related Party Transactions Table Related party transactions Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Warrant [Member] Warrants Employee Stock Option [Member] Options Share-based Compensation, Activity [Table Text Block] Summary of all outstanding warrants and options to purchase of common stock Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of fair value outstanding warrants and options issued to non-employees for services Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of stock-based compensation Basis of Presentation and Going Concern Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Warrants Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Convertible Notes Stock Options A table or schedule providing information pertaining to short-term and long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. Schedule Of Debt Instruments [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Debt Instruments [Line Items] Notes and Loans Payable, Current [Abstract] Short-term Debt Principal value Debt Instrument, Unamortized Discount, Current Debt discount Notes Payable, Current Total carrying value of convertible notes payable, current Notes and Loans, Noncurrent [Abstract] Debt discount Principal value Amount of fair value of bifurcated contingent put option. Fair Value Of Bifurcated Contingent Put Option Of Convertible Notes Fair value of bifurcated contingent put option Debt Instrument, Unamortized Discount, Noncurrent Debt discount Convertible Notes Payable, Noncurrent Carrying value Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Instrument [Axis] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Information pertaining to 2018 debenture. Debenture2018 [Member] 2018 Debenture [Member] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input Exercise Price [Member] Stock price Measurement Input Expected Term [Member] Terms (years) Measurement Input Price Volatility [Member] Volatility Measurement Input Risk Free Interest Rate [Member] Risk-free rate Measurement Input Expected Dividend Rate [Member] Dividend yield Measurement Input Discount Rate [Member] Discount rate Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Fair Value Measurement Inputs and Valuation Techniques [Line Items] Convertible Notes Debt Instrument, Measurement Input Input Accretion of debt discount Amortization of the debt discount Accretion of debt discount Interest Expense, Debt Long-term Debt, Contingent Payment of Principal or Interest Costs incurred to defer monthly contingent payments of convertible notes Information pertaining to 2019 debenture. Debenture2019 [Member] 2019 Debenture [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument Redemption Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument Redemption Period One [Member] Within first six months Debt Instrument Redemption Period Two [Member] Thereafter Debt Instrument, Face Amount Aggregate principal amount Issue Of Debentures, Amount Debt Issuance Costs, Gross Legal Fees Debt Instrument, Interest Rate, Stated Percentage Interest rate (as percent) EX-101.PRE 9 qbio-20190831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R40.htm IDEA: XBRL DOCUMENT

Subsequent events (Details) - USD ($)					1 Months Ended			3 Months Ended		9 Months Ended
Subsequent events (Details) - USD ($)	Oct. 07, 2019	Sep. 23, 2019	Sep. 05, 2019	Aug. 28, 2019	Oct. 31, 2019	Sep. 30, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018	Nov. 30, 2019
Subsequent Event [Line Items]
Debt Conversion, Description				The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.
Conversion of note							$ 293,726			$ 293,726
Debt Conversion, Converted Instrument, Shares Issued							334,556
Induced Conversion of Convertible Debt Expense								$ 197,078		$ 197,078
2018 Debenture [Member]
Subsequent Event [Line Items]
Conversion of note							$ 293,726
Debt Conversion, Converted Instrument, Shares Issued							334,556
Issuance of common stock upon conversion of convertible notes , Shares							146,863
Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities							187,693
Induced Conversion of Convertible Debt Expense							$ 197,078
Common Stock
Subsequent Event [Line Items]
Issuance of common stock upon conversion of convertible notes , Shares								146,863		146,863
Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities								187,693		187,693
Subsequent Event
Subsequent Event [Line Items]
Common Unit, Issued					148,261
Legal counsel in exchange services					$ 91,922
Subsequent Event \| 2018 Debenture [Member]
Subsequent Event [Line Items]
Conversion of note	$ 531,992	$ 531,992
Debt Conversion, Converted Instrument, Shares Issued	1,163,204	1,163,204
Issuance of common stock upon conversion of convertible notes , Shares	265,996	265,996
Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities	897,208	897,208
Induced Conversion of Convertible Debt Expense	$ 589,223	$ 589,223
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Common Unit, Issued					1							1
Subsequent Event \| Warrants
Subsequent Event [Line Items]
Common Unit, Issued					1.5	1.5
Subsequent Event \| Research Collaboration And Master Services Agreement [Member] \| Chemveda Life Sciences India Private Limited [Member]
Subsequent Event [Line Items]
Value of stock to be issued			$ 300,000
Cash paid			210,000
Subsequent Event \| Research Collaboration And Master Services Agreement [Member] \| Chemveda Life Sciences India Private Limited [Member] \| Maximum
Subsequent Event [Line Items]
Milestone payments			660,000
Cash payable			$ 360,000
Subsequent Event \| Securities Purchase Agreements[Member] \| Common Stock
Subsequent Event [Line Items]
Common Stock, Convertible, Conversion Price, Increase						$ 0.86
Common stock closing price (as a percent)						110.00%
Dividends, Common Stock, Cash						$ 208,000

XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2019	Nov. 30, 2018
Condensed Consolidated Balance Sheets
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	15,182,227	14,290,236
Common stock, shares outstanding	15,182,227	14,290,236

XML 12 R7.htm IDEA: XBRL DOCUMENT

Organization of the Company and Description of the Business	9 Months Ended
	Aug. 31, 2019
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed” or “the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies. On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”). The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

ZIP 13 0001104659-19-054220-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-19-054220-xbrl.zip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�(?-,C$"FS, M('CG/39FD(T99&,&07'.V)A!-F;04(S4Q@RR,8-LS" ;,\C&#(*Q+K,Q@VS, M(!LSR,8,LD%;AAQ%R 9ML4%;AA:X"%H+0^LX-FC+$)F]-FB+#=IB@[: #]J2 M_E*61/RN6J"6['=+'[;T84L?MO1A2Q^V]&' ]&$;O\7&;['Q6[H92&S\%AN_ MQ5Z]&$3\EN:NV[;($C2H$/X5DBY: :0#SL:KL?%J!C.*V7@U0,8U&Z_&QJNQ M\6ILO)IV[<[&JS$[9!(NN@U5RQXTO3<\:!*U[8K5B9.OSYXU->#WN.=XC">7 MH<\M+7$#A;]3D6X(9TT:\7MR-FU(\P>.I[#0:?1P='3"!WK[K E4T<9,@[AI6J;)MW+4Y M9;4S_;+I;7X$1:5N8),,??O9*YKEXEI-@7K0%K[#8$>4/JVS[ C+CH#'CE!= M5]S8'JA'3W7:7X'I4- $T 97>VPWV&.[4D/J\(_+X/6=!9DI#:LK%_LZ$C>D M4#I\T/LH=H/\]].(QM=1_!\4WR(O>@SQ7\C/!P,JXI.U6_=P#L Z:I#6 P-\ M"\FBZI49:A:1^96BE+ NFWO+Y(9_SE1:I7Y\IW?) T4_$J;%^3,J^VKJ_FBT MO^XC71;H(%'B8+R@JRVA]85*D_8RNZY)HM]I*E,#\I)J4%B99U6J )A;);+I M-Y+J]$!V@P5F5@ ,(.I[8]" ]'8V"5?S'LY6$-1>7%"D!;&5+S)$#4B F+.W MB"*F__0X],_8=!]$3\+EL/1(S"^FWT=LG3.)R.PB(N-XB@@]>2V8K1HJ&Y _ MU7!N:TCQ89M'X=#<4-E 9MA&.U)#Q@1L[@9O3*#7!+ -K+/SU+FTIU' 3" B MZ78\]+^Z-$:+=ZV.'PD2LJM/"BH6!&'MT6A'6O@Z*C9(ZTZI>40;1&\2)IY+ MT4(&S4&022X(7NEVL#31OF6/MA')Y31*.._UR27Q*S_24G##Y,EZ6!BJO,0% M"T.U#GW=DT5/ZW:Q+I^25E0B+P!.F,["%M=MS37:9KQ +G\:Q[ [YM<4S9Z1 M[_*X:'<>1J'' T#[V+TA^-F-T16>X1CY&B98N0+Z9H:5MM$E)ZR10G4) MSO0$3Z\0 )C6!-,ZD!1I@7@7C0QNA9$B5P< *$RF610*8HOV[$>2#H+O16M3 M>00D\@-H_8PFT)GYK98%@O[< XYJ:D- 4,3+$BOT^.D'I:\DU M0947"8+]W@*VVAZF0@ M(OV46-]L:M!Z3[I"C_Q24A)2%%R&YS^]*7?+SKD?LDY3E*/31O]8LW\4*0.S M*X@!]Y3?+B,Q9E-K^B??3(HPG9>A1Q"_DU/H9S,IHU,\#YOJ1,;JM=[#YGR< M\20O&=M]\'<12?IRI\>4N(\RAJ-"_[YI:@.'FW M?I!1_?ZE5@4<1N@A7O;[,T0]@I\T=]DUZ;M%J0%7B487V#!E8S;R<\[.&6>5 MJ"(RFV?O%L0:CI+RJ@T.4W%CGJ;+W,K(KA72+;XU/"A5%82&LAC[4^G.$K)X MYSF5>JG8>,*W-&J:1+E"ND6YAB^EJH+M\^MU EV&?N*E86RBO'"YM?22:RY; ML#99>K=8UW6V-*DYM*Z>BN\K).<#&8\O'"HWG27R=PMZ VZ;$KK!"!ERA^(X M/1=;> */0_\6,>GXR\_CR?E/3%EMX>,\M%C9("-OBX.,L-\68C@+.42@YH4D M_!G0A2S+8,XV/HF-3V+CD]CX) "AL=$M[)7"=F)-V"N%]DJA>D]W$F(>*)95 MQ;8/(CHW\N\C]JN:EE>8I?<;(I7OEQ6J!FU[=<5:]U$KFXA[F)_1.(F]:(;&$\-IRR ?A G, MP%CS !IHU9/'X89$?N+%XWEL,H6G1YYL./?MU3KTV^[\@9DY-5;IV=&D!>#) MT5G06M/+-!AR^X.<96ICTEEPI[N8\"$TF9U.@XA@'QT>:6(1JA/W[50KM*4< MG4&I!#3WF;T'"^D>;&[#O#CA3TDPXB$AE_Y# :]IYJ'=J375"P:]>8W(7(?'?&#"8]Z@*UNV]G^J51<6J5( D%H^LM1I(6SN"A\: M*M !W#!EJ9!]4"$;BK)%:>*&'IM+12RQG+E=1(L'VP-*T%N\]E28,O#,A#,PKXGR!9566 M*&") I8H8(D"$*&Q1 '[X'P3 '5I8:P M"E0:T<*_J], G O)>GB'Z^&]FT8DOD=D=A(1$KW@\%&)FRSET+RU4B5:/TL7 MK]+FNK+Z85]5RJ'X5K5*0!NXMO.AKP9>".KCG2\5!8N)LJR7_^LL7=)<\KC+ MB,:W;BR8L,C7AQ"H6-"@[I]7U+%]QI;OX[1 (PFEC*ZR10SJ+GII[6 /I<-Y MVK*!&^8#>]ER:5SJUXAU,YYA_J'=*"^A&FQ4;Y&/9D(>_6/.I7-WBFB-MYQ+ M*];Z]/>5[0*GP2)\#UL83Q A;G"!"M[:-LS8K4NCQI/-991J_QWT165S"3*1 MT@>EI=NSXCS=8E'#G6&H3R4FS&][:&UL[7WK<^0VDN?W MB[C_ >>]B+$C2NYN>W?6[9W9C=++IUNU2B?)XYWHV)B@2)2$-8LLDRRU:O[Z M0P)\5A$@^$12W@_C45 M"Y[^_-4N/G%BE[&O_NU?_^?_^-/_.CGYC].[:^*%[FY#@X2X$742ZI$O+'DF M#^%VZP3D$XTBYOOD-&+>$R7DX[?_^.W[;W_X0$Y.4AJG3LS[A $1Q+[[]D/^ MS5E*+PQ^)!_>O_OPQW??O?_PD7SWX_?_^./W'\CR4][R$Q=PS9J;^BSX]4?X MSR-G2KBJ0?SC:\S^_-5SDFQ_?/?NRYN+]WW]X]Q^?KN_=9[IQ M3E@0)T[@TJ_27D"DTNWU,?*SCM^_RWADS>%;IFE_2/[UB'XJUH>/'S^^$]_R MIC'[,1;B78>NDXA?K%$BHFP!_SK)FIW 1R(7^*0I_> MT341 OR8[+?TSU_%;+/U07#QV7-$U_52^%'T#OJ_"^@3_*S X2-P^/!'X/ / MZ[*Z5"'RNTTD["=D:_RCNIC_0'Z'S-_ZJH15\3&GC4RQ0# M=AK20AKQLPC*0#MT*P1]^(W"J&JHWQY9> *N^OX':>A_@$_^=IZ&U#+P+H*$ M)?NK8!U&&_$;+Q_C)'+<)",DQ)>43/NU-!,H TR6454C)W(S(?B?#09*6[QS M0^[FV^3$3W\RT7T=A9MV*D@QPA:=_N8_=G"13/>*XA&-PUWDTE:^4=:W[6^6 MR\Y[ A#3X.3G^Q;*_&O&A#B!1R0;4N+S)RE>*]<%KC%G*UC&U/WV*7QYYU$F MD!?^$'Y]\OY#"B'_P#_ZFV1]1Y\8*!8D-\Z&'AA%TPRIWS8I!FZJ:H/0*QM% M[>J$J=\55 F0G@0(3SR2GNVBB$MQ M1[=AE/ YVGWB)+M8">C*YH@=TD31Z@A;WQ:I>QJ)W'/$3:F3G#R1]"=SUB4/ M%0_"Y=)WGFJ,L527SO\J72!VN7L:N'I93(T!N:O3C?"/'O^+S]-=_ MIWMU=!VU0^Q@6M4.@*[:"*G#Z67M"VV2+!%T"2<\F0NFH'K)8M?Q_TJ=2)T& M:IHB=L0F!3-?5+5#ZHZ-XG;UR&R4E90)D+:6%H:;31C<)Z'[Z_VSPZVWVB6P MP S+^.H(U7="[*GF2A_@IZ8'4N]M(7A?9!4\B&"R()(-*?&9V*4OF4^C,QY* M3V&D'ND/6Z%WVEJUJEY::8+:+>LE[>F'@BC)J$Z^Q%.,$Y?\D[JIM;HE8N]K M4.]PH>>@&5(O;)*V]V)/>6@7I"VYHUQT,G/(:MO9N&2-BO5.66HX"[>LDWX[C&7$BJ9.4_,1N>K]Q?/]T%[. QNIU\L-6Z-VR5JVJ.U::H';#>DE[NI\@ M2C*J4WO=,_7])DP\:(3?YVJ4.G"Y4@O<'EN_CD MR7&VTN>HG\39)X?.EW[\-]CIH9 CK-:7+' "E_$4)(R9YBA9RZY(';6+ .#X=9(01HTAEK^_O^,HXY_P8O M/VJ$W)_KE2I[;K4%8A]5"-IY+U*0L^UNZ3: D=<=MYV%\RE4//;!@X;H75$E M;]\M(4=0_]&>:YXY\;-"\_0KY(Y75J#L9_ Y8K>JB-?9BS@1>ZYS&]&MP[R+ MURV,]*E'*]15M47N7%H5R]Y6VQ"Q^^GE[>J/*55")5DL(ZX)LN/WQ5J5E",K M8M^KE[-?;K?(CC(>NMP@VB1AXOC7DZGT .R(6TD1[(42GR2RA%ZS%^I=!0G7 MB#WZ5"I\0U6QU=@)>;"9*5V./GT/Q.%H*'A79RYHIIZ\( $]"M.I1P9M'.-W MSZH2QX, 8G<[$+ ?[)//YW3M[/R$"'3^3YOH/Q#LVUZKN&;.(_-9PFB\##QQ MR.LY]#T:Q1>_[5BR;UB^:-$=>8RU-40Y"DW[(H[3UBIT=?OKJ^7IU?75P]7% M/5G>G)/[A]79O_^?U?7YQ=W]'\C%__OYZN&O*,+!;/U.VV$^+F^PDJ=N/0^W M'FM-SR]86%S86[INN N2^-;9.SSY:I@*JQHC=UB]DI6\J+8E8D=M$+ASWI22 M)2G=D2?.?+B@VM1I9"VWDJ[5,(QVU#N&';5!E.WQ!Z->U8-XK&^,.R0;9.[A MKT"9E$C;#\R1=46P2%P%GSOJPR&%6R_!M'ZA4:/8:L1%X?RT\7\5<"AC\:)45JL;(P\KO5*EB.Y MOB7BV&T0N*_#LI2\_<3Q+ S$M/07ECR?[>(DW- H&XWW>KN .:A/!>X1S1IX(^DA6=R94.^#TLT&[ M=H=YFJW L35VHF@/5^5>'']G,3DQ7LZ:XSJ6V0+6K%:N1EC&F6ZIJBGF1E"N M>@*KM*%C,>3"X.F!1IMS^MBX!5G?%'O8:12L!%Y-.\RAIQ.W<_!QHB=\^-UH M-QNG6E(:6<5K%/NIBI&]71Z /PH;U#3(QA''8I/$0R6B\?B9J$%8CJ6M'!S] M/#[=2E)*PC5Q#^V!8]@T@"_\ 5JGD&IX1!R*M6(.,RTR\L")4M,AM2SBCAP. M_2AF@LWI^0RBZU@=Q:0/8N:TQ5--%>KD:TCPR#]_8VN9UZ[> M?SS2>\HJ.BTO2,SY2D2[2Q"SO/8PXD6',ND_$$E\G#6;QHB=3,MSNF8N2RRN MV]QR6C2*J+S"\A>8("B,4M\2>4AJU#NH3W#8#'$0ZJ3M49M TB2Q+%S^O]]_ M^_[]!SB/)J>-_T(^O'^_>"__1V)9UMS9)<]AQ/Y.O7_A\\CL4Q;'<%@(QJ.P MJ'M.G!BFGLO=TRY.R/V3286!VON_^R>M]W_XI\6''[Y;?/?=/PN/_O"/B^\^ MOE]\]_T?APN*!>%TMM1-V OU+9X177J>J(;G^+<.\ZZ",V?+^,11\4.I6R,/ MF 8U*P>^ZYLB#I\FB3L?%,WI$B!,6$!2TI;N:8RO)Y3T.>%ZNO5Z3A>7=S1Q M6$"]"R<*.+3$2]?=;7;B6'F:9RJ,9-01>;2:*U\.W.9>B&.XA?!=W3QC03(> MY.L2EVSZ8FE=90+]R\IZDB:FM13CZ2O^^%4KIU\S01R?&F&'7",ARR2)V.,N M@=UKDH1\X!WML-DV>PNXW>K) *7!1;+\*.LC+\AR Y>T1E3Q/G&B9&(E3^D3 M"X*I]&S<61I!0[G!5+L$AF*+MK:22_/&FZH;1]FCO6*A,K+0KBZ4\G%Q%8GR_IY8,KJED7B=T6B55=,9>9BW,X)Z M55S5$W'(MU1@L+7S?-D0B^O+5TB7^7JED;UJ.LW*U55*JUW\L,=L7%LI^& N M?;3DC@M;Y1UFZ-)599O<6;:>F2L?"#V8&\M=&%R^JWYCW+S7#+U8 M\9^?.0[XP?.778_W'Q03?.6R;:9CV1>W@+]14[[C/,K]M(/\R^/(+, MNJ2T85JM[S$?QS9)J#7-Y^'(@Z?250=&E$5^;H'@G-&XM3H:DLC!TZA6;RHE\H0/*5OY36] M&JQKC]R1&U4MN[*R,6)G;I:YJSOGE/.2MQ:OO/Q$ RZ-OPR\I;=A 0,=X4QU MJK7".,V]D+NOH=IE)V[H@MB5327OZM I?;'I[50X("C M<3H5*U%7UQ!SY&GE[1Q]0!7#?"5[TT&?P!VW0NZ."K7JGM_ GY:I).U>?#]] M:"/U/WO>=[%YI)X'5ZHB]B)F.#\Y++@.XW@5''^G?O*\"QWD'MS9-&4?;TT$ M<11TUZ7S.NDS[T?AFO':85%1X)"FW'@^G[$;.'GZ*,T1T"=8F=6E3_.RRI3C MFK=SJ2?KL,8L#%;K4DU6J G9-.*9]T>.)*U-41TE#3LC1H[V.G0?604G4K"" MR"B7* 9NV8S+SGK'=-8 %"+R".>4/!^\W?+*^<3*GB@HAE%40!VS)4YQND;<)SAH$YK+^6*8\[ MSK8.SZ$43=Y#,WR7*@]+-O9#'EJ':E44L?1?$\65\O)GR(D:=/R0EY!"9RNUFRL>?COU#V],PE6/)IG_-$;W90 M1*U,4"WZ9M 1<8BTDW_4$^-R8R"&G0$1H:DH_Y:5DOM:5='10J0\:-X//&HT M%]]_4+T66&TQ!V]^&.2UO)P<^2P(_B<"SY/!OUH7R4?):$CYQTFBU.RTI:N;3\2;SGH#!(73OD$:A437$G639"''EJ M67O>/A8DR6=)U%+$C:L2=V[).@#M4'@X=X?L1N8(ZE9\Z8*@F60:Z[I M%?^S<>VCW!!Y"*J5JUWER%LA#CV-L ,LR@%1(JA:"KD1U/O%B2(G>S%YM:VM MH#*(@PG5Z^\R9"O[-N'%<.*73,LTV54FVM.!;F&K\(E*2[(2EUX:Q"M MS!XH&ER]P_>)) >K[Q,-KF/-\T3U:D[\(IJL>'B^B[AHM\(XH@"M_/@RC.YI M],)<9>F$MC2P8U$7DQP]L69* #.&==*C%[[!@1-QAV8#)WY%93:R#B,2IUS& M?<_+Z%'[Z0PB5CS31X_+1D"'%N6ZJ9WA0DUDGGC18!0#P%!0F!]B-"DR,F2, MF$ITA8S1+*+"#/(U"](3?E9/)JD!M'Q5\^> )5VRC3H:\T0/O4E,LXTC O/# MC@8].M]AYHP@ X/WA"))+P9G+)5*(5 M_%N-6'$NW[>CP%4=J".PI9QX2?9$\B=2@ 41(BQ((01Y""OE<@HYIIVD(K"; M$NN=.*VH(PPV3JK9#NW3.?N128ZJ"W6"_F[49S@.]#!CTZ#0@?1,1X@^FG:^ MARTNIHI1HOR85V;YOW?!15WL-XV!BPZ8S M&EG$6'N>/DE[Z^Q!L"''EJ[T9SBZ]#*ET:2C+?&9CC#]=/WO*0DZTQK,4#*9 M2"K48F;#C!W#ZI:K/!"&\(^29SF\0(DT&':V4KJZ];ZI9C(C#CB=&]DS.FI[']/;#!:UV1N,_>!QY)I$8\\F6B@>GYI=AEXV<6!RS Z<^+G M&YJLUJLU%Y5+=Q;&22S/]]79OC])S*/+0 ;+QY.>]!!NW0ZJUO"K"H%'OF2W M8N#DEJ@;K'V^2WIN+MP.U M+,>;[6L6MU&X9HFF>'2E =*X42M3/B)4?(O0IS5"]BE/*VLVDZ^!X#>P5._Z M.W&=Z3:,Q('D99)$['&7B#,J/#N[X5;F*1F7TX=FV5MEM@[X#&P.NS6G2\4B M 9HN_?!+TW.4#5V0QZ.)PHIJH$?M$<>LD=CCUO[D;(G@:_4E A"#1^P+\ZAW MNO^9"WT5Y _,+MV$O8CI98//=R*$/!*Z&^?@X8.65!!'30]E.L<2A,D:PH3 MSU-ZI-C)F5E\#';I_=12.:>!J2:[A M^2".Y%'5[5X)*Q<*\MHH$TM,Q,2K#?Q3^!NF9V0' RP+:A'!%:Z M1*C*0E2-D0>E7LFC,AM'+1$'1H/ O6Z7GLC;I67"EBZ2CJADTQ7: =W\J9MBCN\&!?-05K3#?H:C M2>S.&:78&@,W#+B!(6M,GW_D?@K+JC*#9.F*:?XE3S.=3*+LX67BI4)-? !C M--/D"J[6\HWM\U$5U)^%&%_+PY\1PYK!91AQ#XT2]G?=+$'7'BEF&:M:/P4_ M:(PPYS"7N0=TY<0R8!IPQ(09_BJH>=D>PJ\N0ILZ(/5$WZM^SU+3%#E%Z]')OJ MFV$'I0:I)T$C+L.)F $<9OL3Y_,CV8*3E5O*&6%R49\S3( ZXZE8_PO:2^6O M CZ]X,*=4_G_I?V1] V/ADV]5@20XE=W8Y2S?_/>B*<#'93HM]X6'^R Q3%- M"^G[S'EDONW]\6.#W$9TZS"O?OQNT6UVP5"ON#X$JGUFY?@*T3N?W4T9P)O( M\J]OP/53+N,,=LW+[).IG^F9CG@6-[B/55VZ8D$MOI4E#HQ-=-QO=C&M4%T? MU >=9A75*MD'#NN,#;FU6QQU? /DFF9%!V'LALT'N.&(--I!MNLBO6ACN^.N M M5)E2X3G?/VS/$']#"USIKTUD&]HC]7%C5?/4 M5M<8^]:PD>R3;!!GDA 0A62RD$R8B;>)1[5+@ZI6Y@#3*"QPBF4*.PJ%)ZWE MD6O-O566TXI7Z_OG,$H>^)2HYCA>V[Y(<:Z3"0Z*@S1W1#QBMY-_&-?_NF!$ MPO4W1/ Z@;FWA2-JE@P149>R%WC34(!!J2A07%CCL)Q=40TH8D\\S_&+CMF) M:4 M9H)-'10:,$;Y,,U,ZG8IRG7-80+?>T:'/]3:&Z/;1!UQ2'508J3EOIPEUN6^ ML6PBEONV)9O4K5C80PPP!?SOXK<=>W%\2(+N^$0E8BZ?.,$7''&K'Y1:RN+! MAUN6%Z]I]3C^AS@P>,HI;9$0RLW!YXY2LA&5OD^<*,&C]B-]8H'8 M!%$J/V'IM-UVZXL"J8Z?%66]*K9LFLKN&O=&CGXMS5"IMF;6%3$"MM6@B3P E@<#KV:I\#R'\X:480"RR%U^*,,=3K+ZT$0<3H.IUKO$P6!' MZ88)0-B +\K'I _0P4H]UUN<[Y*%]CXH[-JB._* :FN()'VTVM;%U\GTUCT["???F./+)R=!@-0RUF_R@'4R MP<4#93P/V\&Y"/F.9SI\K*);J4#Z[X?("6* 9P*&4@F1/8(;\J6\"E#*DC^44D4>QANUX+97411@#8_S63Y M?-(J>G*"M,!H\4X5++*)[(^=T]B-V+;\]>DN9@&U^2)A)D%).&ZT4R=F ML3B@F=ON@;XFI[[Z5&\G0L@#LKMQRM'7G@KB4.NA3->XREA6 @@"2G"%4"KS M)9^!,Q&L!RX_8)HA6+#1Q-BCN%%9HZ)B9#=HCA0;3!7-KU-JVF*_36DB>E>/ M#=XYTUZ!'%.96B0:-[!4X[%)^YF%5NWHVMAXAL$UW'CPP &>4V41+1U' =] MS#QU6^([\67D<;,%9$F!)8TMOD(RP$.[9$TZ38N#-R-V]G MA,H90J.>B-V_I0*=0T'O_PAFM5,98@:8<.%$<,H9+I>(1VH;!CA-<^1QWZ1H M.=)5;1''=J/(O9XRVM*(Q$ 6CZ,VC5>Z]C-S5>VHI&P\(V<=#G(SRG SD,A7 MM^T/-^.IBR4XLY=)C0Z7*ALC#TN]DH>G+F9UO+-!X"&.;MW :6CU9D)3TH7 MLH"V#W!.JFD,:>J#W&&-5*X<8-9U0.R^9G(/X<7BQ,]GP8!8'U>F4UL$K\W8 MW6Q8(H\X!/!:)TR>:."VNM+0D@;ZV.Y@DFJLMR" .O:[Z-$]*')N\J)XF1_R M &D>[5H2>0LATC >MJ$P]R 9&_3 M=I=!-^088:IX&16:^B#& 6/1N]<5EP\T"0[E ^X(G=M\9&Q'8:8N;S@FMN@^ MPT 8 _/5,8%K*,1A$XO;XW"[[CGT/6XHJ#"4[&':VU1:?.AKTW_6;JZX;!GW'EV 3 &O-?& M C##->)9-LC7*3I\8W'C+M=UM89+%I2/PS ,I^.SN!0J]BQ!#9X:[$WN./8F MBAQ(AC%:9<.P%T7$D#.08EW#[I?T"02QUK+:=DXP%7<9,O+:"PQUC9 ZN%ZI M_*K"40OL]Q/4 @][*0'J@E5<+I0N-_&EA.'5K8NC<9327SZ81C.;A5X?8_K; MCGO6Q8O!0*MICA1A3!6MUFZM;XMXV&L4N?N1XHPPH8(R'E]MG$EJVL_,6_4S M157C&?GKD&?@5I,>?]AD4\9I$7]L!>D._E&XW1&' _W1EH1!Q[V O_]L4 MMQW(( _GKH:I/KS5C@;BX.^L2O?%?Q?BPRGNP6PK7&U6>8:8#2/#T- T1QX" M38I6ZS[7MT7LTHTB]W5=C\_LJ(?&;^_=9^KM?+I:+WE >R%WE-W%XD" MN?*1(.K!HY6P#+/+BDBUO54S"B/DL3*><2MIX^!<$,?GB,IV3MQ2D>"V9EDH M4DA%,K'D^\@EP:!3[=6C20Z*FR2\^ R.Y>[2=1@\94]I-\&?JBUR!-.J6 :A MVH:(<40O;W?/#)[2M\ZS)[]$R6E9B?F@&K4]Q[UT6"0>O5K&,17'5Z^9\\A\ M$="?J -+TMXJN(,@CV2M_ILPB+)_BEHKT#^MX>(^!XQ/7&.CFU%3\48>6)/^ M!.5 G80QXL"?5O^N0 )2RM<"22H3S!/(5<#'5[GCD,M "B'LG(68D44E&&]* M%F6%15]RBR9*B_;8\BT2J>S%JXM7V-5NOE3:H3M2].MJB'P#N45?[%O+753I MO.GL/.Y\)SHH@Y>]C4:H9#SQ9O.4!LCG:*LUR;B1E-T"Q]U<>S:I<04,"U)9 M;=ZE^]N.Q4QLL)_N2__*KT#!LRHQ\VAD5*1[6 Y(D79$<]:O/?4FCSAG'$/+ M(:(V+PI>%H<\[LO_7A0W!1-2D0GE(I-] Q]>M'1Q7+0L3*2Z;6,T_>Y 9C8( MU\XP]3!F1F,66-52E1$NJ3W4/2DVT0%]6V;8"C,D*.ZE+;\XD?? N2Q?6:PP MU&$;Y-%>JU*EO'"Y >(XK9>S\VM80(T .?(9"!Z-Y!,.5+ IM_9MJ^U)(8\G/L9J7YIJPTEQ$#04Z%>F?C) MXU$FOB 90^L[B+8M5#Q:XO@^"7=)G#B!!X?@OM1<;29)2+9<]V?>69Z/VVPX M[L: >+C0J3SY* %R<6AE&<>[S;;+(OQ 3&:(9OV-VH1RW3G,#/T&4'2(W<@R M0E:6(!:5S"I>E,ZNE21##9](3+PN#K$UPBOC$O%?@J-L$ 8G-$TH8U%J(J;1 M"W-M;F>6R[MT7PIJ MKAN2!'VI',JJHX- +Q%@[EJ9=D>"\LL )7.;X]XF34%VY-/->2.&J MI=KY\=_F+@CAI*WD7;WVM/;19T@)?@HA2SB#WR.R^"CR5>#*4_>.?R8F>R*. MXV621.QQEXBT*3SC<\ YJI>QN],#F%0#:E5UX K M\2:2N1QK8U)F#QGX>78E^&*]IFX"00HR93,B$:2J[9)IAF";=K2_462FO;C M&8O+S7 I90D9X]4S9K90:M<+OB7N"]3B(89L<:S M)Z)7[HQ,\0O7.Z'![2Y)(;R/7>N(O06P4AJI-48=49H[-*D5ZE7:?(3BRL4" M+H3\5<#G5^(JIER9K9N=-?9 ZMLMU*VY0EO7?#ZW9K72=SY'3>0H"&ODV2+0 M-@I?F%AG9\$ZC#9R7KWEV.\PJ' #0V;\'$:)K/P!N;R?UP'Q8*ADA9A V2DM M9BWXEU! 1Y#WH##TFKGIQC(0X W6U$EVW)@+XH8^7#*(^ @>T=]V+*+%-:4P M>:911<* NC2.84>6"^C(O8-M:6G VG7?47ZY\@U?D9^4.*0+G9U.A3C__! U0@S[?DX9FW+]K L>Y=+#?RTNO[%*ARO!%(58YX)XY#S@&N(7UA MR3/QQ %FLA$GQV*.15P&R2T,!,9MG&!/G%(;YT]F/QL%T6PCZ&OVF[6$RFF=%"_4C:WN1OB#+N-]%W= M7? 0N8#@0E(V"Y(R(I\S5E9OAW'@@L)KIV$4A5^@0*#J&$9M2^3.K5&O>K7J MJ!EBY]5)V_TX99XP TS;NH,TO&*W$1_5V98/\^*? V7!EV=^I M![OM4#X[A075GKQY=^0QV=80E<,NAGT11V]K%09*MQ:DQ(MDS/+1:-B(_RCM M$- GR'ZU9TTF-8>7$K6<;58S#EV.7!KU#O*'JO-$(>L3MI^V>%A3FAG MW!U#OX<0-K8,RNZ2;68#M]X&TQ>0KLP.&N: 37V0QZN1RG6%I6L[((YA,[D' MFNLMR TW/:)I7G64/4NCQ[=26'?%1E L\Z[KR+.#B\ZK,/"HH5*=>%7:U)P M+Q?YY/RS(@:K[.26YIC2N,"*PF#&CH0E8:I9EB@2O*X+&Q4*2&&ZASE:+=L5 MW6>3;)EI,?+B7<$1[?K=T$:QOX17 L7*K#)=05$8JKD7<@PP5+L<]PU=$,>Z MJ>2#G58NE@+'BNDL-8"%.5U$CZYZ94WP;;ZZI3#MR"R1 \@4!I_J:2W$T#6) MVM,^I-7GP.@8\P%-_>[:AL@#4ZV<.HE'7LY;(^Q *;GUPMY5%1N+JNZMX1,($[1I+E] ?W!U>U0M-2$=[1E!,ZY825VDTWI)=2 M8I$1-[P5HVF.%&E,%2T/Z:JVB(?T1I&[>NS1G G'&S-U^FJ346V'&?JN.B%5 MMYZ9_PZ4J*D\V&I:BD=?>S%[\4HCE\7T-F(NU3[+8-9S9E&L45\7SC7=9A37 M.NF'<_B,"Q%L++_D,(4)9"&-+5#$%-];ZB;4@_V4R>*O\$3V@*[_A+Z3@*[//M6T:WJ.[, MUYI %^.U'6<4YGKYAXMT.787C) %^SAF* CB"?8[%O]Z&5%Z%7 CT3BYO<\8(E(;>H37WGUK'N4OL89'K8R=W4E2LQD> M8^CSYJX07BNJUT_(%FE03VWX":X37B,ISZ];:)A,]:FO%5ZK"]!/LX*!WK*( MGM6J7AXZ7/M1&+BQ$W*D,U-:?07NL =BE#$4?+ K8D=(@>%.W.!JUVHV7= N M93T8)\G?_,M65&^YEFRW45C%I!_RT#56O1R]C9T0!["Y[)TKTKEN1)/TV4O/ M?GW*"30N<0"EX56@\17G0_YC:%UUXQ][RJ<]Y9$2V$T.8@IJ*^Q3WQ(Y9&G4 MJ[ZX>=0,,2SII.T^JJ;'GU*BB]IG4Z8O70Y2E"HY.GM()%;KO-3M*LHD5QBK M$R'D7MW=.'65S\VI((Z)'LIT#9GK_!%.8+JHE$B5? 'GBZ+,890?,K0SN%NP MT5D8RW<(H0"/$1Q4Y!JX(7AR*/4O#B(XJ"%T.I6J&)I>#%4,H)G3 5O*BN?=Q1CVY$X>=; M&K'0,RZSINB(%'W:*Z]>WJOKA3CM:"'\8,M\!9<%D7RLU\O0FZ%%&3=EUUF[ MOFEYM_I^LW7_D'BF$7767!XLL7_IN+3%NXR5YK.* M[F-%U>%;AD@/1HUJ%J%(T5C MU'C4)',_0.+^"W2)(+P@@K3%#7 .&_XE/7I!M>Y[Y)YYI$IE%SK[$K'G'<\8*!$@A24_*]>4N4_@=3R>D[JP(?>D>O6I%0'DOMG>&.JL3M<;L7=W4&*P MS*]2=6E!)$-2<,20#HYJD=P 4(Z!?.W$L!\-Q#N58U0?>2CI(XXVTK6S\]L$ M?R]"2$&@OW'*!RO:4YG!T8L>2G4-B8(485ETN,].],21(0RR \-RBN'Q)N(3 M^I*>M_*DA-.?W+!@J2,X%1^DG+&!JVT['9LEAURG%^B.O&(.A4!;IF2ZWDBA MN*,9C%;,JUUGDXDU:S#"9K*LB[M EH*-9XJLA$!46""[E)&! HZ5NO%,4/KQ MM_*F"U)0+%W=E7_&F34^&)E0WW]6P&A@"C4T:CK/!AQ-=!@,'DO,LG_$.59B MP,4 ^LXR)ZP3DD8K,@&[XQ.EQ3WP:>#2".:<3[.4A&ZL3S9'- MIE[N71!&E:1+K\OQ6167FYJ5'4KM]$ M83;Q8*S(8$&2B6K5_WK6B*.[@:!NU_9CV-2H4L^"\H6[\S \[FK]3** MH((TQ*?FEJBJ+7)'U:I8]M/:AHC=5"]OYT/%/"VV?@6T)&PLBSJ61"U+JKWYT9X*-*LYHYN*B;8D<8 \FG@9E"$+++)9D8:T8T1DF]@K9- MU)E&U^*G1+3]?MWP J"V U+$,E=6NQ5_/8/W\@R$'G)+_MKV*W8CZGL6;C8L M*?9=*FP&S!A6XOS>0[AT?]NQB*93'2C_7P=-VM9(X\]0S3QC4#?%GC$82-ZC M8!P1;UB$:Q+*X\L\,W DHVQM8^*<8$1U5[F**7&24E\0H&\A*1CSMVWZ7+ ^\.(L!/GQ]2X;*B+5*$,E*Q6@RIIB'FO$ K;Z_%_H6H MPV5I^!]/+>)RK6 >Q@?_P.93W]PESUW1;#T. RJ'&X_64O-1UJ3PRBO5DII4CY0"MI"9C.%^E?% M;S\%9BV#8.?XGQPH&2KJP[=%+P6!6>*8SAC-B%;7>[;8IE5F&)1S! NR*7B MT\:KGL%J301S^?;3I5QA4\"(W M88+G21M=K9_ZELA=7J.>NLHO]A(_.FD[+ZJYS]3;^:)Z"H3$B=@W.:C9B*#F M3U7WZX;#L>K6L_+;(S75OGL]@S.Q31(/5&%4>QIV.H^]H[YXE,.)DGVI-$B: M><67_'00,9+9RI/0DB3BBAM*L>_HOB)$M4"-)PV.7A^%^]\<:P'#JK+RBOI[,ABKG<5N.%&OA$D@!4Y0]_CHF5G/!&>ZQS?>.EYSXBZX5/ _DX]XL2EIQ+DT\6/0]:, MD1SOZ(Q)=B" %G'Y&R8]-M:: _>A4=X4&.#X5915K8G$Z M*CZ*$A_J0_#XJ(9*&6,@;"8^3#6]R5+X*%@243AC%93?H^2&*6_*GM?@R02G MJJP9I[77# FV#:.+K/&1W#I[B,6*"6#OO-:.O4FB!N)A#%; KNY.'#X5:S4' 0?I(530[9E ZJO/F6/ MAA5"D-O";(>G;&P .@K3]?>X\>'^+XZ_HX.BO3G%&8)]2W,U8;TAN9E"?5OM MADW.-:C_ H+-"O2G,J4&\X4(LX/\:0W7V]L&+< +;R,EL>+$M:H-9E!6J50J ML5MM@!TXE?)V3GI#/DUTBQ/R_8<% 60;T5+WB1,E ML[;53?@BZ^I__UY8ZX?Y#C<_B>'R*I"Y_4]1&"O/((S"Z8T/.1KS#CGHU+!Y MP\..3EL, X^4#XH]9'6MA(R6CCP@-+9<5$!Z1DM\F2I_\4HCEW'#=#E/HB*$ M'?(Z&\?X_%4M%K%PJ)!)_2+C6UTF/D"Y!2J9DQ(RB5'+B+X M6%ZK1&"!^4[_2B# GTK"=XRUG*JQ%7P0N-$0.M% MD(A"$@_/3G+F^.X.*C7>T&09QS01C3FD"O0M.MU1CVX$]-Z$"8=4";H?%/ ^ M/E>D2#6QV%3! /GG+"A[;RD7D^5HJ)$FXE"07DW YB1 T MO9O%!9'Y7[D_*<1=$"FPU5,5V'\%O$NV_2QWS7[;,4\\+5TV8CHDC8G3IIS? M-%:W,O]P>&W$]LUB=COM,>!V2>(2K44I=YPO=D_S:]A>>.UGHV)4N^.=(R8* MI4O3C/*;Z/F]:40V,/5P.*QA]F;1UT1G#)A;R$E*@LX8:,/?*^(>&7\2Z,VY_AXQ^%AYO&"\R(K0L(!(J=\8+@_W8[0[ MM&DM.,G'A!:TRB, MTD)N.SF?"/T7\?T]C5Z8Z -TXE5TS9Q'YHN?Z& ? );>FWYH=-+.981 9SCU ML()+U#F,14@MUG\ (X5F"P*Z09&NJG8DC.3@=?(H%"2YAN7#& M2*/F'K%+F M+EW6R?14U)RQ#Q2#*-WABN)!62DI*HUBZ'SN,'N KX]"B(F2M' MY?EBL/;$N?@2AM!\9!WIQVHOQ1O'Z8X_RWA%D!I%>,-8WM42&-#=X.:,:"+G M$L4\8YZ@/_4OA??@J1"8@\\PFXA/^& 6Y-P+4=RS^ M]3*B]"K@OP^-DZE@6L'W]P32.M./!M%U3'\O *W5'2$\@[P$!":9Q&\%G4?Y M)8#HR1K,%=58::;XG(UCY^R%>33PIDZC#_C^GO!99_K14^@RT]\+/FMU1XC/ M>?J<"?Q6X'F4'R(WTIY1O]-=&47=G^SPA::DSW$3I$"F4R@OQ'/P/?8:.RIQ MNSI2\,Z9N%3.T!JD].P6PQ])J3>3=XU8TMZ$(5* FL[8(Z98;Z0:8W^E4295 M,ZBP:,_RN7F&/;\01TD):/F_#D&6?_2W!Y;X=+6^"CQ(Y7:.OWQEAT]-ZMHA MA;1&U0")E(T0 DBSK)UW=($JW/XIZ/(DAE,^2F F]L1?6/)\1WT1I_$SVSZ$ MX@;J_CR$2BHF]FFD,"?O-3.'TJ_UW>?B\89:](N%5246@"4I\R0/H;SPO2>? M)=^)4WT;EJD8(&DT0(^I_QEGLO,3.("[#+R+S=8/]Y3&GVCY:?CRI*>I ](@ M-UY1X>=+REVX:"CY3UT@?"P#9(0%XN1KH?;P9GQ%2S^BO?71#$AE M*0%:O\AQ$XHB/M03ZQGQ0Y@X?OG[LS!.;L+DKS2YHV[X%+"_4Z_\[+-B164J MWD@1T\I/4%Y G80QPHFA'?T[+^ZE4I)43*):9X6BY:FLT^*;9II%E;G\3/\'$0Y81(#Y?0G<$M2#)@MEOE5%IPW8905D*DM M=]N^-U)\[&B&/,Q MMF*H^@JX$^YR[QYC^MN.^]#%"]2-@@I-JFVL^J9(,<$T[Q!F(5MS. M^[ Y42*HDL^"[G"[,;W=D_.KV25L;CTS)SU04^>G:=,9N>JAQ(-Y*U >>O]P M"(^MW34T:3\_KSW>$6QL/"_/'6A/2^&[5O;TL&EK+59K%]6;VLXK1H\7U;4- MYQ.; RVQ'F= 5M:1IU727@#>T9AR9WY>!MXY?:%^N!5GWXJ3<=DKG@\AGRC! MYL9E&*WXC#**3_<-R>!0M)$'^* F+ /"((01 \BP^G7?O9-2B#V=DAS5.M>9 M*+"5EPHCUE:D. L.GH#5NH!Q]GS*#2^Y69]YK+E[#1G)8UZ809: M<[5S5&WN@AU"6V@P/%[&.7.R3;D7P#C.,1@E,$Y@B((%R7@4@6SUE*5UY?N@ M6/>K:F?A#HH<;9THV=\XF[H%,$TSI%C6I%AVLZRN#<))::.HW>\:%$0)4+5R M6_*.;@\C[E!;Y3W)-GT1.VMK$V0>;-P1J5NWE[_'M88CS"4U 6#M&N1TIC#7 MNL_=QV>Z>:&> \_]W;N,AUVS#$NII[D*V)( TO+L;H[@K MV:8W]FR[FS*_RX6*:4V5<1.OE9*,G[@^[I"4(TE96KU^.3^K6#N!I70 MC>$!QW)SI'!JJJCF*$K>%F%.9"SR< =2@#81Q,?8SSC8\RDRF])I>?BP]NY( M%R)(_;:?48[V,(PI8$\'NBO4XUX)3W^A2E#YYH@R83Z-DS"8O-+"])92;S]G3 ^N]4F^%CH\8+O*/9IC\%"C*PXQ8,PH)0%-QJ/8CU9#ID[ MEW"=U)U8K36FP6@8)6ZY._:2U@UFA M/9J*M YXXT;/P2R4IK''^DZW(\#UVH3!SP%+:G-833.D6-BD6'GE_[ -XA5_ MI:C==_F!( &*"T7.TF.4OJ9/4/9J%\34OPHN7MUGN$.1'VP4TZ0SJ.H7)>S1I_+/&-:TX!&3J\"-J(A##6Z;TT"*; M\ ;-D>*AJ:+ET5_5%O% WRAR5Q_."2_(P?!>LYG;8^P^#=@R\&Z="&Z6B<>- MJ/<0\D_59^N;NR#UR38*Y^-R0WOL8[&I^,.?D3^]N1('XK>2-XDD<]@'XU]- M/!Z/;09.22QDIQS(74E9_I7%$^^C:Y[^S'6:\Z_LGVJ_9@E[$@YZS\-D%VNJ MM"F:(H4S$P7+PVM=.\1#JU;\!D63Q*=>(9J^%*^R-?*8;%"S<@>JOBGBJ&R2N'L5 M#D&7E/S6^XI.%YD_<6" &GM\AD$#EV>;I_L;#AJ1KO)N4Q_D46JD2M)X!5Q5.EM5F@OL>L'+I67;4[5YK/QIGKI1[( ME?>Y'UO-#Z?4>-&D\G3!>QO&?(!\H:M=XH8;NEH;9HTF_9 'LK'JY7!N[(0X MJ,UE[[R3EW(@*0NR6N/)-"VH'QJI/VZ!L=LH]'9NLLJJEBIJW"F:(8WA)L6R M"F%U;1!&:*.HG3U2$A4+W-F[M3:JW*5RP"O>V=DZ954[75O\[JA6\< GCQOB M=DR-O#V]4[XUGY$;G1-JW$X?-FY^R2"+'.W.7OVPXAY](>/FGK-FL9( MX\Q,R:(ZLZHE]DWO9L%'J,6<\21NRG3B+>[QE,XIDX*TU6K+XVMZDI$F&E7[ MW( IME/$0BNXLW@Q/A8/PU/OD@>L>#8$]M7W=59H3P(S*G4T2'%IIEU_[ C6 M59VNCG^S P\7U[,%%^)(-@1^(A("(W&09S_UG9J)[5#>C\P9+HAD299EHPBN MXMC+WL;%&R0.,C(FRNM>M2JI:E9U(S,W;#0TC!8?&VC,$2--5>IY_5"%CG!% M[;]VWI.XR!Y"%>!,,'%C,1<8 8J.;2D%DJ8&5"'I0I0_0(*G8YLH+6BP+\H> MC VG=^'>\9-]RG/U0J.?HC".^?1ZS9)8?TVK)[VY 6Q;4VF1UI38'"&WM6[# M7/6*)-NZTJN!1RO0:ZL$NU5K*? WY9_##DA A @DE<'R13&K1CNT3O_K8BW M>;5+XL0)/!8\75)ZMHN3<$.C56",QCH"XX VZQ,_V(::TK% MXCI]A3I&V;,5GGQD#@0A/!)X'!"> 6&%UO'L5(NEI,2/<(8DXT@X2R3 .9Y) MRLJ#\Y1\8O4EX)[SN!?W?[@#7<7A \^;G2W=)#HF5E_AM%Q[63(B,]@-%%@:.<*6H<'<(H+7#T\GR)XIJ:R?K( M@6&[4T&*N#W-HKCQ9D("X2F7OII,N\1H_?[<)+9Y"!/')TZZ7'TP#-F#D:7K M1CNXKN0\,E^\9GRVBR*P1>#=\'"3_U#8T+@S9(B=(*&TLME#7#GG@*E6KW%@Z;(0X'-6R M=KZK(REBJ:Y045!_J:ZVY9P<4G.)[KC97)QRJ"MD!VYI]ZZNIFRC"*HW M_\G&/;K9^N*=47UNA)0WDT=K)))4Z#&T((([P;GIT/M0+ MW(A@5YRV*!B2$D?;Q1RFM\O)H\HN"R/#]%B]/V<1=7GC2,5\^5W5$/M*>Z/,<*J:(&WS?L7HBBZ,-!T M6GYAOL^[P>.)$C/P79^5,_5K1T"IR>D02M D4%K3J\UHIMP&.RSH1!X>&H ;R=E-_23H"*I6%;()$Q:UZP$7JRUX"937 M^,6!=9I$DSYHVF(&CB85<_10-<0.(8UR#X\CH60I3B9^29E.C":C:9T2%A5P M,M(V@06'HM/M\L#3L X/Z=5:/$]3TOLRS"IQQ:OHS'?81G40H"T-I/C5RR3E M79Y6!!#O\G33HS/^I=S@'+9\_LPIAPH'QZ)$%O];@!.?Z?;&%.V1(T*CJD=[O'6-$4=ZL\R]]BCC] 7RA7S)$.ZG MRHHLML)W/'TO7FGDLIBFSQ7"79&X3M,>LXB_./Z. \\Y?>1YZBZB4HVZ9$;9 M$FF\&:B7SQ_JFV&?/31(W?\&DQP5B$.\C(48.>&^$I]/) Q>XTX?U.2MX>,' M/IS$CBOF':$KCK-Z$\\N1K**( MJ%K:XZCQHJC8"/(^!Z1R?2Y]!.7P[&J38:&C7'WO =U6G,Q+D_+*J!U!N M@Z4LB,O'HB>.#SS6(?;SP/"@\!%\0E_26D>>%&[J30U[Y@(6I. H_YWR)!E3 M EP'A(]/89 \^WEA# Z!:\KS>_^2-KRY;MH1,U2T4CX'"*->V&&AG1+#%-SQ M4A[BFNI&"D"V4H*)PWP:]5,N^=E(;H.,D;RH/'*=',U$9$(KG&M^]O'JXQ0* M9/Q3->6[V+73%8,^F.',5.43W)9F+LFE+K/'8S"$MY M6-@8&5WM<\7/.P!&#;/@69HH/W!>FIN1]2V18I>!>N7ES9IFB!U>B[2C6X\DM=C%RY<> M-2=RM*V1QI&AFGE*JFZ*/1DUD+SS/%*0(:+,D]R(+N]5%^PF3D1'U#C7;U76 MS^:YG"F4#1N5_=.[0K!K_A?_,/LH)?>O_Q]02P,$% @ LHM/3]&MN*77 M-0 $%@$ !4 !Q8FEO+3(P,3DP.#,Q7W!R92YX;6SM?5MSXSB2[OM&G/^@ M4_LPLP_5Y5NYRAW3NR'?.KRGRG+8[JF=IPZ:A"QL4Z2;%U>Y?_T!0%*B1.)& M@F(28FR<,]46 "+S^Y"X92;^\5\_EO[D%44Q#H-?WAW^=/!N@@(W]'#P_,N[ M-'[OQ"[&[_[K/__/O_WC_[Y__S_G]U\F7NBF2Q0D$S="3H*\R7><+":/X M7AC\/#D\^'!X^N'HX/!L3Z==5R:^D@W,L+^KCX(^?Z?_W1#XZ M(:(&\<\_8OS+NT62O/S\X!ELY[',2) M$[CH75Z+-K)1[<=3Y!<5CS\4WRB*TU^QH/QV\S\J[>?=.CP[._O ?B5%8_QS MS+KW)72=A"$F[=&$6X+^U_NBV'OZI_>'1^^/#W_Z$7OOB/8FDW]$H8_NT7S" M.O!S\O:"?GD7X^6+3SO._K:(T/R7=W\^X? ]1>#@O]NPEM_[?[FPTQ:%L_N>'R _WQ@UH[3(E*\'QH*]A#0CA*>W(1 M!AX*")?)/^+0QQ[E[KGC4U@?%@@EL8I\6LW!%//.B4BY!4JPZ_B&9=YJ&XP" M5K_&L_GL!46,AP8 Y[4+4O"+A1,\H_@F>%@0F!:A[Y%YY.K/E(Q.LYH0?@BF M:IQX<>V'WPU3HM3L#L6^Q+'KAW$:H5GT[ 3X+\9*TIMP2:;\-V*2+U'L1O@E M^_-Y&N, Q4JB-VZZ%_')T@43%.XB%!,\U.)/2!K] 0_ M^>@V3'1QJ=;N28CE$B?,DI%Q33I%64$V&]H\$S;4BVCWR*>FFJQ6DK?'R EB MQU5>$*BTTH^)2$+WCXW)]A*108T33:O ;Z87L;XY$=$MH\[LI0%*=?5[,N%/ M,?HS)6]FOF?$9K%V( EV2^>^!+]J'@?)6P.U MC&O$46ECT$:B28O4\".PSF@:R2YO#2!J*(/VTMSR:S4,1'1F MMIA;$;TV),OEYM9?NW$0)[_-C#VO$1 B/: D\=F.;_H<(92[_MRCEXC,1\'S M;'[U \FI,K4NOF%O*LO M):>%+Z3]_"NTG?;^>R4AT(\$!1[R5G_%"?W" >GBP>3]I&BH_$^R0)EDK4Z: MN04R"2D[N^>_D3[]G7[]'SYA^-$ANG27:ZC"O MV.^GQY\.3C^='1Q\.C@[/3P^.SXJ=;G,G&FTV7TGMSV;XV"M?D+W6+04[)X<.D(UBQ MUSWH'ZMLIZ&&5JFL;7C)1"L0Z^5X(I/I:HFB9V*;?XW"[\DB#^3B&L':TL-' M35>X K=>#C.RSCXL'=\O!=C5X[51RA:T%N.5;ODWZNF)^6V)WGC$^WD -J$+?@Z M=^(GUEX:OW]VG)>,M,A/XN(OV^S-__S[2IS9_!H'I-N83&5AC 5W(Z0WO^?5 MU6KK#\3V(T%](3"C4EO!Z[&I(9G!ZQ)3<.4' TJH;94% YX& CS8 M5$0#A1Y-?L !B_X$%!L5-5.2)&H[%'X%, ;04D(^N!V,7D"DOC.>:.1]I)U M5VUAR/ V7(6IR\D%4]/4$^ZAW-2O3PE/>N-$E)*.5]3(IT5]>2N9H2$JUZ / MFQSEL5$*S57AB;3JAAX_G9Z='9\.GS+-I#:TBGQ%T5-8PY]&WI+M^5-DDE": M<.H+V\<1#3FY?K"]G(&& 1/S&TX6%VF;F^O@/FBO)B5+(TLX(3BC)RO8@'=@P5!L^/*%I>HB?I M&41-4ZKS?#T=]FC?&2IJW4*Z M:$K>Z1ZO)[;<%5UGNF!)OOC>6]LEP?%#$] J(U2%!+4:+(5'B@#<+F8?>DH2 M@MJ2K?.)WCG8NPDNG!><.#X'04YI^X#4$=34VAZ25;ZGV<0"Y%TY44!6,/'4 M==-ERBZQUB_GU#%$7M$^LC24V=3^ !)OJKI47O/9QPM%&4WM >"<#=0NC1LZ M#(*C17>G".KR=W;(WUMDXO8CNR4R% M64E24-O)NOYG:>LUH,TJV ZK0$J#"2N[@92?%TRQENW@RD0%YM"W.K72G(<5 M:MJ$=%-Q#2;+-(JVXO0KJ&$INCH3KXGLFAV@*IQU.:6M1E,^WYK(O-D!DO+) M5CD]I6V8*DZSO#2,4,0:5TW(=*2:D&G]E4DXGVQ\!_ 9QTU ME(A6?9I4XE<4D+[[T\"; M>DL"2'")7I$?OE!.BT$6 MUK$.8GUI01T_5<17-<'6 :DFH25NR;-D@2+5V;>N+!CX&\Z\RC*!&JU;[\MS M -LJ!08J?>57@5.1#=0,>K5\0IY'_5HB_,HF_U\=''P)XW@65'_C)_72;LBI&B C:;4D#44'M3K\A_+P@/9T2LCG/ MZ#8E>ZEH-F?"E*X*U8!OUIA-?#"H \G?"GOVJ,@+\UF(3 #7E_# MU1&O(!HH@[_J;R8:?: K#%CRA1^8MW 7U@&#I@8B AB5102%:LG-YRNBM_ YMEVN M@,^B;R[3B'#]CG6+A M4PP2Z ON@=E=%,YQ(@A=61< PX361UT2F;B)H(86Q&#R[O1PH%@KRI9C?F;D M$NTJ\/J^0C-V=SI8W!6%*TSS02?(]Q:K0&:H:S_\KIHS[J1A9 +YS*3XSC"" M$%::T8H]J*G54ZPI[0F9OUXQ@?'\[3<"T$VPRM\S=1/\FCT/(8Y1U&\(S.RO M#%#5)AB2&I3_^W##CPVC4@NW6J2R:%W>TZWCU/O?-,[>!GT,[Y$;!B[VT89$ MCZ$96]#%I\"0K(6UV)E>X/E;GCML;;&DF1P82J*-0Z4P&/!WCB1G^Z&FH4X/ M+D\,'5!EL:@WP;6#(W9(/)L72:A*Q[4O&_F*RZ=1.O5''IE26L?9O[3G2 ZY MIJX;H82=]],(]$LSC77>K\.H^DRC!+\EV@FXY8? M&=5428:>K>'8BBP!8DTJ.TKW.HLAK#"BW%A+G;I-F;I7NPT#JBQQ$EE!R9$? M^NKIU'>DMX2C9%HEJ_E+E/UO29]Y7+5DLZW> !C*M=A"MY065#Q*59:["+TX MV).EF!57 P.S(WSEO@BQ"TGK[R"(5%1B* MC>S_*K]6_"@E_5\_":Y#GJVJ>\H?%2UTNCLVM;ZEB?O(%Y9\-O"*V8N\EL1M M8]=@SC?J5VNM[XGMY9$A7720^QH0I?*G&=N[( @: D,Q\RX(NE)W>[9&>NT5=#Q!J<_=^*5&N[))N\M M]T=[6(114F06YGL:R^O:3Z?VZN@@?U^+BV3SQ%I[Z-\5 A5.^MD?$/F1_46! M:>J-[2?U6NH'U!&>NL):KUGVARPM==+!.T&]I"$F*J#_C[J:OSH^-=7W9!$0 M89?,SO0',EXV_U JF<5 ;F]8KGZX?NJQ%W5*M4N!P;@-'W16;7%I0L5.9K]2C\P/%,ARW"UH/I9+ H")7"JEOP\!E M+FKT%)8:J\"K,5S4(]H/XS1"$AO>MEEP3.ETQ6!<4X+ _)ZW+_3\=>TAFRZ(N?*'8C_)+]^3R-<8!BM?04AP?D_R;O)^MOD/\H?X:FHD@6:))_ M;.($WJ3TN>+GTDURF &O3IH&Z?@S84 M8,-> 9>2K=^&B?*D_+$Z5$LM38JF (_6(E6*\&*@1"!>^5ZN/]:JIMUB[\+* M1JNP#L01*P9HXS)"6[2AC]GE$F<)(:C71LC6%"C06%.?U@W?5:/L4&V[6-%B :!U5 R_:@K.R(+(2VDOE*AOU9==@7;;$=Q+HUP,.]Y,PP+Z=M MSF>$]6M/M(/%:W6R8_JVC1JY>2NP$%ZW50J!&\QF %K=Q*D)//#Y/'V*T9\I M:>+JE2I#;3P?'M1=M!4M35#1%.#!O"VX-&2#5[R?\)/-WDCG9UYY<$-8!LMF MU(B.5!W[?G;N0*=V4:YU87YT0/ZO^87YY._%O_X#]E@W>'?.J/7QT]'AYZ-/ M9R>?3PZ.>G+ZO47?2[V,PH#\,WM-/./ 6_;_RRR#;C/@#(8F5%4K8D0#<%\, MHC[. 6E;D0^\XO;AKB6IP/=Z9TNULI<$N[=2,_+'!R<'QV)?BJ9:FX=@S$N S9QX-FLRU2O\EL0VU9B,-;W:=#7210 M8>:K9[NF<8S8F6HI&_%7Y%"QO5EP3XU4E 6IW89!5/PG\Q.G]7,7<7<18+(9 MCI4\?';R[6&SJC\5=1KH9^I1MO6,NO7HB]3+3+?Z,&ED1,K=/,'6@^^9UBKC MM&Z5(?! &\B*8W]M/@ M%R":F]9.;%WK9X ;'YX?CY9I^E0U37SGMH'8)=N\W-;<%T*N;F+4FH%H1YKX MNQF1>]B7Y%6W%RTC<58U$G7.+P,Q#Q9XP9ARFLMS)SP*GFC;+ 3&)ICWF-$0 M&.YEV?2[$WF/Y"O3'YB7['VC##A %=1?Q4PN$ES(&#O/*3O+_)U2\_J*> MOZW+Y QF J^E#KP[WPENG26Z#)<.YN7#ZN)3X @DYT+-F-^58CI81O3!V7SV M_XJ63RCBD&VC##B6[ SQ*MGDBK&$)5?+%S]\0UG(1;9&%#*&6WYD3U,E=7 2 MW^M*E6Q^T WY)V]M4RT(CSM-%CB*8/ K\B&'JC 7J7, MWPP*E\LP8'V*ITD2X:/QX>GA\;'NT)9& M'; WEE:/?L5U/C@*-< ,O 8*70_#IH+"]>K8%$'@C5,M" ;2IJC4')*I"3D4 M.*6.-KSB8*#5!$:&*'2O%XXQ)D*0SA,S17^J=4W@%0,.I+)7@99\0X#QLQJ, MGRV'421?[SXA?!C+\PO/U4-8%@R@[>=.?3EU([YXV* M?T$?%"5SCGA]KE 3%N9:B%7GU:;RPETZ/2S"**'9#<[#* J_TQTYUSVY4A(, MMFWQJ7%W4)2VT^/2CQ"6T[\%SI+H O^%/+ISI%FQ-#>7I>G2G[10]-3IQT M,COUQ(DB'=.&-B7K5&$=,#PQL4+5EQ3NOF13%1=.%+U11Y@EG4"5UAZ;5<#@ MW!PKV4I#06!8CN&1FT<)%YI#5'1^-*JY_-+)\'-&\-:LH MTX4N.KVPU[[5V]'VYS8,W'8[H'4+5C',E/QME[+@=T ;2L[7TD3;JZCR M.$?5J^C]A'YNPKXW*7UPDGUQC[R.[ OOZ"&J YPQ@I&P=V"71C:X3_4&Z^A_ M-?I?C8X[UCKN##TMT/:B4I*NCE<<' 4 V'DM7<$]EJ\30VCO^17 L40+(C6$ M(5O^;@AQ]0-%+H[1781=),PIIE!S$!31RA'65&AKV?*"W 1Y]$A(DRS;%?>! M*THR]^Y$W U5V CY9^@3",F\_:;%EMJZ]A-&7>P.TMA X,P]CO^XCA J7LBY M=Q*].8G?@/WLT92] W"CQM"O$;L)]"FK(;NJR!1J'BXEN; M.M6*]E-&4>:<*J>PJ!)'28DFY+^V*4+^]/L]33E7H@YP[4#?^A4,R'(-UZ QN-VJ$GA?<8"7:?UFM/([/ %_=J$4"Y'I\ZB MASM$U/DA1K3\^Y 1E:>!,7ZFH-RY! MMQ?=2G?UVY7VA:]BLLCN_Y6T!BLNPPSCIIG?MY.L\O\56[L[H@Z<+CFDD]8; M>5?/NV:*VTW>_5VYQU:>0M?SB:UY"[SJ$UM\8Y)_9'2#[3R)9N5]>TZO:TJ" MLQ;J3J>JTAB:/7P@@0_[,W&H4Z%7VRX-?N@G!IQJH12\F#W9,9O?D3G5Q2^. M/XN* <0AC'Y# V:0(6&'_=[)]G)AZGDX$^ FF(?1DC6LNV@X45DTK+\T*7UJ M7#J,27JU1_28D1=B2,F8D7>,"-F;B) Q(^^8D=<>&$%GY.W")-\C#V4O<]XA M,EEXRC-N744PM.AJ!E86&F[4CE@@C=FYOBH8"K0$4)<)D&?Q71!G%HC]&15K M#XP^6NZ-;52P%QQZ_!ZVX-"J]OYR2*P"F.L7"_UDVZ\^1C?7T\5;CJ2;FS%:Z^UPEZ=OQK MQ'T0?/7[AEQG1Q_/3@Z&BYY8*H&C?.]CL2QV.8+](:%IH+<46!' W)H32\IAY3:"YD_HZ8#=OR K0#8O?04BVZ7A!7-+.*IA'A MUK:"3"9DSAGT"?I\4G+PR_X9%P(>*C%!4-]B+NA*G;/A\\XGD_S,:,W=;%MZ M$WP-@V0AGT/$]:U V(S4.<)GMLT8:WI?HMB-,)-+8!EJRUO!DV92%F<]!S G M@K4@N4E#7LDMD+%>- ^H5+<8?$VA"RX ]7,5RO6P('J-;^(X15YC1FPTLE^\ MD(M>L /@<>!#$KI_9'V_3&F<;W9=G\FT%GLV_RW "??45ZL1J]AA0/2"'4:/ M$WF!*:+NW@1>ZK(< (]AN>NE)?$##0=G$>-U"TQSK5O!D5WHI" /P-/-3#B/ M(Q?5:1XRS+$JRO6M((L9J0LZF$Q.N=/(Q^42)TQOTV#]YJ=+V*\7[WAZ<%B- M=URU/7$";[+1^E!"'$4*4HU\U&RCG^#I.-[HF.@QL/K"8(Q"*^@V8Z.5Y80; M=4*%\=>7 @6P"J*W]@;+< M< $F:R$E@*OE]@-@1;E[#X+@ 8Q=NM]0@;BVY%Z K"YY[X^8<&#^Z@0!#A10 MKBT(!F1=.+: 5!<.JCW^YL0+LA9-PN"W +,S!,XS1)+2MB"J*6'O5GB7H6@0 MK'&C_9-<) 4/;#/[I0ZCT/J$1Z[A&C0@F\L^'EL :"2J5238\@@-@XE'!B( M4CE@SG#MSXB_2%Y&X%< [>1,T5-.7>3*[/EHG;&>O483MT_4QRA?#5( ['J M%K7\TO"1%H.UM;;5%-3&!/[9\4K@W5/@?/&-RBA+V:G:?4_]D6(.$9H M]H(BAZJ0*8-H GUW_!I[H5C+1I+H"]SI5*%-%\7C2MXD45?.'ICU1+3Q+2&A MX]4M^LY^:N31N*IL#UT,R-W!L[B]SR7W!$&B_0693"_1*_+#%SJ,Q(L,81W[ M&*,O;J<1F*9FD:L?KI_&^!5MV]"; ">819O732H*U>RA0"N)!5&4<+:=7.&F M09 Z_E<'!PEB&2-T^5#7P+XP0UEV06REGBM4;+DTHC]O#* MH/R"J,Z>8S.GWA('F/J!)F3PT+0FX@4'M[Q]N.N)*@K0;&\_5K>'NWH&*/=0 MGZVUV\0)?OO1GY7C._DU9$UWXO[.F6!9'Q[#+.T262VP%!Z98TZ]$[MB+<:' MCY^.#C\??3XX.#PZ/>SI&;!M$.^<-X$K.Z)]7H9O[?4 MV8R:+^51K/#>9S&*)ZO6@0>RT(?>B%U=;L4V7:11Q%:(U"O/S?]#',[2H*42 M/S^=G1X>GWX"D;A'%.124Q*,53"-1-52J$JO$"1A!FF+_;%4=5WC_M,F> 5\ M2G 0;B"C,];HQP,;Q)9SX!>)$P^G-!B@FUO1)A)R[^_[!]),\G!X4.H>66B) M::.#SCXFN>V".DTSG7;CW ."3/N0X;(+*C7,<0G$1=30*?LR)!KXBT&8/?5! MCUBH9;Z+T!*G/$1C MS#:0N$].7.?L/)HER%ZX3>JE4P MHUT+ONHP[T(-G9[1'G7OE,+-0CGU/)S)*^B M5'4R=!JYF2:K]V4V]W355-B=94UJ WP6UC5-DP7ITE_KLRL^X-LUK 1:2MUUU8](SUFOF[!!',9KZUZH(.C%F80 M6U*JO@WK&:4A-JR'/,8$#;U3REQN!B#/@HRY&6#R2"$M0]VC(3UO=H1S^%K> MV;R4G^L!N:1H@ILMB*2-VL.9#O0@>")DT+9H/Q/HM;)&K7/G=?0(B2D'T6R8 MW",W? [HUI*ZT9O/B)SUWZ;.JNW31$,MUDG^%>E%G'YJ$ M\\GWHL1 G*?7XE&2+*D7%D,@3Y1S$<9)S*P4[:"7\XF7CLE4HZ/S=<.L:4; M-.^* ..)3M#O$HV MN6(L8C+YT%9_OS+0;H+L MF.G7*(RY\Y?Y+XT,UM +K D4!GLAV=[#_:.NHEH,A;=DUO#L+A)\7"?*FKRARGE$A$7-!$.XV%.J! M(4/+'4A343N=&:$>F*J;9I%>NY\O15\'0]QV_.MT8M76WP[V.I^ C@GN<6;M M4KN+<6&N!_L[-CK6X;B/LF>VZ'7/9<-TL8O=V5!GBT)WO4X86IT8YXSNU#C$ M7>8]HC>VQ"I0ST&J[M3QO^ Y^A=R(O$=5X-VP)#/Z"ZTN>B&[*H/) GQM8.C M+,HT>$5Q]MS659"P.)S'A9-<.+Z;4G>T6Y1,XQ@E&^D-UI76KXG?ADGVG#@9 MCKS E8Z_"H:S9JE7-:!]Z+'3R^*>%A7M]/@%_YEBCV6I+ZLTA[G+D:#TY7$T M=*S+3K>>/5V"M-/EVI[_./*"&,\M#)-)MB0_^5_9ZEM:%U:#OQ+/J"G2?L,\BVF$)9(1M# ML'J[?P-O /JW,OE6R\/F]=/OZ[ T6>!@I]\$,W+:9T/9N9ILG([,.F1NF0KV M([57*S.V$W=9:2_@#8*=<[EKU]QF&'1Z"G:Z^^#[E;2S>?G:L6$D_I%B)#[] MZN25?I8&XX?K#X^!^6-@_AB8#R3*>PS,'P/SQ\#\,3!_#,QONS@> _/'%]DD M;X"-+[)U!,OX(MOZ138[\+\:4,^!3SG3C M>M!GI(?4XQR6-[B9>Y'.(][@X?PD/[I^VMX@U%ROQO059C=!WB.*ECS7DNX^ M:!D/=Z>C,5)-487_#'W2C$_DNG# MR/^G\N:BK@?$L:('1/$OS#XXF8?1),X_.;H^C*X/H^O#Z/HPNCZ,K@^CZX/5 MK@]7RQ<_?$.HE!U1Z ;!+0^./3VZ1.@IR1(FC9=(%KU;4/C,"U*Z;!6!BZ'J M=E99JDZOA[1?Z(01XP(I<7:/88XJ]#%X@ +MS8+389)W?+.@9P*#>+)@H-&% MD"QOG^DSX9K>7>3$[,ORCB\6M&+? !XLT#:+XX,%XX,%L.;%0:6@AI.D99@9 MJ,<'"YHF(!@?+ R-L8'"\;98GRP8'RPH._98GRP8#@#9'RP8'RP8#@/%O2\ MMQS?'MBU[8.3:7=\>\",'L>W!VP8#>/; V,>]G$\F,O#;N>S!+ R:\O&$*S> M[M_ &X#^8=V8PC@"'?.PPXN0'/.PCWG8H0V",0^[]7G8L[_H1AZ?-,N]GO]] MC#D>8X['F.,QYGB,.1YCCL>88YLC1<>8XS'F>$S)/J9DAY ,>DS)/J9DMP'$ M,27[F))]C[-IC/E=^?D4.W1?EWX0+A=W=H733$=C"OHQ!?V8@I[+ZU<4/86B M>Y-!6^PQ"?T@;/B8A'Y,0K\W=!^3T(])Z/>&['N;A)[='E2TJ.L(\E'1$81] M[3U;64[*WQM]049?D-$79/?W.(]T",_F-X%'[5[J^)QKMMIRX #5OG)3%PLX M;-]PLF"TI79V@5\>0Q8 \U;KWM&@!3!0ZZ$F0;N!S+W?&'&BX"^(!*F?Y'-[ MX1H0UUX/R2N41#\\./A\>'9R @CN!K"MB=!0^-YQ[]_?KU\F=.+O5\&W>_>* M/?;W@T$@.1=V[N\'R,SPDJQ4]HW\F857%AP3=H;JUNRCI:#>&0')NP$(;XQ[ M-U3@WH.+ ZTY""X'Q'"J3B6Z0[_G-IMN0I6- F;6,'\/$\U;W)0_H4HS]3TL35*UT8:MV/$/D/ MM^]'U@U.$&MQ*#<@VYJ0I8O@%N]E);+9&^'=14U1>(-8 L;&PD-5(+C+CFT1 MQ.=8G-+00>0#(\=4X81K&+"*CZEXY<%#JWGJI"6G+0<%FT(+PT1KRPZ!!$IG M1?I26D*!>P(14>]B&GB79''DAR_LX&U]+E>D+GL,R5IS'D;+ZS":)0O2[?,W MR:1@I&WP%-.80KI3"-PKE18R2R,!JHU/C9:0LJ27CG8BZ# /F R6\HJJ4 P>_ M.G15V-6DLP3RW&U;"/=&&:N@EDL&\XA+/\0;/24W09Q$*3M!Y$_?U8+@ &\Q M9RM*EX-^"F^BWA1 &OO$*PX.4T5@9(@.]$R+"$$ZGT:(_/29?W)54PPXD'I' M4JKR]0YC)TY!7V0Q1)SBX"A@SO5/+&-.@T\5&AB]OMZZ>UL?O);\Q.D?:UWI MM1N!#J88$KA[MMPY;W1$W 073KQH29J-MO:5.W(E=!JTTP.% M6)XOMD%]#,_131RGKPK?X3R=YI7 M4ILS)L\-?PMP4FN+>,5LX8>6?%U< G!&_A?T3"->TR!&_DUP]<-=T&NNP@.P M;I"+:]B"5U-1!<=" Q^Z;+*[H/'248+)6BK[9TP75S2U_TW@1HB&9DJO ^1M MV$(B<\)S]['F+4+AW%)(SES7IS!O&=8V[!+%+L1?A$DN.&6MPY?+4&+LZL# M <+'$!#.IR[DE2YAEM2WE/C"AV7$R61:BSV;T_TOWSE0IQ';"&) ^H(@1F-Q M>&%VHN[>!%[J9OD"PW+72WN@=5!9W5["7.NVT&07:BGXT[V[O[:!R83S.')1 MXTJ?,PFXIQ#*]6WABQG!"T8H'4CN*A/9 TH2'VT/!=I9W5SEQW)1OZVZ,5GU@[W]LNK)))Q/5GU9OP\SICT;TYZ-:<^T MX!O3GHUIS\:T9U9[.(YISP:?]FS,K=%-;HWN#WS&W!IC;@W9B<]Y@.G;'T0" MC.+\P<#'D/R5'Y,@J0(*:Z/Y,YH(WCON9J;U+V2W^\Q HU&VJ2@:O*XH&$X8 M6+0KR[>S'$JMT10NU^L+@T-4&18YHI#-N*%5.COE\M:"B]?I]:7!4T!OF:XA MI"4L^)5HAZ83Q,$S"EPRIYV3"9$&XPFLN[ ..$:T,//Z@NXLK5)+H',YA$9? M4 ,X7#+@L%0"XA: M_!2%ZWVL>*P>2S(&+O42)O&LB-$O33H\/W^H&KF83T($4H[$UHDW(/HBD M$76"9N[CM8+R\D4T:,9ZOC21?Q!9(NJ$O0_?'#]YR]]RG[VBZ-]HX<0*/[(ZO$;I(XX3L<*-9H,P?;@/6$T9/ M\DY306B'E;5FR./WL!U#2 -[RA">Y(*3A!X88OR^466ZEE]$JK1B"Z],BM]I M.HN3?L@U==THI1=WSA/V61C,11I1+*:!=QL&;O8?'$ZI5;:-2BVD%F2NT&$0 M65<]A2(.[2KL9"O I$U\R;%*?$DEC&2,(NG;7WV,(AEZN,$813)&D8Q1)/9> M=HQ1)(./(M'W6:(+(H2D[L:5ZE M9W/Z).TK]E+'YWB(%?'L.K("&] MXGJB:;8 !G ]U"1H-Y"Y]Q'/>^((1\@EA2]1@.,+PLAZGV)A6=@@-P!KZ[Y( M2V[H0'_#OH^=Y7U(0(D3QZO?MZE4V1?8=<3O_5E"#OK3"/^WDWQ',1_MK2*V MHZLB;@>N(F:>#L'N'W=.@-W4=04QX#7%;$=55>0.7#S&A\"!+-";"PHW.'!\ M"+P.X0$]!,ZQY#/6$1IA4=PN\\TYKRPX:)N\_*PO8>^0CB$C@$)&JJYXO>3* MC>/4"5RRJ&'Y@DM$O@Z+J+AX%EWX#N8BK-4&=-C%V%6A;R^\(;,@]7WJX;@^ M3U%?O&S#_B8ZFJ\K;QMA] 0UM#T'XQBW'BZK-[JU/>).5#SBB@]1A[CUIT9/ MN-$3;O2$&SWA1D^XT1-N](0;/>'L\813R\I+G3XX[@^KW\!#J^CR(!8(6+ID MVM?:4;CU*QAPY!JN0( MR0*?=%ZR^JTI"09@ RM?5?'@YB0N22!<[5;*@8-1%0LABI!7MIP+I[H3(_Z5 M$[\T9$#5+YPTY>L=U/'*"="54]5-H)^;@3!*'E&T/ ^C*/R.@V%*,T$%23P MZOG\9I/II=?(U\(Q)QK18D*IOHT$:"ZXH7QVFD9[8.8D^0W%LY*Q*OH9!LO!7N7G)CHUVSO&O$9\5ZA5M(41+B7,NG'7$ M!5,Y:M=2%*+ELE[2@*_ZLPQ9':L8T$C8XO#JH-L,UK4^K/_XD &&,V?.__S_ M4$L! A0#% @ LHM/3T+*%)OEL 7'P, !$ ( ! M '%B:6\M,C Q.3 X,S$N>&UL4$L! A0#% @ LHM/3Y:*VZ6&#@ YY< M !$ ( !%+$ '%B:6\M,C Q.3 X,S$N>'-D4$L! A0#% M @ LHM/3[&91NM/" OF@ !4 ( !R;\ '%B:6\M,C Q M.3 X,S%?8V%L+GAM;%!+ 0(4 Q0 ( +*+3T^U:$^;I2( *V@ @ 5 M " 4O( !Q8FEO+3(P,3DP.#,Q7V1E9BYX;6Q02P$"% ,4 M" "RBT]/*?HN*A9) !CP@0 %0 @ $CZP <6)I;RTR,#$Y M,#@S,5]L86(N>&UL4$L! A0#% @ LHM/3]&MN*77-0 $%@$ !4 M ( !;#0! '%B:6\M,C Q.3 X,S%?<')E+GAM;%!+!08 !@ & + (H! !V:@$ ! end XML 14 R29.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Apr. 09, 2019

Mar. 09, 2019

Dec. 31, 2016

Oct. 29, 2015

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Nov. 30, 2018

Commitments and Contingencies

Research and development expenses $ 786,600 $ 989,140 $ 2,672,715 $ 2,624,753

Rent expense $ 7,500 $ 7,500 $ 22,500 $ 23,000

Legal agreement

Commitments and Contingencies

Term of option to acquire license (in years) 3 years

Lease agreement

Commitments and Contingencies

Lease cost per annum $ 30,000

Renewal term (in years) 3 years

Mannin agreement

Commitments and Contingencies

License agreement (in years) 4 years

Shares issued in exchange for extension of option period 100,000

Research and development expenses $ 1,900,000 $ 1,700,000

Washington university

Commitments and Contingencies

Initial fee $ 88,000

Washington university | Minimum

Commitments and Contingencies

Annual maintenance fees 15,000

Washington university | Maximum

Commitments and Contingencies

Annual maintenance fees $ 75,000

X

- Definition
The amount of annual maintenance fees to be payable in the agreement.
+ References
No definition available.
+ Details

Name: qbio_ExclusiveLicenseAgreementAnnualMaintenanceFee

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of initial fee to be payable in the agreement.
+ References
No definition available.
+ Details

Name: qbio_ExclusiveLicenseAgreementInitialFee

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The term of the Exclusive License agreement.
+ References
No definition available.
+ Details

Name: qbio_LicenseAgreementTerm

Namespace Prefix: qbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The term of option to acquire license.
+ References
No definition available.
+ Details

Name: qbio_OptionToAcquireLicenseTerm

Namespace Prefix: qbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_AdministrativeFeesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_LegalAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_LeaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_ManninAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_WashingtonUniversityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes (Details) - USD ($)

Aug. 31, 2019

Aug. 28, 2019

Nov. 30, 2018

Notes and Loans Payable, Current [Abstract]

Debt discount $ (65,000)

Carrying value 485,000

Total carrying value of convertible notes payable, current 485,000

Notes and Loans, Noncurrent [Abstract]

Fair value of bifurcated contingent put option 658,000 $ 262,000

Debt discount (481,291) (1,388,728)

Total long-term carrying value of convertible notes 3,976,709 2,873,272

2019 Debenture [Member]

Notes and Loans Payable, Current [Abstract]

Principal value 550,000 $ 550,000

Carrying value 485,000

2018 Debenture [Member]

Notes and Loans, Noncurrent [Abstract]

Principal value 3,800,000 4,000,000.00

Carrying value $ 3,976,709 $ 2,873,272

X

- Definition
Amount of fair value of bifurcated contingent put option.
+ References
No definition available.
+ Details

Name: qbio_FairValueOfBifurcatedContingentPutOptionOfConvertibleNotes

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleLongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermNotesAndLoansAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesAndLoansPayableCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=qbio_Debenture2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=qbio_Debenture2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions (Tables)
9 Months Ended

Aug. 31, 2019

Related Party Transactions

Related party transactions

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Consulting and legal expenses

$

78,000

$

60,000

$

270,000

$

180,000

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Aug. 31, 2019

Summary of Significant Accounting Policies

Recent accounting pronouncements

Recent accounting pronouncements

On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

Recent adopted pronouncements

Recent adopted pronouncements

In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016‑10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions
9 Months Ended

Aug. 31, 2019

Related Party Transactions

Related Party Transactions

Note 7 - Related Party Transactions

The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Consulting and legal expenses

$

78,000

$

60,000

$

270,000

$

180,000

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes (Details) - old - USD ($)

Aug. 31, 2019

Nov. 30, 2018

Basis of Presentation and Going Concern

Total long-term carrying value of convertible notes $ 3,976,709 $ 2,873,272

X

- References
No definition available.
+ Details

Name: qbio_NotesToFinancialStatementsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R34.htm IDEA: XBRL DOCUMENT v3.19.3

Stockholders' Equity Deficit (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Nov. 30, 2018

Common stock, par value $ 0.001 $ 0.001 $ 0.001 $ 0.001

Common stock, shares authorized 250,000,000 250,000,000 250,000,000 250,000,000

Preferred stock, par value $ 0.001 $ 0.001 $ 0.001 $ 0.001

Preferred stock, shares authorized 100,000,000 100,000,000 100,000,000 100,000,000

Stock issued for services $ 341,127 $ 1,181,450 $ 1,349,608 $ 1,953,317

Shares issued for conversion 334,556

Conversion of note $ 293,726 $ 293,726

Shares recognized as conversion of debt 146,863

Conversion price $ 2.00 $ 2.00 $ 2.00

Shares recognized loss on conversion of convertible debt 187,693

Stock issued during period shares contingent payment of convertible note 30,894

Stock issued during period value contingent payment of convertible note $ 31,000

General and Administrative Expense

Stock issued for services (in shares) 526,541

Stock issued for services $ 886,000

X

- Definition
The amount represents the shares recognized loss on conversion of convertible debt.
+ References
No definition available.
+ Details

Name: qbio_SharesRecognizedLossOnConversionOfConvertibleDebt

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of stock issued during period shares contingent payment of convertible note.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodSharesContingentPaymentOfConvertibleNote

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount represents stock issued during period value contingent payment of convertible note.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodValueContingentPaymentOfConvertibleNote

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R38.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options - Fair value of options (Details) - Options - $ / shares
9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Exercise price $ 1.53

Expected term (years) 5 years 5 years

Volatility 98.75%

Risk-free rate 2.03%

Dividend yield 0.00% 0.00%

Minimum

Exercise price $ 3.00

Volatility 128.00%

Risk-free rate 2.52%

Maximum

Exercise price $ 3.61

Volatility 130.00%

Risk-free rate 2.71%

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 24 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent events
9 Months Ended

Aug. 31, 2019

Subsequent events

Subsequent events

Note 10 – Subsequent events

Research Collaboration

On September 5, 2019, the Company entered into a research collaboration and master services agreement (the “Agreement”) with Chemveda Life Sciences India Private Limited (“Chemveda”), a contract research and manufacturing services company. The Company and Chemveda have been engaged in a collaborative joint research program since February 2017. Under the Agreement, the Company will continue the collaborative joint research program with Chemveda regarding the synthesis of Uttroside B, isolated from the leaves of Solanum nigrum, and any of its analogues for use in the clinical trials and treatment of Hepatocellular Carcinomas and any other targets and therapeutic areas (the “Program”). The term of the Agreement is for up to two years from execution.

Under the Agreement and depending upon reaching certain milestones, the Company have agreed to pay Chemveda total compensation of up to $660,000, $360,000 of which will be payable in cash and $300,000 of which will be payable in stock. To date, the Company have paid Chemveda $210,000 in cash compensation under the Agreement and have made no compensation payments in stock. The Company have also agreed to pay royalties (capped at a total amount) to Chemveda based on net sales of any and all drug product(s) resulting from the collaboration, being developed by us.

Subject to the terms of the Agreement, Chemveda shall have the first right of refusal and, if exercised, the exclusive right to manufacture any products developed as a result of the Program for precommercial and commercial production.

Securities Purchase Agreements

In September 2019, the Company executed securities purchase agreements with various investors to purchase units, each unit consisting of (i) one share of common stock and (ii) one and one half (1.5) warrants to purchase a share of common stock, at $0.86, which is 110% of the closing price of the Company’s common stock as listed on OTCQB on September 18, 2019, raising approximately $208,000 in cash.

In October 2019, the Company issued 148,261 units (with each unit consisting of one share of common stock and 1.5 warrants to purchase a share of common stock) to the Company’s legal counsel in exchange for $91,922 of services provided. The Company’s Chief Legal Officer and a Director is the Managing Partner at the law firm where these services were provided.

Amendment to 2018 Debentures

On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020.

On September 23 and October 7, 2019, holders of the 2018 Debentures converted an aggregate of $531,992 of principal and accrued interest outstanding under the revised conversion terms and received an aggregate of 1,163,204 shares of the Company’s common stock. Had the holders converted $531,992 of principal and accrued interest under the previously existing conversion terms, the holders would have received 265,996 shares of the Company’s common stock. The additional 897,208 shares received upon conversion had an aggregate fair value of $589,223.

Settlement Agreement

As described in Note 6, above, the Company commenced litigation against BNI and parties related to BNI in the Supreme Court of New York, New York County o December 28, 2018. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. Pursuant to the terms of the settlement agreement, the Company settled its dispute with BNI and all parties to the litigation dismissed their claims in exchange for entering into a Second Amendment to the License Agreement (entered into on September 23, 2019) pursuant to which:

·

BNI agreed to immediately transfer and/or assign to the Company all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89;

·

The Company agreed to issue BNI 50,000 shares of its common stock upon the entry into the settlement agreement and 100,000 shares of its common stock upon the approval of the U.S. Food and Drug Administration (“FDA”) approval of BNI’s Prior Approval Supplements filing

·

The Company agreed to make a cash payment to BNI of $25,000

·

The Company agreed to an on-going royalty payment of 3% on all gross profits derived by the Company from the sale of Strontium-Chloride 89 and MetastronTM; and

·

The Company agreed to assume fees and expenses related to (i) all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), (ii) all outstanding fees owed by BNI to the FDA relating to Strontium-Chloride 89 (approximately $208,000) and (iii) related fees for the development and approval of Strontium-Chloride 89 following the date of the settlement agreement.

The agreement to (i) make a cash payment of $25,000 to BNI, (ii) pay all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), and (iii) issue to BNI 50,000 shares of the Company’s common stock are recognizable subsequent events with an aggregate fair value of approximately $125,000. All other portions of the settlement agreement are not recognizable subsequent events. As of August 31, 2019, the Company had recognized $125,000 in accrued expenses related to this matter. The agreement to assume fees owed by BNI to the FDA relating to Strontium-Chloride 89 is not a recognizable subsequent event as of August 31, 2019, as the fee is contingent as of the settlement agreement date and payment of the fee by the Company is not probable as of the settlement agreement date.

Repricing of Existing Warrants

On September 24, 2019, the Company reduced the exercise price of 950,000 options and warrants previously issued to Denis Corin for services as a director and for services as an officer to $1.25 per share and reduced the exercise price of 1,250,000 options and warrants previously issued to William Rosenstadt for services as a director and for services as an offer to $1.25 per share. On September 24, 2019, the Company reduced the exercise price of 360,000 options and warrants previously issued to Ari Jatwes for services as a consultant to $1.25 per share and reduced the exercise price of 50,000 warrants previously issued to Rick Panicucci for services as a director to $1.25 per share.

Distribution Agreement

On October 3, 2019, the Company entered into an exclusive distribution agreement for Strontium-89/Metastron™ with Jubilant Radiopharma for the U.S. market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.

Issuance of Debentures

On October 11, 2019, the Company entered into a securities purchase agreement with an accredited investor to place convertible debentures with a maturity date of eighteen months after the issuance thereof in the aggregate principal amount of up to $750,000 (the “Transaction”), provided that in case of an event of default, the debentures may become at the holder’s election immediately due and payable. The initial closing of the Transaction occurred on October 11, 2019 when the Company issued a debenture for $500,000. The second closing is scheduled for within thirty days of October 11, 2109 provided that the holder has converted a minimum of $250,000 of a different convertible debenture previously issued to the holder. The debentures bear interest at the rate of 5.5% per annum. In addition, the Company must pay to the holder a fee equal to 2.5% of the amount of the debentures.

The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days’ notice.

Any time after the six-month anniversary of the issuance of a debenture that the daily VWAP is less than $0.50 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date as that term is defined in the Transaction documents, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies
9 Months Ended

Aug. 31, 2019

Commitments and Contingencies

Commitments and Contingencies

Note 6 - Commitments and Contingencies

Legal

Periodically, the Company reviews the status of significant matters, if any exist, and assesses our potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

BNI matter

On December 28, 2018, the Company commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County (removed to federal court in February 2019). The litigation stems from a license agreement that the Company entered into with BNI in 2016 and amended from time to time. Under the agreement with BNI, the Company were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy.

The Company believes that it has fulfilled the obligations under the agreement to exercise an option to acquire the BNI IP and has notified BNI of such exercise, but BNI has not transferred the BNI IP to the Company. As a result, the Company has commenced litigation to, among other actions, obtain all of the BNI IP. The Company also seeks judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. See Note 10 - Subsequent Events, below.

Advisory Agreements

The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received.

Lease Agreement

In December 2016, the Subsidiary entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years.

Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows:

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Rent expense

$

7,500

$

7,500

$

22,500

$

23,000

License Agreement

Mannin

On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License.

On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.

During the nine months ended August 31, 2019 and 2018, the Company incurred approximately $1.9 million and $1.7 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License.

Washington University

On March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones:

·

The first commercial sale of a companion diagnostic product;

·

Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent;

·

PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and

·

The first commercial sale of a diagnostic product.

In additional to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options - Stock-based Compensation (Details) - USD ($)
3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Share-based Compensation $ 1,349,608 $ 1,953,317

Unrecognized stock-based compensation $ 136,000 $ 136,000

Unrecognized Compensation, Amortization Period 5 months

Consultants and employees | Warrants and options

Share-based Compensation $ 183,000 $ 946,000 $ 463,000 $ 1,500,000

X

- Definition
Amortization period for the stock-based compensation.
+ References
No definition available.
+ Details

Name: qbio_UnrecognizedCompensationAmortizationPeriod

Namespace Prefix: qbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=qbio_ConsultantsAndEmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=qbio_WarrantsAndOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

Debt Instrument [Line Items]

Conversion price $ 2.00 $ 2.00 $ 2.00

Amortization of the debt discount $ 389,000 $ 907,000

Shares issued for conversion 334,556

Convertible notes value $ 293,726 293,726

Interest Expense, Debt $ 55,000 $ 166,000

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 28 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options - Summary of warrants (Details) - Warrants - $ / shares
9 Months Ended 12 Months Ended

Aug. 31, 2019

Nov. 30, 2018

Warrants

Outstanding at November 30, 2018 4,984,058

Outstanding at August 31, 2019 4,984,058 4,984,058

Exercisable at August 31, 2019 4,921,558

Weighted Average Exercise Price

Outstanding at November 30, 2018 $ 3.48

Outstanding at August 31, 2019 3.48 $ 3.48

Exercisable at August 31, 2019 $ 3.49

Weighted Average Remaining Contractual Life (years)

Outstanding at November 30, 2018 3 years 6 months 4 days

Issued 0 years

Expired 0 years

Outstanding at August 31, 2019 2 years 9 months 4 days

Exercisable at August 31, 2019 2 years 9 months

Intrinsic Value

Outstanding at November 30, 2018 $ 250,000

X

- References
No definition available.
+ Details

Name: qbio_WarrantsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_WeightedAverageExercisePriceAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_WeightedAverageRemainingContractualLifeYearsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average life of securitized assets for initial fair value measurement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719
+ Details

Name: us-gaap_FairValueAssumptionDateOfSecuritizationOrAssetBackedFinancingArrangementTransferorsContinuingInvolvementServicingAssetsOrLiabilitiesWeightedAverageLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining period of expected liquidation by investee of underlying asset of investment measured at net asset value per share or unit. In 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentRemainingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining period of a redemption restriction related to investments for which net asset value per share is calculated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period when redemption restriction has been in effect for investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPeriodInEffect1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) - BNI and Parties Related To BNI [Member] - USD ($)

Sep. 23, 2019

Aug. 31, 2019

Subsequent Event [Line Items]

Accrued expenses $ 125,000

Subsequent Event | Positive Outcome of Litigation [Member]

Subsequent Event [Line Items]

Number of shares awarded 100,000

Subsequent Event | Settled Litigation [Member] | Positive Outcome of Litigation [Member]

Subsequent Event [Line Items]

Number of shares awarded 50,000

Cash Payment Agreed $ 25,000

Royalty Payment (as a percent) 3.00%

Total amount agreed to settle $ 125,000

Subsequent Event | Settled Litigation [Member] | Positive Outcome of Litigation [Member] | Strontium-Chloride 89 [Member]

Subsequent Event [Line Items]

Outstanding fee settlement Owned by BNI to IsoTherapeutics 67,000

Outstanding fee settlement Owned by BNI to FDA $ 208,000

X

- Definition
Amount awarded from other party in judgment or settlement of litigation.
+ References
No definition available.
+ Details

Name: qbio_LitigationSettlementAmountAwardedFromOtherPartyCash

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of fee and expenses agreed to settle as per the settlement agreement.
+ References
No definition available.
+ Details

Name: qbio_LitigationSettlementOutstandingFeeCustomerOne

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of fee and expenses agreed to settle as per the settlement agreement.
+ References
No definition available.
+ Details

Name: qbio_LitigationSettlementOutstandingFeeCustomerTwo

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of royalty agreed to be paid under settlement agreement.
+ References
No definition available.
+ Details

Name: qbio_LitigationSettlementRoyaltyPaymentOverGrossProfitsPercentage

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares awarded from other party.
+ References
No definition available.
+ Details

Name: qbio_LitigationSettlementSharesAwardedFromOtherParty

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount awarded from other party in judgment or settlement of litigation.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementAmountAwardedFromOtherParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_CounterpartyNameAxis=qbio_BniAndPartiesRelatedToBniMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GainContingenciesByNatureAxis=us-gaap_PositiveOutcomeOfLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=qbio_StrontiumChloride89Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R2.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Balance Sheets - USD ($)

Aug. 31, 2019

Nov. 30, 2018

Current assets:

Cash $ 301,673 $ 2,684,413

Prepaid expenses 28,546 12,500

Total current assets 330,219 2,696,913

Intangible assets, net 462,500 500,000

Total Assets 792,719 3,196,913

Current liabilities:

Accounts payable 751,402 172,628

Accrued expenses 1,302,527 219,602

Accrued expenses - related party 25,000 7,500

Accrued interest payable 101,626 29,639

Investor advances 193,250

Convertible note payable, net 485,000

Total current liabilities 2,858,805 429,369

Long-term liabilities:

Convertible notes payable, net 3,976,709 2,873,272

Total long term liabilities 3,976,709 2,873,272

Total Liabilities 6,835,514 3,302,641

Commitments and Contingencies (Note 6)

Stockholders' Deficit:

Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2019 and November 30, 2018

Common stock, $0.001 par value; 250,000,000 shares authorized; 15,182,227 and 14,290,236 shares issued and outstanding as of August 31, 2019 and November 30, 2018, respectively 15,182 14,290

Additional paid-in capital 33,866,087 31,994,129

Accumulated deficit (39,924,064) (32,114,147)

Total Stockholders' Deficit (6,042,795) (105,728)

Total Liabilities and Stockholders' Deficit $ 792,719 $ 3,196,913

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermDebtAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R6.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Cash flows from operating activities:

Net loss $ (7,809,917) $ (7,172,514)

Adjustments to reconcile net loss to net cash used in operating activities

Share based compensation for services 1,349,608 1,953,317

Change in fair value of embedded conversion option 396,000

Accretion of debt discount 907,437

Amortization expense 37,500

Loss on induced conversion of debt 197,078

Non-cash interest expense 32,438

Changes in operating assets and liabilities:

Prepaid expenses (16,046)

Accounts payable and accrued expenses 1,646,699 236,015

Accrued expenses - related party 17,500

Accrued interest payable 165,713

Net cash used in operating activities (3,075,990) (4,983,182)

Cash flows from financing activities:

Proceeds from investor advances 193,250

Proceeds received from issuance of short-term convertible note, net of original issuance discount and lender's fees 500,000

Proceeds received for issuance of common stock and warrants, net of offering costs 4,945,251

Net cash provided by financing activities 693,250 4,945,251

Net decrease in cash (2,382,740) (37,931)

Cash at beginning of period 2,684,413 824,783

Cash at end of period 301,673 786,852

Supplemental disclosures:

Cash paid for interest 31,524

Cash paid for income taxes

Non-cash financing activities:

Issuance of common stock to partially convert notes payable 293,726

Accrued debt issuance costs $ 15,000

X

- Definition
Amount of noncash expense included in interest expense to accretion of debt discount.
+ References
No definition available.
+ Details

Name: qbio_AccretionOfDebtDiscount

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_ChangeInFairValueOfEmbeddedConversionOptions

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_LongtermLiabilities

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the information pertaining to the Loss on induced conversion of debt
+ References
No definition available.
+ Details

Name: qbio_LossOnInducedConversionOfDebt

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the information pertaining to the Non-cash interest expense.
+ References
No definition available.
+ Details

Name: qbio_NonCashInterestExpense

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the information pertaining to the Proceeds From Investor Advances.
+ References
No definition available.
+ Details

Name: qbio_ProceedsFromInvestorAdvances

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Loss per share (Details) - shares
9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Loss per share

Warrants 4,984,000 4,955,058

Convertible Notes 2,171,000

Stock Options 1,200,000 900,000

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of outstanding written put options using the reverse treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e2366-109256
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToWrittenPutOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies (Tables)
9 Months Ended

Aug. 31, 2019

Commitments and Contingencies

Commitments and contingencies

Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows:

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Rent expense

$

7,500

$

7,500

$

22,500

$

23,000

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Aug. 28, 2019

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Debt Instruments [Line Items]

Debt Instrument, Convertible, Conversion Price $ 2.00 $ 2.00 $ 2.00

Debt Conversion, Description The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

Conversion of note $ 293,726 $ 293,726

Debt Conversion, Converted Instrument, Shares Issued 334,556

Loss on induced conversion of debt $ 197,078 197,078

2019 Debenture [Member]

Debt Instruments [Line Items]

Issue Of Debentures, Amount $ 500,000

Short-term Debt 550,000 $ 550,000 $ 550,000 $ 550,000

Debt Issuance Costs, Gross 40,000

Legal Fees $ 10,000

Debt Instrument, Interest Rate, Stated Percentage 10.00%

Debt Default, Interest rate (as a percent) 18.00%

Debt Instrument, Convertible, Conversion Price $ 2.50

2019 Debenture [Member] | Maximum

Debt Instruments [Line Items]

Debt Instrument, Convertible, Conversion Price $ 2.00

2019 Debenture [Member] | Within first six months

Debt Instruments [Line Items]

Debt Instrument, Redemption Price, Percentage 110.00%

2019 Debenture [Member] | Thereafter

Debt Instruments [Line Items]

Debt Instrument, Redemption Price, Percentage 125.00%

2019 Debenture [Member] | Thereafter | Maximum

Debt Instruments [Line Items]

Debt Instrument, Maximum Redemption Amount In Month $ 150,000

2018 Debenture [Member]

Debt Instruments [Line Items]

Conversion of note $ 293,726

Debt Conversion, Converted Instrument, Shares Issued 334,556

Issuance of common stock upon conversion of convertible notes , Shares 146,863

Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities 187,693

Loss on induced conversion of debt $ 197,078

X

- Definition
Percentage interest charged on the debentured in the event of default.
+ References
No definition available.
+ Details

Name: qbio_DebtInstrumentDebtDefaultInterestRateStatedPercentage

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of maximum debentures can be redeemed by lender in any month.
+ References
No definition available.
+ Details

Name: qbio_DebtInstrumentMaximumRedemptionAmountInMonth

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: qbio_DebtInstrumentsLineItems

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodSharesInducementToConversionOfConvertibleSecurities

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
No definition available.
+ Details

Name: us-gaap_DebtConversionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph e
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentRedemptionPricePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 40
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99385385&loc=d3e6835-112609
+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=qbio_Debenture2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=qbio_Debenture2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Dec. 31, 2016

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Loss Contingencies [Line Items]

Research and development expenses $ 786,600 $ 989,140 $ 2,672,715 $ 2,624,753

Legal agreement

Loss Contingencies [Line Items]

Term of option to acquire license (in years) 3 years

Lease agreement

Loss Contingencies [Line Items]

Lease cost per annum $ 30,000

Renewal term (in years) 3 years

X

- Definition
The term of option to acquire license.
+ References
No definition available.
+ Details

Name: qbio_OptionToAcquireLicenseTerm

Namespace Prefix: qbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_LegalAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=qbio_LeaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options - Options issued for services (Details) - Options - $ / shares
9 Months Ended 12 Months Ended

Aug. 31, 2019

Nov. 30, 2018

Options

Outstanding at November 30, 2018 900,000

Issued 300,000

Outstanding at August 31, 2019 1,200,000 900,000

Exercisable at August 31, 2019 1,050,000

Weighted Average Exercise Price

Outstanding at November 30, 2018 $ 3.68

Issued 1.53

Outstanding at August 31, 2019 3.15 $ 3.68

Exercisable at August 31, 2019 $ 3.38

Weighted Average Remaining Contractual Life (years)

Outstanding at November 30, 2018 3 years 11 months 27 days

Issued 4 years 9 months

Outstanding at August 31, 2019 3 years 7 months 13 days

Exercisable at August 31, 2019 3 years 5 months 16 days

X

- Definition
n/a.
+ References
No definition available.
+ Details

Name: qbio_OptionsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_WeightedAverageExercisePriceAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_WeightedAverageRemainingContractualLifeYearsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average life of securitized assets for initial fair value measurement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719
+ Details

Name: us-gaap_FairValueAssumptionDateOfSecuritizationOrAssetBackedFinancingArrangementTransferorsContinuingInvolvementServicingAssetsOrLiabilitiesWeightedAverageLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining period of expected liquidation by investee of underlying asset of investment measured at net asset value per share or unit. In 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentRemainingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period when redemption restriction has been in effect for investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 6A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258
+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPeriodInEffect1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Loss per share (Tables)
9 Months Ended

Aug. 31, 2019

Loss per share

Loss per share

The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.

August 31,

Potentially dilutive securities



2019



2018

Warrants

4,984,000

4,955,058

Convertible Notes

2,171,000

—

Stock Options

1,200,000

900,000

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Stockholders' Equity Deficit
9 Months Ended

Aug. 31, 2019

Stockholders' Equity Deficit

Stockholders' Equity (Deficit)

Note 8 - Stockholders’ Equity Deficit

As of August 31, 2019 and November 30, 2018, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock.

Issuance of shares for services

During the nine months ended August 31, 2019, the Company issued an aggregate of 526,541 shares of the Company common stock to various vendors for advisory services, valued at approximately $886,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

Issuance of shares to partially convert notes payable

In August 2019, the Company issued an aggregate of 334,556 shares of the Company’s common stock to convert $293,726 of principal and accrued interest outstanding under the 2018 Debentures. Of the 334,556 shares, 146,863 shares were recognized as a conversion of debt at a conversion price of $2.00, while 187,693 shares were recognized as loss on induced conversion of convertible debt in the accompanying Condensed Consolidated Statements of Operations. See Note 5, above, for further discussion.

Issuance of shares to defer monthly contingent payment of convertible note

In August 2019, the Company issued an aggregate of 30,894 shares of the Company’s common stock, valued at approximately $31,000, to holders of the 2018 Debentures to defer a monthly contingent payment that became due. The estimated fair market value of the shares issued was recognized within interest expense in the accompanying Condensed Consolidated Statements of Operations.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Loss per share
9 Months Ended

Aug. 31, 2019

Loss per share

Loss per share

Note 4 - Loss per share

Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.

August 31,

Potentially dilutive securities



2019



2018

Warrants

4,984,000

4,955,058

Convertible Notes

2,171,000

—

Stock Options

1,200,000

900,000

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Basis of Presentation
9 Months Ended

Aug. 31, 2019

Basis of Presentation

Basis of Presentation

Note 2 - Basis of Presentation

The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year.

The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business.

Going Concern

The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern.

The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations.

Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: qbio_BasisOfPresentationAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of basis of presentation.
+ References
No definition available.
+ Details

Name: qbio_BasisOfPresentationTextBlock

Namespace Prefix: qbio_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent events - Issuance of Debentures (Details) - USD ($)
1 Months Ended 9 Months Ended

Oct. 11, 2019

Sep. 23, 2019

Aug. 28, 2019

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

Subsequent Event [Line Items]

Conversion of note $ 293,726 $ 293,726

Debt Conversion, Description The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

Conversion price $ 2.00 $ 2.00

Subsequent Event | Issuance of Debentures [Member]

Subsequent Event [Line Items]

Value of debenture Issued $ 500,000

Conversion of note $ 250,000

Debt Default, Interest rate (as a percent) 5.50%

Additional Debt Instrument Debt Default Interest Rate 2.50%

Debt Conversion, Description The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days' notice. On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020.

Redemption premium (as a percent) 20.00%

Deferral fee monthly payment (as a percent) 10.00%

Deferral payment divided (as a percent) 93.00%

Subsequent Event | Maximum | Issuance of Debentures [Member]

Subsequent Event [Line Items]

Principal value $ 750,000

Conversion price $ 0.50

X

- Definition
Additional percentage interest charged on the debentured in the event of default.
+ References
No definition available.
+ Details

Name: qbio_AdditionalDebtInstrumentDebtDefaultInterestRate

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage interest charged on the debentured in the event of default.
+ References
No definition available.
+ Details

Name: qbio_DebtInstrumentDebtDefaultInterestRateStatedPercentage

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of deferral fee monthly payment.
+ References
No definition available.
+ Details

Name: qbio_MonthlyPaymentOfDeferralFeePercentage

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of deferral payment divided.
+ References
No definition available.
+ Details

Name: qbio_PercentageDeferralPaymentDivided

Namespace Prefix: qbio_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of issued a debenture for the initial closing of the Transaction occurred.
+ References
No definition available.
+ Details

Name: qbio_ValueOfDebentureIssued

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
No definition available.
+ Details

Name: us-gaap_DebtConversionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph e
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentRedemptionPricePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=qbio_IssuanceOfDebenturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Operating expenses:

General and administrative expenses $ 968,383 $ 1,996,391 $ 3,406,853 $ 4,547,761

Research and development expenses 786,600 989,140 2,672,715 2,624,753

Total operating expenses 1,754,983 2,985,531 6,079,568 7,172,514

Other expenses:

Interest expense 476,627 1,137,271

Change in fair value of embedded derivatives 118,000 396,000

Loss on induced conversion of debt 197,078 197,078

Total other expenses 791,705 1,730,349

Net loss $ (2,546,688) $ (2,985,531) $ (7,809,917) $ (7,172,514)

Long-term Liabilities:

Net loss per share - basic and diluted $ (0.17) $ (0.21) $ (0.54) $ (0.53)

Weighted average shares outstanding, basic and diluted 14,756,302 14,019,683 14,580,630 13,579,917

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2229187
+ Details

Name: us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 40
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99385385&loc=d3e6835-112609
+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermDebtAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes - Fair Value Measurement Inputs (Details)
3 Months Ended 9 Months Ended

Aug. 31, 2019

USD ($)

Aug. 31, 2019

USD ($)

Nov. 30, 2018

USD ($)

Convertible Notes

Amortization of the debt discount $ 389,000 $ 907,000

2018 Debenture [Member] | Stock price

Convertible Notes

Input 0.91 0.91

2018 Debenture [Member] | Stock price | Minimum

Convertible Notes

Input 1.95

2018 Debenture [Member] | Stock price | Maximum

Convertible Notes

Input 2.97

2018 Debenture [Member] | Terms (years) | Minimum

Convertible Notes

Input 0.50 0.50 1.2

2018 Debenture [Member] | Terms (years) | Maximum

Convertible Notes

Input 0.66 0.66 1.4

2018 Debenture [Member] | Volatility

Convertible Notes

Input 79.78 79.78 76.5

2018 Debenture [Member] | Volatility | Minimum

Convertible Notes

Input 72.1

2018 Debenture [Member] | Risk-free rate | Minimum

Convertible Notes

Input 1.89 1.89 2.4

2018 Debenture [Member] | Risk-free rate | Maximum

Convertible Notes

Input 2.1 2.1 2.5

2018 Debenture [Member] | Dividend yield

Convertible Notes

Input 0.0 0.0 0.00

2018 Debenture [Member] | Discount rate

Convertible Notes

Input 35.17

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=qbio_Debenture2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options (Tables)
9 Months Ended

Aug. 31, 2019

Schedule of stock-based compensation



For the three months ended August 31,



For the nine months ended August 31,



2019



2018



2019



2018

Stock-based compensation expense

183,000

946,000

463,000

1,500,000

Warrants

Summary of all outstanding warrants and options to purchase of common stock







Weighted



Average

Weighted

Remaining

Average

Contractual

Warrants

Exercise Price

Life (years)

Intrinsic Value

Outstanding at November 30, 2018

4,984,058

$

3.48

3.51

$

250,000

Issued

—

$

—

0

$

—

Expired

—

$

—

0

$

—

Outstanding at August 31, 2019

4,984,058

$

3.48

2.76

$

—

Exercisable at August 31, 2019

4,921,558

$

3.49

2.75

$

—

Schedule of fair value outstanding warrants and options issued to non-employees for services

For the nine months ended August 31,



2018

Stock price

$2.14 - $3.61

Term (years)

3.0 – 5.0

Volatility

123.00% - 128.49%

Risk-free rate

2.47% - 2.78%

Dividend yield

0.00%

Options

Summary of all outstanding warrants and options to purchase of common stock







Weighted



Average

Weighted

Remaining

Average

Contractual

Options

Exercise Price

Life (years)

Intrinsic Value

Outstanding at November 30, 2018

900,000

$

3.68

3.99

$

—

Issued

300,000

$

1.53

4.75

$

—

Outstanding at August 31, 2019

1,200,000

$

3.15

3.62

$

—

Exercisable at August 31, 2019

1,050,000

$

3.38

3.46

$

—

Schedule of fair value outstanding warrants and options issued to non-employees for services

For the nine months ended August 31,



2019



2018

Exercise price

$1.53

$3.00 - $3.61

Expected term (years)

5.0

5.0

Volatility

98.75%

128.00% - 130.00%

Risk-free rate

2.03%

2.52% - 2.71%

Dividend yield

0.00%

0.00%

X

- Definition
Tabular disclosure of share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 131 271 1 false 40 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.qbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.qbio.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.qbio.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.qbio.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.qbio.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity Condensed Consolidated Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.qbio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization of the Company and Description of the Business Sheet http://www.qbio.com/role/DisclosureOrganizationOfCompanyAndDescriptionOfBusiness Organization of the Company and Description of the Business Notes 7 false false R8.htm 10201 - Disclosure - Basis of Presentation Sheet http://www.qbio.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.qbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10401 - Disclosure - Loss per share Sheet http://www.qbio.com/role/DisclosureLossPerShare Loss per share Notes 10 false false R11.htm 10501 - Disclosure - Convertible Notes Notes http://www.qbio.com/role/DisclosureConvertibleNotes Convertible Notes Notes 11 false false R12.htm 10601 - Disclosure - Commitments and Contingencies Sheet http://www.qbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 10701 - Disclosure - Related Party Transactions Sheet http://www.qbio.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 10801 - Disclosure - Stockholders' Equity Deficit Sheet http://www.qbio.com/role/DisclosureStockholdersEquityDeficit Stockholders' Equity Deficit Notes 14 false false R15.htm 10901 - Disclosure - Warrants and Options Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptions Warrants and Options Notes 15 false false R16.htm 11001 - Disclosure - Subsequent events Sheet http://www.qbio.com/role/DisclosureSubsequentEvents Subsequent events Notes 16 false false R17.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.qbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.qbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30403 - Disclosure - Loss per share (Tables) Sheet http://www.qbio.com/role/DisclosureLossPerShareTables Loss per share (Tables) Tables http://www.qbio.com/role/DisclosureLossPerShare 18 false false R19.htm 30503 - Disclosure - Convertible Notes (Tables) Notes http://www.qbio.com/role/DisclosureConvertibleNotesTables Convertible Notes (Tables) Tables http://www.qbio.com/role/DisclosureConvertibleNotes 19 false false R20.htm 30603 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.qbio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.qbio.com/role/DisclosureCommitmentsAndContingencies 20 false false R21.htm 30703 - Disclosure - Related Party Transactions (Tables) Sheet http://www.qbio.com/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.qbio.com/role/DisclosureRelatedPartyTransactions 21 false false R22.htm 30903 - Disclosure - Warrants and Options (Tables) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsTables Warrants and Options (Tables) Tables http://www.qbio.com/role/DisclosureWarrantsAndOptions 22 false false R23.htm 31003 - Disclosure - Warrants and Options (Tables) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsTabless Warrants and Options (Tables) Tables http://www.qbio.com/role/DisclosureWarrantsAndOptions 23 false false R24.htm 40401 - Disclosure - Loss per share (Details) Sheet http://www.qbio.com/role/DisclosureLossPerShareDetails Loss per share (Details) Details http://www.qbio.com/role/DisclosureLossPerShareTables 24 false false R25.htm 40501 - Disclosure - Convertible Notes (Details) Notes http://www.qbio.com/role/DisclosureConvertibleNotesDetails Convertible Notes (Details) Details http://www.qbio.com/role/DisclosureConvertibleNotesTables 25 false false R26.htm 40502 - Disclosure - Convertible Notes - Fair Value Measurement Inputs (Details) Notes http://www.qbio.com/role/DisclosureConvertibleNotesFairValueMeasurementInputsDetails Convertible Notes - Fair Value Measurement Inputs (Details) Details 26 false false R27.htm 40503 - Disclosure - Convertible Notes - Interest Expense (Details) Notes http://www.qbio.com/role/DisclosureConvertibleNotesInterestExpenseDetails Convertible Notes - Interest Expense (Details) Details 27 false false R28.htm 40504 - Disclosure - Convertible Notes - Additional Information (Details) Notes http://www.qbio.com/role/DisclosureConvertibleNotesAdditionalInformationDetails Convertible Notes - Additional Information (Details) Details 28 false false R29.htm 40601 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.qbio.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.qbio.com/role/DisclosureCommitmentsAndContingenciesTables 29 false false R30.htm 40601 - Disclosure - Convertible Notes (Details) - old Notes http://www.qbio.com/role/DisclosureConvertibleNotesDetailsOld Convertible Notes (Details) - old Details http://www.qbio.com/role/DisclosureConvertibleNotesTables 30 false false R31.htm 40603 - Disclosure - Convertible Notes (Details Narrative) Notes http://www.qbio.com/role/DisclosureConvertibleNotesDetailsNarrative Convertible Notes (Details Narrative) Details http://www.qbio.com/role/DisclosureConvertibleNotesTables 31 false false R32.htm 40701 - Disclosure - Related Party Transactions (Details) Sheet http://www.qbio.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.qbio.com/role/DisclosureRelatedPartyTransactionsTables 32 false false R33.htm 40702 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.qbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 33 false false R34.htm 40801 - Disclosure - Stockholders' Equity Deficit (Details) Sheet http://www.qbio.com/role/DisclosureStockholdersEquityDeficitDetails Stockholders' Equity Deficit (Details) Details http://www.qbio.com/role/DisclosureStockholdersEquityDeficit 34 false false R35.htm 40901 - Disclosure - Warrants and Options - Summary of warrants (Details) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsDetails Warrants and Options - Summary of warrants (Details) Details 35 false false R36.htm 40902 - Disclosure - Warrants and Options - Fair value of outstanding warrants (Details) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsFairValueOfOutstandingWarrantsDetails Warrants and Options - Fair value of outstanding warrants (Details) Details 36 false false R37.htm 40903 - Disclosure - Warrants and Options - Options issued for services (Details) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsOptionsIssuedForServicesDetails Warrants and Options - Options issued for services (Details) Details 37 false false R38.htm 40904 - Disclosure - Warrants and Options - Fair value of options (Details) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsFairValueOfOptionsDetails Warrants and Options - Fair value of options (Details) Details 38 false false R39.htm 40905 - Disclosure - Warrants and Options - Stock-based Compensation (Details) Sheet http://www.qbio.com/role/DisclosureWarrantsAndOptionsStockBasedCompensationDetails Warrants and Options - Stock-based Compensation (Details) Details 39 false false R40.htm 41001 - Disclosure - Subsequent events (Details) Sheet http://www.qbio.com/role/DisclosureSubsequentEventsDetails Subsequent events (Details) Details http://www.qbio.com/role/DisclosureSubsequentEvents 40 false false R41.htm 41002 - Disclosure - Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) Sheet http://www.qbio.com/role/DisclosureSubsequentEventsSettlementAgreementAndRepricingOfExisitingWarrantsDetails Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) Details 41 false false R42.htm 41003 - Disclosure - Subsequent events - Repricing of Existing Warrants (Details) Sheet http://www.qbio.com/role/DisclosureSubsequentEventsRepricingOfExistingWarrantsDetails Subsequent events - Repricing of Existing Warrants (Details) Details 42 false false R43.htm 41004 - Disclosure - Subsequent events - Issuance of Debentures (Details) Sheet http://www.qbio.com/role/DisclosureSubsequentEventsIssuanceOfDebenturesDetails Subsequent events - Issuance of Debentures (Details) Details 43 false false All Reports Book All Reports qbio-20190831.xml qbio-20190831.xsd qbio-20190831_cal.xml qbio-20190831_def.xml qbio-20190831_lab.xml qbio-20190831_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 47 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent events - Repricing of Existing Warrants (Details) - Subsequent Event - USD ($)

Sep. 24, 2019

Sep. 23, 2019

Ari Jatwes [Member] | Options And Warrants [Member]

Subsequent Event [Line Items]

Options and warrants issued $ 360,000

Exercise price per share $ 1.25

Rick Panicucci [Member] | Options And Warrants [Member]

Subsequent Event [Line Items]

Options and warrants issued $ 50,000

Exercise price per share $ 1.25

Share-based Payment Arrangement, Nonemployee [Member] | Director, Denis Corin [Member]

Subsequent Event [Line Items]

Exercise price per share $ 1.25

Share-based Payment Arrangement, Nonemployee [Member] | Director, Denis Corin [Member] | Options And Warrants [Member]

Subsequent Event [Line Items]

Options and warrants issued $ 950,000

Share-based Payment Arrangement, Nonemployee [Member] | Director, William Rosenstadt [Member] | Options And Warrants [Member]

Subsequent Event [Line Items]

Options and warrants issued $ 1,250,000

Exercise price per share $ 1.25

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=qbio_AriJatwesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=qbio_OptionsAndWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=qbio_RickPanicucciMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=qbio_DirectorDenisCorinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=qbio_DirectorWilliamRosenstadtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Aug. 31, 2019

Oct. 14, 2019

Document and Entity Information

Entity Registrant Name Q BIOMED INC.

Document Type 10-Q

Document Period End Date Aug. 31, 2019

Entity Current Reporting Status Yes

Amendment Flag false

Entity Central Index Key 0001596062

Current Fiscal Year End Date --11-30

Entity Common Stock, Shares Outstanding 16,720,871

Entity Filer Category Non-accelerated Filer

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Entity Emerging Growth Company false

Entity Small Business true

Entity Shell Company false

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_DocumentAndEntityInformationAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)

Common Stock

Additional Paid in Capital

Accumulated Deficit

Total

Beginning balance, Shares at Nov. 30, 2017 12,206,409

Beginning balance, Amount at Nov. 30, 2017 $ 12,206 $ 23,187,408 $ (22,843,370) $ 356,244

Share based compensation for services, Amount $ 159 1,953,158 1,953,317

Share based compensation for services, Shares 159,028

Issuance of common stock and warrants for cash, net of offering costs, Amount $ 1,712 4,943,539 4,945,251

Issuance of common stock and warrants for cash, net of offering costs, Shares 1,711,875

Net loss (7,172,514) (7,172,514)

Ending balance, Shares at Aug. 31, 2018 14,077,312

Ending balance, Amount at Aug. 31, 2018 $ 14,077 30,084,105 (30,015,884) 82,298

Beginning balance, Shares at May. 31, 2018 13,987,130

Beginning balance, Amount at May. 31, 2018 $ 13,987 28,902,745 (27,030,353) 1,886,379

Share based compensation for services, Amount $ 90 1,181,361 1,181,450

Share based compensation for services, Shares 90,182

Net loss (2,985,531) (2,985,531)

Ending balance, Shares at Aug. 31, 2018 14,077,312

Ending balance, Amount at Aug. 31, 2018 $ 14,077 30,084,105 (30,015,884) 82,298

Beginning balance, Shares at Nov. 30, 2018 14,290,236

Beginning balance, Amount at Nov. 30, 2018 $ 14,290 31,994,129 (32,114,147) (105,728)

Share based compensation for services, Amount $ 527 1,349,081 1,349,608

Share based compensation for services, Shares 526,541

Issuance of common stock to partially convert notes payable $ 147 293,579 293,726

Issuance of common stock to partially convert notes payable (in shares) 146,863

Issuance of common stock as inducement to partially convert notes payable $ 188 196,890 197,078

Issuance of common stock as inducement to partially convert notes payable 187,693

Issuance of common stock to defer monthly contingent payment of convertible note $ 30 32,408 32,438

Issuance of common stock to defer monthly contingent payment of convertible note 30,894

Net loss (7,809,917) (7,809,917)

Ending balance, Shares at Aug. 31, 2019 15,182,227

Ending balance, Amount at Aug. 31, 2019 $ 15,182 33,866,087 (39,924,064) (6,042,795)

Beginning balance, Shares at May. 31, 2019 14,677,136

Beginning balance, Amount at May. 31, 2019 $ 14,676 33,002,224 (37,377,376) (4,360,476)

Share based compensation for services, Amount $ 141 340,986 341,127

Share based compensation for services, Shares 139,641

Issuance of common stock to partially convert notes payable $ 147 293,579 293,726

Issuance of common stock to partially convert notes payable (in shares) 146,863

Issuance of common stock as inducement to partially convert notes payable $ 188 196,890 197,078

Issuance of common stock as inducement to partially convert notes payable 187,693

Issuance of common stock to defer monthly contingent payment of convertible note $ 30 32,408 32,438

Issuance of common stock to defer monthly contingent payment of convertible note 30,894

Net loss (2,546,688) (2,546,688)

Ending balance, Shares at Aug. 31, 2019 15,182,227

Ending balance, Amount at Aug. 31, 2019 $ 15,182 $ 33,866,087 $ (39,924,064) $ (6,042,795)

X

- References
No definition available.
+ Details

Name: qbio_IssuanceOfCommonStockAndWarrantsForCashNetOfOfferingCostsAmount

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: qbio_IssuanceOfCommonStockAndWarrantsForCashNetOfOfferingCostsShares

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodSharesDeferredPaymentConversionOfConvertibleSecurities

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodSharesInducementToConversionOfConvertibleSecurities

Namespace Prefix: qbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodValueDeferredPaymentConversionOfConvertibleSecurities

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
No definition available.
+ Details

Name: qbio_StockIssuedDuringPeriodValueInducementToConvertibleSecurities

Namespace Prefix: qbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 51 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies
9 Months Ended

Aug. 31, 2019

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2018 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

Recent accounting pronouncements

On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.

Recent adopted pronouncements

In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016‑10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes - Interest Expense (Details) - USD ($)
3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Nov. 30, 2018

Convertible Notes.

Interest Expense, Debt $ 55,000 $ 166,000

Accretion of debt discount $ 389,000 $ 907,000

Costs incurred to defer monthly contingent payments of convertible notes $32,000 $- $64,000 $-

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of conditions, facts and circumstances that would trigger a payment of principal or interest which was not otherwise immediately due and payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtContingentPaymentOfPrincipalOrInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options (Tables)
9 Months Ended

Aug. 31, 2019

Basis of Presentation and Going Concern

Fair value measurement inputs and valuation techniques

The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs:



August 31, 2019



November 30, 2018

Stock price

$0.91

$1.95 - $2.97

Terms (years)

0.50-0.66

1.2 - 1.4

Volatility

79.78%

72.1% - 76.5%

Risk-free rate

1.89% - 2.10%

2.4% - 2.5%

Dividend yield

0.00%

0.00%

Discount rate

35.17%

35.17%

In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and

X

- References
No definition available.
+ Details

Name: qbio_NotesToFinancialStatementsAbstract

Namespace Prefix: qbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Related Party Transactions

Consulting and legal expenses $ 78,000 $ 60,000 $ 270,000 $ 180,000

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options - Fair value of outstanding warrants (Details) - Warrants
3 Months Ended

Aug. 31, 2018

$ / shares

Dividend yield 0.00%

Minimum

Stock price $ 2.14

Term (years) 3 years

Volatility 123.00%

Risk-free rate 2.47%

Maximum

Stock price $ 3.61

Term (years) 5 years

Volatility 128.49%

Risk-free rate 2.78%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Warrants and Options
9 Months Ended

Aug. 31, 2019

Warrants and Options

Warrants and Options

Note 9 - Warrants and Options

Summary of warrants

The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at August 31, 2019 and the changes during the period then ended:







Weighted



Average

Weighted

Remaining

Average

Contractual

Warrants

Exercise Price

Life (years)

Intrinsic Value

Outstanding at November 30, 2018

4,984,058

$

3.48

3.51

$

250,000

Issued

—

$

—

0

$

—

Expired

—

$

—

0

$

—

Outstanding at August 31, 2019

4,984,058

$

3.48

2.76

$

—

Exercisable at August 31, 2019

4,921,558

$

3.49

2.75

$

—

Fair value of all outstanding warrants issued to non-employees for services was calculated with the following key inputs:

For the nine months ended August 31,



2018

Stock price

$2.14 - $3.61

Term (years)

3.0 – 5.0

Volatility

123.00% - 128.49%

Risk-free rate

2.47% - 2.78%

Dividend yield

0.00%

There were no warrants issued for the nine months ended August 31, 2019.

Options issued for services

The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2019 and the changes during the period then ended:







Weighted



Average

Weighted

Remaining

Average

Contractual

Options

Exercise Price

Life (years)

Intrinsic Value

Outstanding at November 30, 2018

900,000

$

3.68

3.99

$

—

Issued

300,000

$

1.53

4.75

$

—

Outstanding at August 31, 2019

1,200,000

$

3.15

3.62

$

—

Exercisable at August 31, 2019

1,050,000

$

3.38

3.46

$

—

Fair value of options issued in the nine-month period ended August 31, 2018 was calculated with the following key inputs. No options were granted in the nine-month period ended August 31, 2019.

For the nine months ended August 31,



2019



2018

Exercise price

$1.53

$3.00 - $3.61

Expected term (years)

5.0

5.0

Volatility

98.75%

128.00% - 130.00%

Risk-free rate

2.03%

2.52% - 2.71%

Dividend yield

0.00%

0.00%

Stock-based Compensation

Stock-based compensation expense is classified within general and administrative expenses as a result of the shares, outstanding warrants and options issued to consultants and employees and included in the accompanying Condensed Consolidated Statements of Operations as follows:



For the three months ended August 31,



For the nine months ended August 31,



2019



2018



2019



2018

Stock-based compensation expense

183,000

946,000

463,000

1,500,000

As of August 31, 2019, the estimated unrecognized stock-based compensation associate with these agreements is approximately $136,000 and will be fully recognized over the next five months.

X

- Definition
The entire disclosure for Warrants and options.
+ References
No definition available.
+ Details

Name: qbio_WarrantsTextBlock

Namespace Prefix: qbio_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes
9 Months Ended

Aug. 31, 2019

Convertible Notes.

Convertible Notes

Note 5 - Convertible Notes



August 31, 2019



November 30, 2018

Convertible Notes Payable, current:

Principal value of 2019 Debenture

$

550,000

$

—

Debt discount

(65,000)

—

Carrying value of 2019 Debenture

485,000

—

Total carrying value of convertible notes payable, current

$

485,000

$

—

Convertible Notes Payable, long-term:

Principal value of 2018 Debenture

$

3,800,000

$

4,000,000.00

Fair value of bifurcated contingent put option

658,000

262,000

Debt discount

(481,291)

(1,388,728)

Carrying value of 2018 Debenture

3,976,709

2,873,272

Total carrying value of convertible notes, long-term

$

3,976,709

$

2,873,272

2019 Debenture

On August 28, 2019, the Company entered into a securities purchase agreement with an accredited investor pursuant to which the Company sold a convertible debenture (the “2019 Debenture”) with a maturity date of twelve months after the issuance thereof for $500,000. The 2019 Debenture is in the aggregate principal amount of $550,000, which amount includes an original issue discount of $40,000 and payment of the lender’s legal fees of $10,000. The 2019 Debenture carries an interest rate of 10% per annum. Upon an event of default, as defined, the outstanding balance of the 2019 Debenture bears interest at a rate of 18% per annum. The Company may prepay the 2019 Debenture at 110% of the outstanding aggregate principal amount within the first six months of issuance and at 125% of the outstanding aggregate principal amount thereafter.

In certain circumstances, a premium is due upon the outstanding balance upon written notice from the lender. A premium of fifteen percent is due for each occurrence of any major default, a premium of ten percent is due for each occurrence of an unapproved variable security issuance default, and a premium of five percent is due for each occurrence of any minor default.

The lender has the right to convert the outstanding aggregate principal amount at any time at the conversion price of $2.50 per share. At any time that is six months after the issuance, the lender may redeem a portion of the 2019 Debenture, not to exceed $150,000 in any month. The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture’s outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

2018 Debentures

The monthly payment provision within the 2018 Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs:



August 31, 2019



November 30, 2018

Stock price

$0.91

$1.95 - $2.97

Terms (years)

0.50-0.66

1.2 - 1.4

Volatility

79.78%

72.1% - 76.5%

Risk-free rate

1.89% - 2.10%

2.4% - 2.5%

Dividend yield

0.00%

0.00%

Discount rate

35.17%

35.17%

In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and accrued interest under the previously existing conversion terms, the holders would have received 146,863 shares of the Company's common stock. The additional 187,693 shares received upon conversion, with an aggregate fair value of $197,078, is recognized in the accompanying Condensed Consolidated Statements of Operations as a loss on induced conversion of debt.

Interest expense

Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented:

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Interest expense based on the coupon interest rate of the outstanding debt

$

55,000

$

—

$

166,000

$

—

Accretion of debt discount

$

389,000

$

—

$

907,000

$

—

Costs incurred to defer monthly contingent payments of convertible notes

$

32,000

$

—

$

64,000

$

—

X

- Definition
Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.
+ References
No definition available.
+ Details

Name: us-gaap_ConvertibleDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Convertible Notes (Tables)
9 Months Ended

Aug. 31, 2019

Convertible Notes.

Long-term carrying value of convertible notes



August 31, 2019



November 30, 2018

Convertible Notes Payable, current:

Principal value of 2019 Debenture

$

550,000

$

—

Debt discount

(65,000)

—

Carrying value of 2019 Debenture

485,000

—

Total carrying value of convertible notes payable, current

$

485,000

$

—

Convertible Notes Payable, long-term:

Principal value of 2018 Debenture

$

3,800,000

$

4,000,000.00

Fair value of bifurcated contingent put option

658,000

262,000

Debt discount

(481,291)

(1,388,728)

Carrying value of 2018 Debenture

3,976,709

2,873,272

Total carrying value of convertible notes, long-term

$

3,976,709

$

2,873,272

Fair value measurement inputs and valuation techniques

The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs:



August 31, 2019



November 30, 2018

Stock price

$0.91

$1.95 - $2.97

Terms (years)

0.50-0.66

1.2 - 1.4

Volatility

79.78%

72.1% - 76.5%

Risk-free rate

1.89% - 2.10%

2.4% - 2.5%

Dividend yield

0.00%

0.00%

Discount rate

35.17%

35.17%

In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and

Schedule of interest expense

For the three months ended August 31,

For the nine months ended August 31,



2019



2018



2019



2018

Interest expense based on the coupon interest rate of the outstanding debt

$

55,000

$

—

$

166,000

$

—

Accretion of debt discount

$

389,000

$

—

$

907,000

$

—

Costs incurred to defer monthly contingent payments of convertible notes

$

32,000

$

—

$

64,000

$

—

X

- Definition
Tabular disclosure of interest expense.
+ References
No definition available.
+ Details

Name: qbio_ScheduleOfInterestExpenseDebtTableTextBlock

Namespace Prefix: qbio_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Commitments and Contingencies (Details) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Apr. 09, 2019	Mar. 09, 2019	Dec. 31, 2016	Oct. 29, 2015	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018	Nov. 30, 2018
Commitments and Contingencies
Research and development expenses					$ 786,600	$ 989,140	$ 2,672,715	$ 2,624,753
Rent expense					$ 7,500	$ 7,500	$ 22,500	$ 23,000
Legal agreement
Commitments and Contingencies
Term of option to acquire license (in years)							3 years
Lease agreement
Commitments and Contingencies
Lease cost per annum			$ 30,000
Renewal term (in years)			3 years
Mannin agreement
Commitments and Contingencies
License agreement (in years)				4 years
Shares issued in exchange for extension of option period	100,000
Research and development expenses							$ 1,900,000		$ 1,700,000
Washington university
Commitments and Contingencies
Initial fee		$ 88,000
Washington university \| Minimum
Commitments and Contingencies
Annual maintenance fees		15,000
Washington university \| Maximum
Commitments and Contingencies
Annual maintenance fees		$ 75,000

Convertible Notes (Details) - USD ($)	Aug. 31, 2019	Aug. 28, 2019	Nov. 30, 2018
Notes and Loans Payable, Current [Abstract]
Debt discount	$ (65,000)
Carrying value	485,000
Total carrying value of convertible notes payable, current	485,000
Notes and Loans, Noncurrent [Abstract]
Fair value of bifurcated contingent put option	658,000		$ 262,000
Debt discount	(481,291)		(1,388,728)
Total long-term carrying value of convertible notes	3,976,709		2,873,272
2019 Debenture [Member]
Notes and Loans Payable, Current [Abstract]
Principal value	550,000	$ 550,000
Carrying value	485,000
2018 Debenture [Member]
Notes and Loans, Noncurrent [Abstract]
Principal value	3,800,000		4,000,000.00
Carrying value	$ 3,976,709		$ 2,873,272

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Aug. 31, 2019
Summary of Significant Accounting Policies
Recent accounting pronouncements	Recent accounting pronouncements On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.
Recent adopted pronouncements	Recent adopted pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016‑10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

Convertible Notes (Details) - old - USD ($)	Aug. 31, 2019	Nov. 30, 2018
Basis of Presentation and Going Concern
Total long-term carrying value of convertible notes	$ 3,976,709	$ 2,873,272

Stockholders' Equity Deficit (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Stockholders' Equity Deficit (Details) - USD ($)	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018	Nov. 30, 2018
Common stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock, shares authorized	250,000,000	250,000,000		250,000,000		250,000,000
Preferred stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000		100,000,000		100,000,000
Stock issued for services		$ 341,127	$ 1,181,450	$ 1,349,608	$ 1,953,317
Shares issued for conversion	334,556
Conversion of note	$ 293,726			$ 293,726
Shares recognized as conversion of debt	146,863
Conversion price	$ 2.00	$ 2.00		$ 2.00
Shares recognized loss on conversion of convertible debt	187,693
Stock issued during period shares contingent payment of convertible note	30,894
Stock issued during period value contingent payment of convertible note	$ 31,000
General and Administrative Expense
Stock issued for services (in shares)				526,541
Stock issued for services				$ 886,000

Convertible Notes (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018
Debt Instrument [Line Items]
Conversion price	$ 2.00	$ 2.00	$ 2.00
Amortization of the debt discount		$ 389,000	$ 907,000
Shares issued for conversion	334,556
Convertible notes value	$ 293,726		293,726
Interest Expense, Debt		$ 55,000	$ 166,000

Warrants and Options - Summary of warrants (Details) - Warrants - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2019	Nov. 30, 2018
Warrants
Outstanding at November 30, 2018	4,984,058
Outstanding at August 31, 2019	4,984,058	4,984,058
Exercisable at August 31, 2019	4,921,558
Weighted Average Exercise Price
Outstanding at November 30, 2018	$ 3.48
Outstanding at August 31, 2019	3.48	$ 3.48
Exercisable at August 31, 2019	$ 3.49
Weighted Average Remaining Contractual Life (years)
Outstanding at November 30, 2018		3 years 6 months 4 days
Issued	0 years
Expired	0 years
Outstanding at August 31, 2019	2 years 9 months 4 days
Exercisable at August 31, 2019	2 years 9 months
Intrinsic Value
Outstanding at November 30, 2018		$ 250,000

Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) - BNI and Parties Related To BNI [Member] - USD ($)	Sep. 23, 2019	Aug. 31, 2019
Subsequent Event [Line Items]
Accrued expenses		$ 125,000
Subsequent Event \| Positive Outcome of Litigation [Member]
Subsequent Event [Line Items]
Number of shares awarded	100,000
Subsequent Event \| Settled Litigation [Member] \| Positive Outcome of Litigation [Member]
Subsequent Event [Line Items]
Number of shares awarded	50,000
Cash Payment Agreed	$ 25,000
Royalty Payment (as a percent)	3.00%
Total amount agreed to settle	$ 125,000
Subsequent Event \| Settled Litigation [Member] \| Positive Outcome of Litigation [Member] \| Strontium-Chloride 89 [Member]
Subsequent Event [Line Items]
Outstanding fee settlement Owned by BNI to IsoTherapeutics	67,000
Outstanding fee settlement Owned by BNI to FDA	$ 208,000

Condensed Consolidated Balance Sheets - USD ($)	Aug. 31, 2019	Nov. 30, 2018
Current assets:
Cash	$ 301,673	$ 2,684,413
Prepaid expenses	28,546	12,500
Total current assets	330,219	2,696,913
Intangible assets, net	462,500	500,000
Total Assets	792,719	3,196,913
Current liabilities:
Accounts payable	751,402	172,628
Accrued expenses	1,302,527	219,602
Accrued expenses - related party	25,000	7,500
Accrued interest payable	101,626	29,639
Investor advances	193,250
Convertible note payable, net	485,000
Total current liabilities	2,858,805	429,369
Long-term liabilities:
Convertible notes payable, net	3,976,709	2,873,272
Total long term liabilities	3,976,709	2,873,272
Total Liabilities	6,835,514	3,302,641
Commitments and Contingencies (Note 6)
Stockholders' Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2019 and November 30, 2018
Common stock, $0.001 par value; 250,000,000 shares authorized; 15,182,227 and 14,290,236 shares issued and outstanding as of August 31, 2019 and November 30, 2018, respectively	15,182	14,290
Additional paid-in capital	33,866,087	31,994,129
Accumulated deficit	(39,924,064)	(32,114,147)
Total Stockholders' Deficit	(6,042,795)	(105,728)
Total Liabilities and Stockholders' Deficit	$ 792,719	$ 3,196,913

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Cash flows from operating activities:
Net loss	$ (7,809,917)	$ (7,172,514)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	1,349,608	1,953,317
Change in fair value of embedded conversion option	396,000
Accretion of debt discount	907,437
Amortization expense	37,500
Loss on induced conversion of debt	197,078
Non-cash interest expense	32,438
Changes in operating assets and liabilities:
Prepaid expenses	(16,046)
Accounts payable and accrued expenses	1,646,699	236,015
Accrued expenses - related party	17,500
Accrued interest payable	165,713
Net cash used in operating activities	(3,075,990)	(4,983,182)
Cash flows from financing activities:
Proceeds from investor advances	193,250
Proceeds received from issuance of short-term convertible note, net of original issuance discount and lender's fees	500,000
Proceeds received for issuance of common stock and warrants, net of offering costs		4,945,251
Net cash provided by financing activities	693,250	4,945,251
Net decrease in cash	(2,382,740)	(37,931)
Cash at beginning of period	2,684,413	824,783
Cash at end of period	301,673	786,852
Supplemental disclosures:
Cash paid for interest	31,524
Cash paid for income taxes
Non-cash financing activities:
Issuance of common stock to partially convert notes payable	293,726
Accrued debt issuance costs	$ 15,000

Loss per share (Details) - shares	9 Months Ended
Loss per share (Details) - shares	Aug. 31, 2019	Aug. 31, 2018
Loss per share
Warrants	4,984,000	4,955,058
Convertible Notes	2,171,000
Stock Options	1,200,000	900,000

Warrants and Options - Options issued for services (Details) - Options - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2019	Nov. 30, 2018
Options
Outstanding at November 30, 2018	900,000
Issued	300,000
Outstanding at August 31, 2019	1,200,000	900,000
Exercisable at August 31, 2019	1,050,000
Weighted Average Exercise Price
Outstanding at November 30, 2018	$ 3.68
Issued	1.53
Outstanding at August 31, 2019	3.15	$ 3.68
Exercisable at August 31, 2019	$ 3.38
Weighted Average Remaining Contractual Life (years)
Outstanding at November 30, 2018		3 years 11 months 27 days
Issued	4 years 9 months
Outstanding at August 31, 2019	3 years 7 months 13 days
Exercisable at August 31, 2019	3 years 5 months 16 days

Stockholders' Equity Deficit	9 Months Ended
Stockholders' Equity Deficit	Aug. 31, 2019
Stockholders' Equity Deficit
Stockholders' Equity (Deficit)	Note 8 - Stockholders’ Equity Deficit As of August 31, 2019 and November 30, 2018, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Issuance of shares for services During the nine months ended August 31, 2019, the Company issued an aggregate of 526,541 shares of the Company common stock to various vendors for advisory services, valued at approximately $886,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. Issuance of shares to partially convert notes payable In August 2019, the Company issued an aggregate of 334,556 shares of the Company’s common stock to convert $293,726 of principal and accrued interest outstanding under the 2018 Debentures. Of the 334,556 shares, 146,863 shares were recognized as a conversion of debt at a conversion price of $2.00, while 187,693 shares were recognized as loss on induced conversion of convertible debt in the accompanying Condensed Consolidated Statements of Operations. See Note 5, above, for further discussion. Issuance of shares to defer monthly contingent payment of convertible note In August 2019, the Company issued an aggregate of 30,894 shares of the Company’s common stock, valued at approximately $31,000, to holders of the 2018 Debentures to defer a monthly contingent payment that became due. The estimated fair market value of the shares issued was recognized within interest expense in the accompanying Condensed Consolidated Statements of Operations.

Basis of Presentation	9 Months Ended
Basis of Presentation	Aug. 31, 2019
Basis of Presentation
Basis of Presentation	Note 2 - Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Subsequent events - Issuance of Debentures (Details) - USD ($)				1 Months Ended	9 Months Ended
	Oct. 11, 2019	Sep. 23, 2019	Aug. 28, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018
Subsequent Event [Line Items]
Conversion of note				$ 293,726	$ 293,726
Debt Conversion, Description			The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.
Conversion price				$ 2.00	$ 2.00
Subsequent Event \| Issuance of Debentures [Member]
Subsequent Event [Line Items]
Value of debenture Issued	$ 500,000
Conversion of note	$ 250,000
Debt Default, Interest rate (as a percent)	5.50%
Additional Debt Instrument Debt Default Interest Rate	2.50%
Debt Conversion, Description	The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days' notice.	On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020.
Redemption premium (as a percent)	20.00%
Deferral fee monthly payment (as a percent)	10.00%
Deferral payment divided (as a percent)	93.00%
Subsequent Event \| Maximum \| Issuance of Debentures [Member]
Subsequent Event [Line Items]
Principal value	$ 750,000
Conversion price	$ 0.50

Convertible Notes - Fair Value Measurement Inputs (Details)	3 Months Ended	9 Months Ended
	Aug. 31, 2019 USD ($)	Aug. 31, 2019 USD ($)	Nov. 30, 2018 USD ($)
Convertible Notes
Amortization of the debt discount	$ 389,000	$ 907,000
2018 Debenture [Member] \| Stock price
Convertible Notes
Input	0.91	0.91
2018 Debenture [Member] \| Stock price \| Minimum
Convertible Notes
Input			1.95
2018 Debenture [Member] \| Stock price \| Maximum
Convertible Notes
Input			2.97
2018 Debenture [Member] \| Terms (years) \| Minimum
Convertible Notes
Input	0.50	0.50	1.2
2018 Debenture [Member] \| Terms (years) \| Maximum
Convertible Notes
Input	0.66	0.66	1.4
2018 Debenture [Member] \| Volatility
Convertible Notes
Input	79.78	79.78	76.5
2018 Debenture [Member] \| Volatility \| Minimum
Convertible Notes
Input			72.1
2018 Debenture [Member] \| Risk-free rate \| Minimum
Convertible Notes
Input	1.89	1.89	2.4
2018 Debenture [Member] \| Risk-free rate \| Maximum
Convertible Notes
Input	2.1	2.1	2.5
2018 Debenture [Member] \| Dividend yield
Convertible Notes
Input	0.0	0.0	0.00
2018 Debenture [Member] \| Discount rate
Convertible Notes
Input			35.17

Subsequent events - Repricing of Existing Warrants (Details) - Subsequent Event - USD ($)	Sep. 24, 2019	Sep. 23, 2019
Ari Jatwes [Member] \| Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued	$ 360,000
Exercise price per share	$ 1.25
Rick Panicucci [Member] \| Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued	$ 50,000
Exercise price per share	$ 1.25
Share-based Payment Arrangement, Nonemployee [Member] \| Director, Denis Corin [Member]
Subsequent Event [Line Items]
Exercise price per share		$ 1.25
Share-based Payment Arrangement, Nonemployee [Member] \| Director, Denis Corin [Member] \| Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued		$ 950,000
Share-based Payment Arrangement, Nonemployee [Member] \| Director, William Rosenstadt [Member] \| Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued		$ 1,250,000
Exercise price per share		$ 1.25

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Aug. 31, 2019	Oct. 14, 2019
Document and Entity Information
Entity Registrant Name	Q BIOMED INC.
Document Type	10-Q
Document Period End Date	Aug. 31, 2019
Entity Current Reporting Status	Yes
Amendment Flag	false
Entity Central Index Key	0001596062
Current Fiscal Year End Date	--11-30
Entity Common Stock, Shares Outstanding		16,720,871
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance, Shares at Nov. 30, 2017	12,206,409
Beginning balance, Amount at Nov. 30, 2017	$ 12,206	$ 23,187,408	$ (22,843,370)	$ 356,244
Share based compensation for services, Amount	$ 159	1,953,158		1,953,317
Share based compensation for services, Shares	159,028
Issuance of common stock and warrants for cash, net of offering costs, Amount	$ 1,712	4,943,539		4,945,251
Issuance of common stock and warrants for cash, net of offering costs, Shares	1,711,875
Net loss			(7,172,514)	(7,172,514)
Ending balance, Shares at Aug. 31, 2018	14,077,312
Ending balance, Amount at Aug. 31, 2018	$ 14,077	30,084,105	(30,015,884)	82,298
Beginning balance, Shares at May. 31, 2018	13,987,130
Beginning balance, Amount at May. 31, 2018	$ 13,987	28,902,745	(27,030,353)	1,886,379
Share based compensation for services, Amount	$ 90	1,181,361		1,181,450
Share based compensation for services, Shares	90,182
Net loss			(2,985,531)	(2,985,531)
Ending balance, Shares at Aug. 31, 2018	14,077,312
Ending balance, Amount at Aug. 31, 2018	$ 14,077	30,084,105	(30,015,884)	82,298
Beginning balance, Shares at Nov. 30, 2018	14,290,236
Beginning balance, Amount at Nov. 30, 2018	$ 14,290	31,994,129	(32,114,147)	(105,728)
Share based compensation for services, Amount	$ 527	1,349,081		1,349,608
Share based compensation for services, Shares	526,541
Issuance of common stock to partially convert notes payable	$ 147	293,579		293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188	196,890		197,078
Issuance of common stock as inducement to partially convert notes payable	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	$ 30	32,408		32,438
Issuance of common stock to defer monthly contingent payment of convertible note	30,894
Net loss			(7,809,917)	(7,809,917)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182	33,866,087	(39,924,064)	(6,042,795)
Beginning balance, Shares at May. 31, 2019	14,677,136
Beginning balance, Amount at May. 31, 2019	$ 14,676	33,002,224	(37,377,376)	(4,360,476)
Share based compensation for services, Amount	$ 141	340,986		341,127
Share based compensation for services, Shares	139,641
Issuance of common stock to partially convert notes payable	$ 147	293,579		293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188	196,890		197,078
Issuance of common stock as inducement to partially convert notes payable	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	$ 30	32,408		32,438
Issuance of common stock to defer monthly contingent payment of convertible note	30,894
Net loss			(2,546,688)	(2,546,688)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182	$ 33,866,087	$ (39,924,064)	$ (6,042,795)

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Details) - USD ($)	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Related Party Transactions
Consulting and legal expenses	$ 78,000	$ 60,000	$ 270,000	$ 180,000

Warrants and Options - Fair value of outstanding warrants (Details) - Warrants	3 Months Ended
	Aug. 31, 2018 $ / shares
Dividend yield	0.00%
Minimum
Stock price	$ 2.14
Term (years)	3 years
Volatility	123.00%
Risk-free rate	2.47%
Maximum
Stock price	$ 3.61
Term (years)	5 years
Volatility	128.49%
Risk-free rate	2.78%